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α‐SMA	 	 	 alpha‐smooth	muscle	actin	
β‐ME	 	 	 beta‐mercaptoethanol	
βIG‐H3	 	 	 TGF‐β	induced	protein	Ig‐h3	
ARRB	1/2		 	 	 β‐Arrestin	1/2	
ACEi	 	 	 Angiotensin	converting	enzyme	inhibitor	
ACH	 	 	 Acetylcholine	
ADR	 	 	 Adriamycin	nephropathy	
AKT	(PKB)	 	 	 Protein	kinase	B	
AMAC‐1	 	 Alternative	macrophage	activation‐associated	CC‐chemokine‐1	
ANA	 	 	 Antinuclear	antibodies	
ANCA	 	 	 Antineutrophil	cytoplasmic	antibody	
Ang	II	 	 	 Angiotensin‐2	
ANP	 	 	 Atrial	natriuretic	peptide	
Ap‐1	 	 	 Activator	protein‐1	
APC	 	 	 Adenomatous	polyposis	coli	
ARB	 	 	 Angiotensin	receptor	blocker	
ARF	 	 	 Acute	renal	failure	
ARP	2/3	 	 	 Actin	related	protein	2/3	
Arg‐1	 	 	 Arginase‐1	
ATIIR	 	 	 Angiotensin	II	receptors	
ATN	 	 	 Acute	tubular	necrosis	
AXIN	 	 	 Axis	inhibition		
BCG		 	 	 Bromocresol	green	
BSA	 	 	 Bovine	serum	albumin	
BMDM	 	 	 Bone	marrow	derived	macrophages	
CAV‐1	 	 	 Caveolin‐1	
CD	 	 	 Collecting	duct	
CD2AP	 	 	 CD2‐associated	protein	
CDC42	 	 	 Cell	division	control	protein	42	homolog	
CIN85/RukL		 	 c‐Cbl‐interacting	protein/	regulator	for	ubiquitous	kinase	
CKD	 	 	 Chronic	kidney	disease	
CME	 	 	 Clathrin‐mediated	endocytosis	
CQ	 	 	 Chloroquine	
CRF	 	 	 Chronic	renal	failure	
CVD	 	 	 Cardiovascular	disease	
Cyr61	 	 	 Cysteine‐rich	protein	61	
DAB	 	 	 3,3'‐diaminobenzidine	
DAI	 	 	 Diffuse	axonal	injury	
DALYs	 	 	 Disability‐adjusted	life	years	
DAPI	 	 	 4',6‐diamidino‐2‐phenylindole	
DEX	 	 	 Dexamethasone	
DM	 	 	 Diabetes	mellitus	
DN	 	 	 Diabetic	nephropathy	
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DOCA	 	 	 Deoxycorticosterone	acetate		
DPX	 	 	 Distyrene,	Plastciser,	Xylene	
DT(R)	 	 	 Diptheria	toxin	(receptor)	
ECE	 	 	 Endothelin	converting	enzyme	
ECL	 	 	 Enhanced	chemiluminescence	
ECM	 	 	 Extracellular	matrix	
EC	 	 	 Endothelial	cell	
EDN1‐3	 	 	 Endothelin	gene	(1‐3)	
EDTA	 	 	 Ethylenediaminetetraacetic	acid	
EGF	 	 	 Epidermal	growth	factor	
EMT	 	 	 Epithelial	to	mesenchymal	transition	
ERK	 	 	 Extracellular	signal‐regulated	kinases	1/2	
ESRD	 	 	 End	stage	renal	disease	
ET‐1	 	 	 Endothelin‐1	
ETA/BR	 	 	 Endothelin	A/B	receptor	
FAK	 	 	 Focal	adhesion	kinase	
FcRIIb	 	 	 Inhibitor	Fc	receptor	b	
FACS	 	 	 Flow	activated	cell	sorting	
FGF	 	 	 Fibroblast	growth	factor	
FITC	 	 	 Fluorescein	Isothiocyanate	
fMLP	 	 	 fMet‐Leu‐Phe	
FSGS	 	 	 Focal	segmental	glomerulosclerosis	
Fizz‐1	 	 	 Found	in	inflammatory	zone‐1	
GBM	 	 	 Glomerular	basement	membrane	
GEnC	 	 	 Glomerular	endothelial	cells	
(e)GFR	 	 	 (estimated)	glomerular	filtration	rate	
GM‐CSF	 	 	 Granulocyte‐macrophage	colony	stimulating	factor	
GN	 	 	 Glomerulonephritis	
GNo	 	 	 Glomerulonephrosis	
GPRC	 	 	 G‐protein	coupled	receptors	
GRB2	 	 	 Growth	factor	receptor	bound	protein	2	
GSK‐3β	 	 	 Glycogen	synthase	kinase‐3β		
HEK293	 	 	 Human	embryonic	kidney	cell	line	293	
HGF	 	 	 Hepatocyte	growth	factor	
HIF	 	 	 Hypoxia	inducible	factor	
HMGB	 	 	 High‐mobility	group	box	
hPBMC	 	 	 Human	peripheral	blood	mononuclear	cells	
HRP	 	 	 Horseradish	peroxidase	
HO	 	 	 Hemeoxygenase	
HSA	 	 	 Human	serum	albumin	
HUS	 	 	 Haemolytic	uremic	syndrome	
IκB	 	 	 Inhibitor	of	κB	
ICAM	 	 	 Intracellular	adhesion	molecule	
ICGN	 	 	 Immune‐complex	crescentic	glomerulonephritis	
IFN‐γ		 	 	 Interferon‐γ	
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IGF1R	 	 	 Insulin‐like	growth	factor	receptor	1	
ILK	 	 	 Integrin	linked	kinase	
IMDM	 	 	 Iscove’s	modified	dulbecco’s	medium	
JNK‐C	 	 	 c‐jun‐terminal	kinase‐C	
LDL(R)		 	 	 Low	density	lipoprotein	(receptor)	
LIFE	 	 Losortan	intervention	for	endpoint	reduction	in	hypertension	
LN	 	 	 Lupus	nephritis	
LPS	 	 	 Lipopolysaccharide	
LY6c	 	 	 Lymphocyte	antigen	6c	
LY6g	 	 	 Lymphocyte	antigen	6g	
MAC	 	 	 Membrane	attack	complex	
MAP	 	 	 Mean	arterial	pressure	
MAPK	 	 	 Mitogen	activated	protein	kinase	
MCD	 	 	 Minimal	change	disease	
MCP‐1	 	 	 Monocyte	chemo‐attractant	protein	
MDB	 	 	 Membrane	desalting	buffer	
MGN	 	 	 Membranous	glomerular	nephropathy	
MHC	 	 	 Major	histocompatibility	complex	
MMP	 	 	 Matrix	metalloproteinase		
MPGN	 	 	 Membranoproliferative	glomerulonephritis	
MPO	 	 	 Myeloperoxidase	
MVB	 	 	 Multi‐vesicular	body	
nAchR	 	 	 Nicotinic	acetylcholine	receptor	
NCK	 	 	 Non‐catalytic	region	of	tyrosine	kinase	adaptor	protein‐1	
NF‐κB	 	 	 Nuclear	factor	kappa	B	
NHE	1,5	 	 	 Na+/H+	exchanger	isoform	1,5		
NIDDM	 	 	 Non	insulin	dependent	diabetes	mellitus	
NK	 	 	 Natural	killer	cell	
NKF‐K/DOQI	 National	Kidney	Foundations	Kidney	Disease	Outcomes	and	
Quality	Initiative	
NO	 	 	 Nitric	oxide	
NPHS1	 	 	 Nephrin	gene	
NPHS2	 	 	 Podocin	gene	
NTN	 	 	 Nephrotoxic	nephritis	
Nx	 	 	 5/6	renal	ablation	model	
NZ	 	 	 Nocodazole	
PACAP	 	 	 Pituitary	adenylate	cyclase‐activating	polypeptide	
PAF	 	 	 Platelet	activating	factor	
PAI	 	 	 Plasminogen	activator	inhibitor	
PAN	 	 	 Puromycin	aminonucleoside	
Par3/6	 	 	 Protease	activated	receptor	3/6	
PCGN	 	 	 Pauci‐immune	crescentic	glomerulonephritis	
PCNA	 	 	 Proliferating	cell	nuclear	antigen	
PDGF	 	 	 Platelet‐derived	growth	factor	
PEC	 	 	 Parietal	epithelial	cells	
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PE‐Cy7		 	 	 Phycoerythrin	Cy/7	
PI3K	 	 	 Phosphoinositol	3‐kinase	
PKA	 	 	 Protein	Kinase	A	
PKC	 	 	 Protein	Kinase	C	
PLC	 	 	 Phospholipase	C	
PMA	 	 	 Phorbol	myristat	acetate	
PMSF	 	 	 Phenylmethylsulphonyl	fluoride	
PRP	 	 	 Platelet‐rich	plasma	
RANTES	 	 Regulated	on	Activation,	Normal	T	Cell	Expressed	and	Secreted	
RAS	 	 	 Renin‐angiotensin	system	
RBC	 	 	 Red	blood	cell	




RIA	 	 	 Radioimmunoassay	
RME	 	 	 Raft‐mediated	endocytosis	
ROS	 	 	 Reactive	oxygen	species	
RPGN	 	 	 Rapidly	progressive	glomerulonephritis	
RPMI‐1640	 	 	 Roswell	Park	Memorial	Institute	medium	
RRT	 	 	 Renal	replacement	therapy	
SD	 	 	 Slit	diaphragm	
SH2/3	 	 	 Src	homology	domain‐containing	adaptor	proteins	
SHR	 	 	 Spontaneously	hypertensive	rate	
SLE	 	 	 Secondary	lupus	erythematosus	
SOCS	 	 	 Suppressor	of	cytokine	signaling	
SPARC	 	 	 Secreted	protein	acid	rich	in	cysteine	
SRA	 	 	 Scavenger	receptor	A	
SRC	 	 	 Proto‐oncogene	tyrosine	protein	kinase	
SSH1	 	 	 Slingshot‐1	
STAT	1‐3	 	 	 Signal	transducers	activators	of	transcription	
STX	 	 	 Sitaxsentan	
SYNPO	 	 	 Synaptopodin	gene	
TGF‐β	 	 	 Transforming	growth	factor	beta	
TGRs	 	 	 Transgenic	rats	
TGBRIII	 	 	 TGF	beta	receptor	III	
Th1/2	 	 	 T‐helper	cell	1/2	
TIMPs	 	 	 Tissue	inhibitors	of	metalloproteinases	
TLR	 	 	 Toll‐like	receptor	
TNF‐α	 	 	 Tumour	necrosis	factor	alpha	
TNF‐R	 	 	 Tumour	necrosis	factor	receptor	
Ton‐EBP	 	 	 Tonicity‐responsive	enhancer	binding	protein	
TRAF6	 	 	 TNF	receptor	associated	factor	 	 	 	





TSP	 	 	 Thrombospondin‐1	
TTP	 	 	 Thrombotic	thrombocytopenic	purpura	
UUO	 	 	 Unilateral	ureteric	obstruction	
VCAM	 	 	 Vascular	cell	adhesion	molecule	
VEGF(C)	 	 	 Vascular	endothelial	growth	factor	(C)	
VIP	 	 	 Vasoactive	intestinal	peptide	
VSMC	 	 	 Vascular	smooth	muscle	cell	
vWF	 	 	 von	Willebrand	factor	




WT‐1	 	 	 Wilm’s	tumour	1	

















A	 common	 feature	 of	 glomerular	 disease	 is	 a	 protein	 leak	 into	 the	 urine.	
Proteinuria	 occurs	 in	 kidney	 disease	 and	 is	 an	 important	 risk	 factor	 for	
cardiovascular	disease	(CVD).	ET‐1	is	a	potent	vasoconstrictor/pressor	peptide	
that	is	up‐regulated	in	CVD	and	many	forms	of	inflammatory	renal	diseases.	The	
actions	 of	 ET‐1	 are	 mediated	 via	 two	 G‐protein	 coupled	 receptors,	 the	 ETAR	
which	 serves	 primarily	 in	 the	 pro‐hypertensive	 actions	 of	 ET‐1	 and	 is	 often	
considered	as	the	main	pathological	receptor	subtype,	with	the	ETBR	serving	to	
clear	circulating	ET‐1.	Antagonism	of	one	or	both	of	receptors	has	been	shown	
to	 be	 of	 clinical	 benefit	 in	 the	 treatment	 of	 hypertension.	 This	 research	
demonstrated	a	beneficial	effect	of	selective	ETAR	antagonism	using	Sitaxsentan	
in	 a	 rat	model	 of	GN.	ETAR	blockade	 reduced	blood	pressure	 and	 importantly	
reduced	glomerular	inflammation	as	assessed	by	glomerular	macrophage	(Mϕ)	
infiltration.	 Further,	 we	 aimed	 to	 demonstrate	 that	 Mϕ,	 key	 mediators	 of	
inflammation	 are	 activated	 by	 ET‐1	 to	 adopt	 a	 pro‐inflammatoy	 phenotype.	
However,	 early	 studies	 demonstrated	 that	 ET‐1	 does	 not	 activate	 Mϕ	 as	
hypothesised.	 Mϕ	 were	 more	 phagocytic,	 and	 ET‐1	 was	 chemokinetic	 for	
macrophages,	 an	 ETBR	 medicated	 event.	 ET‐1	 was	 also	 removed	 by	 Mϕ,	
suggesting	a	potential	regulatory	role	of	Mϕ	in	the	ET	system.	This	phenomenon	
led	to	inclusion	of	additional	in	vivo	studies	to	investigate	the	role	of	Mϕ	in	the	
regulation	of	ET‐1	and	 its	pressor	effects.	These	effects	were	 investigated	 in	a	
murine	 model	 of	 Mϕ	 ablation	 using	 CD11b‐DTR	 mice.	 These	 experiments	
determined	 in	 vivo	 that	 Mϕ	 ablation	 augments	 pressor	 responses	 to	 ET‐1,	
suggesting	that	Mϕ	are	required	to	regulate	ET‐1.	In	vitro,	Mϕ	remove	ET‐1	by	
several	mechanisms	involving	proteolytic	degradation	of	the	peptide	and	ETBR	
mediated	 clearance,	 demonstrating	 a	 potential	 mechanism	 for	 the	 in	 vivo	
observation.	 Furthermore,	 proteinuria	 is	 believed	 to	 be	 due	 to	 damage	 or	
effacement	of	 specialized	visceral	glomerular	epithelial	 cells	or	podocytes.	We	
identified	 in	 vitro	 that	 the	 ETAR	mediates	 ET‐1	 induced	 human	 podocyte	 cell	
effacement	by	actin	cytoskeleton	aberrations	and	slit‐diaphragm	protein	down‐
regulation,	 ET‐1	 and	 pro‐inflammatory	 cytokine	 production.	 This	 thesis	
provides	 evidence	 to	 support	 our	 initial	 hypotheses	 that	 selective	 ETAR	
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antagonism	 ameliorates	 proteinuric	 renal	 disease	 via	 its	 effects	 on	 podocytes	
and	macrophages.	 Continued	 studies	 both	 in	 vitro	 and	 in	 vivo	will	 strengthen	























caused	by	 damage	 to	 the	 cells	 of	 the	 kidneys	 filter	 or	 the	 glomerulus.	 Leaked	
protein	 can	 also	 be	 a	 sign	 of	 high	 blood	 pressure	 and	 cardiovascular	 disease	
(CVD).	A	chemical	found	in	the	body	that	regulates	blood	pressure‐	Endothelin‐
1	 (ET‐1)	 is	 also	 higher	 in	 CVD	 and	 CKD	 patients.	 ET‐1	 enters	 cells	 by	 its	
receptors,	the	ETAR	‐	which	is	thought	to	cause	constriction	of	the	blood	vessels,	
and	the	ETBR	‐which	is	thought	to	mainly	dilate	blood	vessels	and	to	clear	ET‐1	
from	 the	 circulation.	 The	 ETAR	 is	 often	 considered	 as	 the	 disease	 causing	
receptor.	Blocking	one	or	both	of	receptors	has	been	beneficial	in	treating	high	
blood	pressure.	The	research	in	this	thesis	tests	the	effects	of	a	drug	known	to	
only	 block	 ETAR	 and	 not	 ETBR‐	 Sitaxsentan,	 in	 rats	 with	 CKD.	 The	 inflamed	
glomeruli	and	protein	in	the	urine	of	these	rats,	in	addition	to	their	high	blood	




damage	 to	 these	 cells.	 It	 was	 expected	 that	 ET‐1	would	 also	 cause	 the	white	
blood	 cells	 mainly	 responsible	 for	 inflammation	 or	 macrophages	 (Mϕ)	 to	
become	‘activated’	to	perform	their	pro‐inflammatory	functions.	This	however,	
was	 not	 the	 case.	 These	 cells	 did	 not	 become	 activated	 but	 instead	moved	 in	
response	to	this	drug	and	ingested	more	foreign	objects‐other	key	functions	of	
these	cells.	The	ET‐1	was	also	removed	by	(Mϕ)	and	this	was	performed	by	the	
ETBR	 and	 also	 by	 enzymes	 released	 by	 these	 cells	 that	 degraded	 ET‐1.	 These	
studies	 suggested	 that	 these	 cells	 might	 in	 fact	 regulate	 this	 potent	 blood	
pressure	 agent.	 To	 test	 this,	we	measured	 the	 blood	 pressure	 in	mice	 lacking	
Mϕ	compared	to	healthy	mice.	We	found	that	mice	lacking	Mϕ	had	higher	blood	
pressure	responses	than	healthy	mice	when	given	ET‐1,	suggesting	that	Mϕ	are	
required	 to	 regulate	 ET‐1.	 Continued	 studies	 will	 strengthen	 the	 evidence	 to	





























Chronic	 kidney	 disease	 (CKD)	 is	 a	 major	 public	 health	 problem.	 CKD,	 also	
known	as	chronic	renal	failure	(CRF),	comprises	a	group	of	pathologies	in	which	
renal	 excretory	 function	 is	 severely	 compromised.	 Most	 forms	 of	 CKD	
eventually	 evolve	 towards	 a	 progressive	 and	 irreversible	 stage	 of	 increasing	





of	 the	 National	 Kidney	 Foundations	 Kidney	 Disease	 Outcomes	 and	 Quality	
Initiative	 (NKF‐K/DOQI)	 clinical	 practice	 guidelines	 for	 the	 evaluation,	
classification	 and	 stratification	 of	 CKD	 was	 a	 notable	 milestone	 for	 the	
treatment	 and	 management	 of	 CKD	 2.	 This	 work	 group	 defined	 CKD	 as	 the	
presence	 of	 markers	 of	 kidney	 damage	 (abnormalities	 in	 blood,	 urine,	 or	
imaging	 tests)	 for	 ≥3	 months	 or	 a	 glomerular	 filtration	 rate	 (GFR)	 <60	
mL/minute/1.73	 m2	 for	 ≥3	 months,	 with	 or	 without	 other	 signs	 of	 kidney	








consequence,	 toxic	 substances	 usually	 eliminated	 through	 the	 urine	 become	




However,	 kidney	 damage	 must	 occur	 to	 a	 significant	 extent	 before	 function	
becomes	 altered.	 Uremic	 signs	 and	 symptoms	 start	 to	 be	 vaguely	 detectable	
when	 at	 least	 two	 thirds	 of	 the	 total	 number	 of	 nephrons	 is	 functionally	 lost.	
Until	then,	CKD	runs	apparently	silent.	This	is	due	to	the	ability	of	the	remaining	













































*CKD	 is	 defined	 as	 either	 GFR	 <60mL/min/1.73	 m2	 for	 3	 months	 or	 a	 GFR	
















High	 blood	 pressure	 or	 hypertension	 (HTN)	 is	 common	 and	 is	 estimated	 to	
occur	in	approximately	1:3	middle‐age	adults,	increasing	to	about	60%	for	those	
over	60.	HTN	is	the	most	important	risk	factor	for	cardiovascular	disease	(CVD)	
i.e.	 stroke,	 ischaemic	 heart	 disease	 and	 heart	 failure,	 and	 importantly,	 is	 a	






avert	 over	 21	 million	 DALYs	 (disability‐adjusted	 life	 years)	 per	 year	
worldwide5.	A	meta‐analysis	 in	61	prospective	 studies	 (over	1	million	 adults)	
demonstrates	 that	 the	 relationship	 between	 BP	 and	 CVD	 is	 stronger	 than	
previously	thought	and	clearly	quantifies	the	risk	for	systolic	BP	6.	
In	England	 in	2011	Health	Survey	 found	that	 those	aged	over	35,	31%	of	men	
and	28%	of	women	have	high	blood	pressure,	defined	as	systolic	blood	pressure	

















this	 population)	 living	with	 CKD	 stage	 3‐5.	 Furthermore,	 there	 is	 evidence	 to	
suggest	 that	 a	 large	 number	 of	 patients	with	 CKD	 stages	 1	 and	 2	 are	 grossly	




consistent	 estimated	 global	 CKD	 prevalence	 of	 between	 11	 to	 13%	 with	 the	
majority	stage	3	10.		
Diabetic	 nephropathy	 (DN)	 as	 a	 result	 of	 type	 1	 diabetes	 mellitus	 (DM)	 is	
thought	 to	 be	 the	 leading	 cause	 of	 CKD.	 The	 incidence	 of	 diabetes	 has	 also	
reached	epidemic	proportions	throughout	the	world,	with	an	expected	doubling	
in	the	number	of	patients	with	type	2	diabetes	in	the	next	25	years11.	This	will	
inevitably	 lead	 to	 an	 increased	 incidence	 of	 diabetic	 nephropathy.	 Currently,	

















incidence	 or	 diagnosis	 of	 CKD	 is	 multifactorial.	 It	 may	 be	 due	 to	 the	
development	 of	 guidelines	 and	 simple	 blood‐test‐based	 formulae	 (e.g.	 eGFR)	
that	 allow	 for	 easier	 and	 earlier	 diagnosis	 of	 CKD	 and,	 thus,	 increased	
reporting16.		
CKD	 prevalence	 also	 increases	 with	 age,	 and	 men	 with	 CKD	 have	 a	 worse	
prognosis	and	a	more	rapid	decline	 in	 renal	 function	and	progression	of	 their	
renal	 disease	 than	 women.	 In	 addition	 to	 gender	 and	 age	 differences,	 some	
ethnic	populations	have	a	higher	prevalence	of	CKD	17.	For	example,	South	Asian	
populations	 are	 at	 higher	 risk	 of	 CKD	 linked	 to	 diabetes,	 as	 there	 is	 a	 higher	
incidence	of	diabetes	 in	 this	community	18.	Afro‐Caribbean	and	Africans	are	at	
greater	risk	of	CKD	due	to	their	higher	prevalence	of	hypertension	18.		
A	 variety	 of	 renal	 injuries	 may	 cause	 CKD.	 Disease	 or	 trauma	 may	 be	 of	
interstitial,	tubular	or	glomerular	origin	and	in	some	cases	may	originate	in	the	
renal	 vascular	 tree.	As	previously	noted	 these	may	occur	 as	 a	 consequence	of	
systemic	 diseases	 such	 as	 diabetes	 mellitus	 (DM),	 hypertension	 and	
inflammatory	and	infiltrative	diseases.	They	may	also	occur	as	a	result	of	renal	
and	 systemic	 infections,	 polycystic	 kidney	 disease,	 autoimmune	 diseases	 (e.g.	
systemic	 lupus	 erythematosus),	 renal	 hypoxia,	 trauma,	 nephrolithiasis	 and	
obstruction	of	the	lower	urinary	tract,	chemical	toxicity	and	others	19.		
1.1.4 Progression	of	CKD	to	ESRD	
Once	 initiated,	 renal	 injury	 gradually	 aggravates	 even	 in	 the	 absence	 of	 the	
triggering	insult	and	can	be	diagnosed	independently	from	the	knowledge	of	its	
cause.	 Patients	 with	 stage	 5	 or	 ESRD	 frequently	 manifest	 a	 wide	 range	 of	
pathological	 organ	 dysfunction,	 either	 caused	 by	 the	 primary	 disease,	 by	
intrinsic	pathological	effects	of	uremia,	or	a	combination	of	the	two.	
A	 representation	 of	 GFR	 evolution	 over	 time	 is	 a	 helpful	 estimation	 of	 renal	




due	 to	 genetic	 heterogeneity,	 it	 is	 also	 very	 variable	 among	 subjects	with	 the	




The	 interplay	between	chronic	disease	processes	 is	 complex,	 and	determining	
cause,	consequence	and	association	is	challenging.	However,	it	was	noted	by	Go	
and	 colleagues	 (2004)21	 that	 CVD	 patients	 with	 comorbid	 CKD	 have	
inconsistently	 higher	 mortality	 rates,	 even	 after	 adjustment	 for	 adverse	
prognostic	factors	that	co‐occur	with	CVD.	Proteinuria,	a	clinical	marker	of	renal	
dysfunction	 can	 also	 be	 used	 to	 determine	 the	 rate	 of	 progression	 of	 CKD.	 In	










indicator	 for	 poor	 CV	 outcomes	 i.e.	 stroke,	 myocardial	 infarction	 or	
cardiovascular	death	 23	as	demonstrated	 in	 the	LIFE	study24,	 and	 is	 classed	as	










Establishing	 the	 cause	 of	 CKD	 is	 paramount,	 as	 in	 some	 cases	 treating	 the	
primary	disease	prevents	further	renal	damage.	The	main	therapeutic	focus	for	
CKD	patients	 is	 to	reduce	 the	rate	of	decline	of	 renal	 function	(or	progression	
rate)	and	ensuing	multi	organ	failure.		




CKD	 but	 also	 as	 a	 result	 of	 CKD.	 Regardless	 of	 whether	 it	 is	 a	 cause	 or	 a	
consequence,	current	clinical	guidelines	suggest	that	patients	with	CKD	should	
aim	to	achieve	BP	below	130/80	mmHg.		
Standard	 treatments	 target	 the	 renin‐angiotensin‐aldosterone	 system	 (RAS).	






The	 key	 and	 yet	 unmet	 issue	 in	CKD	 is	why,	 and	 through	which	mechanisms,	
persistence	 of	 triggering	 damage,	 initially	 repairable	 as	 in	 acute	 events,	
ultimately	progress	beyond	a	point	 in	which	non‐reversible	chronicity	ensues.	
The	 development	 of	 early	 diagnostic	 and	 prognostic	 markers,	 and	 effective	
curative	 therapies	 critically	 depend	 on	 answering	 these	 largely	 ignored	
questions.	Information	pertaining	to	new	mechanisms	and	molecular	pathways	
that	mediate	the	development	of	chronic	phenotypes	has	emerged	over	the	last	





CKD	most	 commonly	 occurs	 as	 a	 result	 of	 glomerular	 disease	 whereas	 acute	
renal	failure	(ARF)	is	most	commonly	due	to	tubulointerstitial	damage	or	acute	
tubular	necrosis	 (ATN)	 26,	with	glomerular	diseases	 tending	 to	progress	more	




The	 requirement	 for	 additional	 treatments	 that	 are	 able	 to	 further	 reduce	
proteinuria	 and	 protect	 renal	 and	 cardiovascular	 function	 are	 implicitly	
expected	 to	extend	beyond	blood	pressure	control	alone,	and	will	be	aimed	at	
targeting	other	aspects	of	renal	glomerular	injury	by	preservation	of	glomerular	




This	 thesis	 will	 therefore	 examine	 glomerular	 disease	 and	 the	 mechanisms	
leading	 to	 proteinuria	 and	 glomerular	 inflammation.	 Based	 on	 these	
observations,	 potential	 renoprotective	 agents	 (and	 their	 cellular	 targets)	
capable	 of	 improving	 proteinuria,	 reducing	 inflammation	 and	 resolving	 tissue	


















The	 principal	 functions	 of	 the	 kidney	 are	 accomplished	 by	 filtration,	
reabsorption,	and	secretion	(Fig	1.1	A).	 In	normal	physiology	blood	enters	the	
glomerulus	 at	 high	 pressure	 via	 the	 afferent	 arteriole,	moving	 through	 to	 the	
glomerular	capillaries,	(Fig	1.1	B)	and	exiting	via	the	efferent	arteriole	27.		
1.2.1.1 Glomerular	filtration	barrier	
The	 glomerular	 microcirculation,	 unlike	 other	 capillary	 circulations,	 is	 highly	
permeable	 to	 water	 and	 small	 solutes.	 Yet,	 like	 other	 capillaries,	 is	 relatively	
impermeable	 to	 macromolecules.	 These	 properties	 are	 essential	 for	 filtration	
function	and	are	a	result	of	 the	unique	three‐layer	structure	of	the	glomerular	
capillary	 wall.	 This	 barrier	 comprises	 the	 luminal	 fenestrated	 glomerular	
endothelial	 cells	 (GEnC)	 with	 its	 glycocalyx,	 the	 glomerular	 basement	
membrane	 (GBM),	 and	 terminates	 in	 the	 ablumenal	 visceral	 epithelial	 cells	 or	
podocytes.	 In	 most	 CKDs,	 ultimately	 the	 size	 and	 charge	 selectivity	 and	
permselectivity	 of	 the	 glomerular	 filtration	 barrier	 becomes	 altered,	 and	 the	



























































































A&B	 (A)	 Diagrammatic	 representation	 and	 (B)	 Electron	 microscope	 (EM)	
photomicrograph	of	the	glomerular	filtration	barrier	demonstrating	glomerular	



















injury	 to	 the	 capillary	 bundle	 and	 Bowman’s	 capsule	 (glomerulus)	 of	 the	
nephron	 occurs.	 They	 can	 be	 categorised	 as	 non‐inflammatory	
glomerulonephrosis	(GNo)	or	inflammatory	glomerulonephritis	(GN).	
	
Non‐inflammatory	glomerular	diseases	 comprise	 a	 repertoire	 of	metabolic	 and	
systemic	diseases	that	chemically	or	mechanically	damage	the	glomerulus,	such	
as	diabetes	and	hypertension,	toxins	and	neoplasias.	The	chronic	form	of	GNo	is	
glomerulosclerosis.	 Persistent	 hypertension	 is	 an	 important	 trigger	 of	 non‐
inflammatory	 glomerular	 disease,	 caused	 by	 pathologic	 remodelling	 of	 the	
capillary	 tuft	 as	 a	 response	 of	 an	 increased	 perfusion	 pressure	 and	 physical	
stress.	 Non‐inflammatory	 glomerulopathies	 do	 progress	 with	 renal	
inflammation,	which	is	a	key	mechanism	of	progression	and	an	important	target	
for	 therapeutics.	 This	 inflammation	 is,	 however,	 secondary	 to	 the	 injury	
inflicted	by	the	initiating	cause	31.	
Inflammatory	 glomerular	 diseases	 or	 glomerulonephritides	 are	 renal	 diseases	
resulting	 in	glomerular	 injury,	 in	which	inflammation	is	a	primary	component.	
GN	is	the	third	most	common	cause	of	CKD,	after	hypertension	and	diabetes.	GN	
may	 occur	 in	 isolation	 (primary	 glomerular	 disease)	 or	 result	 from	 primary	
tubulointerstitial	 and	 renovascular	 diseases,	 i.e.	 polyarteritis	 nodosa	 and	 SLE	
(Secondary	 lupus	 erythematosus)	 32	 that	 contribute	 to	 the	 progression	 of	 the	
damage.	 Glomerular	 disease	 and	 GN	 are	 commonly	 used	 interchangeably,	
however,	 GN	 is	 synonymous	 with	 an	 inflammatory	 component	 of	 glomerular	
injury.	In	the	glomerulus,	inflammation	exerts	different	effects	that	amplify	the	
damage	 and	 directly	 contribute	 to	 the	 reduction	 in	 glomerular	 filtration.	
Initially,	inflammation	is	probably	activated	as	a	normal	repair	mechanism	upon	
cellular	 and	 tissue	 injury.	However,	 undetermined	 pathological	 circumstances	
skew	 persistent	 inflammation	 into	 a	 vicious	 cycle	 of	 destruction	 and	
progression.	 In	 fact,	 inflammation	 activates	many	 renal	 cell	 types	 to	 produce	
cytokines,	 which	 directly	 damage	 renal	 cells	 and	 exacerbate	 inflammation	 33.	
Page	|	34		
	
Renal	 and	 inflammatory	 cell	 activation	 and	 subsequent	 cytokine/chemokine	
release	 will	 be	 discussed	 in	 detail	 in	 section	 1.2.5	 ‐Pathogenesis	 of	
glomerulonephritis.	
1.2.3 Clinical	presentation	of	glomerulopathies	
Glomerular	 diseases	 may	 present	 with	 one	 or	 more	 of	 the	 following;	





to	 3	 g	 protein/	 gram	 creatinine	 is	 usually	 asymptomatic	 or	 non‐nephrotic	
proteinuria.	 It	may	occur	with	glomerular	or	non‐glomerular	diseases	 such	as	
tubulo‐interstitial	diseases	(usually	<1	g/d).	Any	type	of	glomerular	disease	can	




power	 field	 in	 spun	 urine	 (microscopic),	 or	 painless	 brown/red	macroscopic	
haematuria	without	 clots	 in	 patients	who	 have	 normal	 renal	 function	 and	 no	
evidence	 of	 systemic	 diseases	 known	 to	 affect	 kidneys.	 The	 differential	
diagnosis	 is	broad	and	urological	problems	(bladder,	prostate,	urethra,	stones,	
and	 renal	 tumours)	 account	 for	 up	 to	 80%	 of	 all	 cases	 of	 haematuria.	 The	
presence	of	RBC	casts	and/or	dysmorphic	RBCs	indicates	a	glomerular	cause	for	
the	 haematuria.	 The	 most	 common	 diseases	 presenting	 as	 asymptomatic	
haematuria	are	thin	basement	membrane	disease,	IgA	nephropathy,	hereditary	






Nephrotic	 syndrome	 is	 the	 major	 clinical	 syndrome	 produced	 by	 non‐
inflammatory	 glomerulopathies.	 This	 syndrome	 is	 a	 clinical	 pentad	 of	
proteinuria	 >3	 g/d,	 hypoalbuminemia	 <3.5	 g/dL,	 oedema,	
hypercholesterolemia,	and	lipiduria	(most	specific	finding	is	presence	of	oval	fat	
bodies	 in	 urinalysis).	 Complications	 of	 nephrotic	 syndrome	 include	
hypercoagulability	 due	 to	 loss	 of	 haemostasis	 control	 proteins	 such	 as	
antithrombin	 III	 and	 increased	 hepatic	 synthesis	 of	 protein	 C,	 fibrinogen,	 and	
von	Willebrand	factor	(vWF).	Venous	thrombosis	is	more	common	than	arterial	
thrombosis.	 Infection	due	to	 loss	of	 immunoglobulins	and	immunosuppressive	
drugs,	hyperlipidemia	and	atherosclerosis	are	also	common	complications.	The	
most	 common	 glomerular	 diseases	 presenting	 as	 nephrotic	 syndrome	 are	
primary	 diseases	 such	 as	minimal	 change	 disease,	membranous	 nephropathy,	
and	 FSGS,	 as	 well	 as	 secondary	 forms	 such	 as	 diabetic	 nephropathy	 (DN),	




RBCs	 and/or	 RBC	 casts,	 hypertension,	 and	 reduction	 in	 glomerular	 filtration	
rate	with	 or	without	 oliguria.	 Proteinuria	 (usually	 nonnephrotic)	 and	oedema	
may	also	be	present.	Distinction	between	nephrotic	and	nephritic	syndromes	is	
usually	based	on	clinical	and	laboratory	evaluation.	The	most	common	diseases	
presenting	 as	 nephritic	 syndrome	 are	 post‐streptococcal	 GN,	 other	 post‐
infectious	 diseases	 (endocarditis,	 abscess),	 IgA	 nephropathy,	 vasculitis,	 and	
lupus	 nephritis	 (LN).	Generally,	 diseases	 presenting	 with	 nephritic	 syndrome	
tend	be	acute	and	 rapidly	progressive,	 and	 time	 is	of	 the	essence	 in	diagnosis	
and	early	treatment,	so	as	to	avoid	chronic	renal	damage	37.	
	
Rapidly	 progressive	 glomerulonephritis	 (RPGN)	 is	 the	most	 severe	 form	 of	 GN	
and	 usually	 presents	 as	 proteinuria	 <3	 g/d	 and	 haematuria	 with	 dysmorphic	
RBCs	and/or	red	cell	casts,	with	or	without	systemic	vasculitis.	The	appearance	
of	 crescents	 on	biopsy	 are	 also	 present.	 RPGN	 can	progress	 to	ESRD	within	 a	
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period	 of	 weeks	 to	 months	 if	 untreated.	 RPGN	 is	 usually	 due	 to	 one	 of	 the	
following	disorders,	which	reflect	different	mechanisms	of	glomerular	injury	38.		
Type	1:	Anti‐GBM	disease‐	in	the	setting	of	pulmonary	involvement	is	also	known	
as	 Goodpasture’s	 syndrome.	 In	 this	 disorder	 histology	 demonstrates	 IgG	




antistreptococcal	 antibodies	 and	 subepithelial	 humps	 in	 postinfectious	
glomerulonephritis,	 antinuclear	 antibodies	 (ANA)	 and	 subendothelial	 deposits	
in	 lupus	nephritis,	and	circulating	cryoglobulins	and	 intraluminal	 “thrombi”	 in	
mixed	cryoglobulinemia.	
	
Type	3:	Pauci‐immune	GN‐	 is	 a	 necrotizing	 glomerulonephritis	with	 few	or	 no	
immune	 deposits	 by	 IF	 or	 EM.	 The	 majority	 of	 patients	 with	 renal‐limited	













































































































































an	 aetiological	 agent	 can	be	 identified.	The	known	 infectious	 agents	 including	
bacteria	 Staphylococcus	 spp.,	 Lancefiled	 group	 A	 β‐haemolytic	 streptococci,	
Streptococcus	 viridans,	 Treponema	 pallidum;	viruses	 such	 as	 Coxsackie	 virus,	
Epstein	Barr	virus,	hepatitis	B	virus,	measles	and	mumps;	and	 lastly	parasites	
including	 Plasmodium	 malariae,	 Schistosoma	 spp.	 etc.	 39.	 Other	 aetiological	
agents	 can	 include	 drugs	 such	 as	 penicillamine	 and	 host	 antigens	 such	 as	
cryoglobulin,	DNA	and	tumour	antigens.	Bacteria	such	as	beta	streptococci	gives	
rise	 to	poststreptococcal	GN	and	viruses	 such	 as	hepatitis	 C	 virus	 give	 rise	 to	
cryoglobulinemic	 membranoproliferative	 glomerulonephritis	 (MPGN).	 It	 is	
likely	 that	 most	 precipitating	 factors,	 such	 as	 infections	 and	 drug	 and	 toxin	
exposures,	 initiate	 similar	 immune	 responses	 that	 result	 in	 GN	 via	 shared	
common	pathways	40.	
1.2.5 Pathogenesis	of	glomerulonephritis	
Although	 the	 pathogenesis	 is	 not	 fully	 understood,	 current	 evidence	 supports	
that	 most	 cases	 of	 GN	 are	 due	 to	 an	 immunologic	 reaction	 in	 response	 to	 a	
variety	 of	 different	 aetiologic	 agents.	 The	 immunologic	 response,	 in	 turn,	
activates	 a	 number	 of	 biological	 processes	 (complement	 activation,	 leukocyte	
recruitment,	 and	 release	 of	 growth	 factors	 and	 cytokines)	 that	 result	 in	
glomerular	 inflammation	 and	 injury	 41.	 GN	 may	 be	 isolated	 to	 the	 kidney	
(primary	GN)	or	be	a	component	of	a	systemic	disorder	(secondary	GN).	A	large	
body	of	 clinical,	 immunopathologic,	 and	experimental	data	 support	 the	 theory	
that	most	forms	of	human	GN	result	from	immunologic	mechanisms	42;	43;	44;	45;	
46;	 47.	 In	 these	 conditions	 glomerular	 injury	 is	 characterized	 by	 a	 primary	
immunological	mechanism	to	the	pathogenesis	that	often	results	in	glomerular	
injury.	 Secondary	 mechanisms	 cause	 further	 glomerular	 damage	 by	






The	 nephritogenic	 immune	 response	 exhibits	 both	 humoral	 and	 cellular	




B‐cell	 differentiation	 and	 antibody	 production	 that	 leads	 to	 immune	 complex	
deposition	and/or	formation	in	the	glomeruli.	
In‐situ	 immune	 complex	 deposition	 can	 occur	 as	 a	 result	 of	 circulating	
antibodies	 forming	 immune	 complexes	 with	 antigens	 of	 normal	 glomerular	
components,	or	with	antigens	of	non‐glomerular	origin.		
Fixed	 intrinsic	 tissue	 (Glomerular)	 antigens	 can	 be	 (1)	 Glomerular	 basement	
membrane	 antigens:	 NC1	 domain	 of	 collagen	 type	 IV	 antigen	 (anti‐GBM	






GBM	 from	 the	 circulation	 firstly	 and	 then	 circulating	antibodies	 form	 immune‐
complex.	 These	 have	 a	 granular	 pattern	 immune‐complex	 deposition.	 The	
trapped	antigens	are	either	exogenous	antigens	(i.e.	infectious	agents,	drugs)	or	




Circulating	 immune	 complex	 deposition	 occurs	 as	 a	 result	 of	 Type	 III	
hypersensitivity.	 Antigen‐antibody	 complexes	 formed	 in	 the	 circulation	 are	
deposited	 in	 the	 glomeruli.	 These	 complexes	 have	 a	 granular	 pattern	 of	
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deposition	 on	 IF.	 Similarly,	 the	 antigen‐antibody	 complexes	 formed	 in	
circulation	are	either	from	exogenous	or	endogenous	antigens.	Primary	immune	
complex	 deposition	 in	 one	 site	 is	 often	 accompanied	 by	 deposition	 of	 lesser	
amounts	in	other	sites.	The	factors	influencing	the	localisation	of	complexes	are	
molecular	charge	of	complexes,	size,	avidity,	blood	flow,	etc	51.	
The	 site	 of	 complex	 formation	 or	 deposition	 can	 vary,	 and	 ultimately	 affect	
disease	progression.	 Sites	 of	 formation	or	deposition	 can	be	 (i)	 Subendothelial	
(between	capillary	endothelium	and	GBM):	These	are	intermediate	in	size,	highly	
anionic	 complexes	 excluded	 from	 GBM;	 (ii)	 Intramembranous	 (within	 GBM):	
These	 represent	 the	 transitional	 phase	 in	 which	 complexes	 migrate	 from	
subendothelial	 position	 to	 subepithelial	 and	 occur	 more	 frequently	 with	
increased	 blood	 flow;	 (iii)	 Subepithelial	 (between	 epithelial	 cells	 and	 GBM):	
These	 are	 small,	 highly	 cationic	 complexes	 which	 pass	 freely	 through	 the	
glomerulus	 without	 being	 trapped;	 (iv)	 Mesangial	 (within	mesangium):	 These	
are	large	and	neutral	in	charge	and	occur	when	there	is	decreased	blood	flow	52.	
1.2.5.1.2 Cellular/T‐cell	mediated	immune	injury	
The	 cellular	 or	 Th1‐regulated	 immune	 response	 has	 a	 non‐immune	 complex	
deposition	 mechanism	 whereby	 the	 infiltration	 of	 glomeruli	 is	 by	 circulating	
mononuclear	 inflammatory	 cells,	 including	 lymphocytes	 and	 macrophages	
(Mϕ).	 Here,	 crescent	 formation	 is	 observed	 48.	 The	 local	 Th1‐regulated	
immunity	 involves	 the	 delayed‐type	 hypersensitivity	 (DTH)	 reaction.	 This	 is	
initiated	 by	 CD4+	 cells	 that	 activate	 monocytes	 or	 Mϕ	 to	 produce	 pro‐
inflammatory	 cytokines	 such	 as	 IL12	 53,	 IFN‐γ	 54	 and	 TNF‐,	 with	 CD8+	 cells	
acting	 by	 their	 cytotoxic	 ability	 55.	 Once	 activated,	 these	 cells	 are	 capable	 of	
producing	 cytokines	 that	 co‐ordinate	 a	 local	 immune‐inflammatory	 process.	
Mediators	derived	from	lymphocytes	such	as	 IFN‐γ	 induce	an	up‐regulation	of	
major	 histocompatibility	 complex	 (MHC)	 antigens	 by	 tubular	 cells,	 allowing	
these	 cells	 to	 act	 as	 antigen	 presenting	 cells.	 In	 addition,	 IFN‐γ	 also	 activates	






Secondary	 mechanisms	 cause	 further	 glomerular	 damage	 by	 both	 cellular	
components	and	soluble	mediators	produced	by	 these	cells.	 In	early	phases	of	
GN,	 there	 is	 an	 influx	 of	 inflammatory	 cells	 irrespective	 of	 the	 nature	 of	 the	
initial	 renal	 insult.	Cellular	mediators	 include	 leucocyte	 infiltrates	and	platelet	
aggregates.	 
1.2.5.2.1 Neutrophils	and	platelets	
In	 areas	 where	 antibodies	 that	 induce	 complement	 activation	 or	
immunoglobulin	deposition	at	areas	accessible	to	circulating	inflammatory	cells	
(e.g.	 subendothelial	 or	 mesangial	 immune	 complex	 deposits),	 neutrophil	
infiltration	occurs	 56.	 It	 is	well	 established	 that	neutrophils	 cause	much	of	 the	
antibody‐induced	 injury.	Neutrophil	 involvement	 and	 localisation	 in	 glomeruli	
through	 interaction	with	 a	 variety	 of	 leukocyte	 adhesion	molecules	 (selectins,	
integrins,	 intracellular	 adhesion	 molecule	 (ICAM)	 and	 vascular	 adhesion	
molecule	 (VCAM))	 has	 been	 demonstrated	 57.	 These	 molecules	 are	
overexpressed	in	response	to	cytokines	and	other	inflammatory	mediators.	It	is	
also	 established	 that	 neutrophils	 localized	 in	 glomeruli	 induce	 injury	 by	
undergoing	 a	 respiratory	 burst	 that	 results	 in	 release	 of	 toxic	 oxygen	




of	neutrophil	mediated	 injury	and	apparently	augment	 this	process	 60.	Finally,	
several	neutrophil‐derived	serine	proteases	including	elastase	and	cathepsin	G	
can	also	cause	capillary	wall	injury	and	proteinuria	in	vivo	61.	
Thus	 neutrophils	 can	 cause	 damage	 to	 the	 GBM	 leading	 to	 proteinuria	 by	
generation	 of	 reactive	 oxygen	 metabolites	 and	 by	 release	 of	 proteolytic	





and	 ultimately	 stripping	 of	 endothelial	 cells	 from	 the	 underlying	 basement	
membrane.	This	leads	to	a	reduction	in	the	available	surface	areas	for	filtration.	
1.2.5.2.2 Monocytes	and	macrophages	
Monocytes	 and	 macrophages	 (Mϕ)	 are	 involved	 in	 the	 acute	 phase	 of	 the	
inflammatory	response.	Mϕ	persist	for	months	positioned	in	a	variety	of	organs	
where	they	function	as	permanent	‘sentinels’	ready	to	initiate	an	inflammatory	
response	 via	 two	 main	 mechanisms.	 They	 protect	 the	 host	 through	 innate	
immunity	 and	 remove	 pathogens	 by	 engulfing	 them	 by	 phagocytosis.	 The	
development	 of	 acquired	 immunity	 with	 reciprocal	 interactions	 between	
macrophages	 and	 activated	 T	 and	 B	 lymphocytes	 provided	 novel	 levels	 of	
regulation	 and	 acquisition	 of	 enhanced	 antimicrobial	 resistance.	 The	 role	 of	
Th1‐derived	 interferon‐gamma	 (IFN‐γ)	 62	 in	 cell‐mediated	 immunity	 to	
intracellular	 infection	 and	 of	 interleukin‐4	 (IL‐4)	 (Th2)	 63	 in	 extracellular	
parasitic	 infection	 gave	 rise	 to	 the	 concept	 of	 analogous	 M1	 and	 M2	





from	 arginine,	 versus	 ornithine	 production	 from	 Th2	 mice	 with	 T	 cells	
producing	 IL‐4	 and	 tumor	 growth	 factor	 (TGF)‐β	 1.	 This	 finding	 led	 to	 a	
consensus	 within	 the	 scientific	 community	 that	 M1	 (classically	 activated)	
macrophages	 exhibit	 inflammatory	 functions,	 whereas	 M2	 (alternatively	
activated)	macrophages	exhibit	anti‐inflammatory	functions.	
This	 concept	 of	 M1	 and	 M2	 activation	 to	 mimic	 Th	 cell	 nomenclature	 was	
standard	 for	 many	 years,	 however,	 an	 ever‐expanding	 body	 of	 evidence	
demonstrating	 that	 many	 stimuli	 combine	 to	 determine	 the	 phenotype	 of	
macrophages,	 and	 this	 M1/M2	 polarisation	 view	 is	 now	 considered	 overly	
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simplistic.	 Recognition	 receptors,	 cytokines,	 and	 the	 signaling	 and	 genetic	




two	 stimuli.	 Firstly,	 interaction	 with	 interferon‐γ	 (IFN‐γ)	 from	 T‐helper	
lymphocytes	 or	 natural	 killer	 (NK)	 cells	 65.	 This	 cytokine	 ‘primes’	 Mϕ	 for	
activation,	 a	 dose	 dependant	 effect,	 and	 is	 able	 to	 enhance	 the	 inflammatory	
response,	 but	 does	 not	 in	 itself	 activate	 Mϕ	 66.	 The	 second	 signal	 is	 tumor	
necrosis	factor	(TNF‐α)	itself	or	an	inducer	of	TNF‐α.	Exogenous	TNF‐α	can	act	
as	 the	 second	 signal,	 but	 the	 physiologically	 relevant	 signal	 is	 generally	 the	
result	 of	 Toll‐like	 receptor	 (TLR)	 ligation,	 which	 induces	 endogenous	 TNFα	




nuclear	 factor‐ B	 (NF‐ B)	 and	 leads	 to	 Mϕ	 activation	 68.	 This	 activation	
generates	 nitric	 oxide	 (NO)	 and	 reactive	 oxygen	 species	 (ROS),	 produces	 pro‐
inflammatory	cytokines	including	tumour	necrosis	factor‐α	(TNF‐α),	IL‐1,	IL‐12,	
IL‐6,	 IL‐8,	 IL‐11ß	 and	MCP‐1	 and	 finally	 induces	 expression	 of	 (MHC)	 class	 II	
and	co‐stimulatory	molecules	which	promote	antigen	presentation	including	CD	
80/86	 and	 granulocyte‐macrophage	 colony	 stimulating	 factor	 (GM‐CSF)	
receptor	CD116	69.	 	M1	macrophages	have	also	been	shown	to	up‐regulate	the	
expression	 of	 the	 intracellular	 protein	 suppressor	 of	 cytokine	 signaling	 3	
(SOCS3),	 as	well	 as	activate	 inducible	nitric	oxide	synthase	 (NOS2	or	 iNOS)	 to	
produce	 NO	 from	 L‐arginine	 70;	 71.	 Classically	 activated	 Mϕ	 are	 also	 a	 major	
source	 of	 the	 potent	 anti‐inflammatory	 cytokine	 IL‐10.	 This	 is	 generated	 in	
response	to	TLR	signalling	as	a	feedback	mechanism	to	curtail	the	inflammatory	
response.	 In	 murine	 bone	 marrow‐derived	 macrophages	 (BMDM),	 TLR4	




two	 transcription	 factors,	 signal	 transducers	 and	 activators	 of	 transcription	
(STAT1)	and	STAT3,	which	are	recruited	to	the	IL‐10	promoter	72.	
1.2.5.2.2.2 ‘Alternative’	M2	activation	
In	 addition	 to	 the	 classical	 M1	 Mϕ,	 these	 cells	 can	 undergo	 ‘alternative’	
activation	for	an	M2	phenotype.	The	first	description	of	this	phenotype	reported	
Mϕ	exhibiting	an	up‐regulation	of	mannose	receptor	 in	response	to	an	IL‐4	or	
IL‐13	 stimulus	 63.	 Later	 studies	 showed	 that	 these	 Mϕ	 are	 distinct	 from	
classically	 activated	 Mϕ,	 and	 their	 phenotype	 is	 that	 of	 a	 ‘regulatory’	 Mϕ	 73.	
These	 cells	 have	 a	 limited	 ability	 to	 destroy	 intracellular	 microbes	 and	 their	
antigen	presenting	ability	is	diminished	compared	to	that	of	classically	activated	
Mϕ.	Unlike	classically	activated	cells,	M2	Mϕ	do	not	produce	NO	as	a	result	of	
arginase	 production	 74.	 These	 cells	 typically	 produce	 cytokines	 such	 as	 IL‐10	
and	IL‐1	receptor	antagonist.	Their	main	function	is	thus	thought	to	be	that	of	a	
pro‐repair	phenotype.	These	alternatively	activated	Mϕ	are	thought	to	mediate	
angiogenesis	 and	 deposit	 extracellular	 matrix	 (ECM)	 during	 wound	 healing.	
Alternatively	activated	Mϕ	produce	fibronectin	and	a	matrix‐associated	protein	
TGFβ‐induced	 gene‐H3	 (βIG‐H3)75,	 and	 they	 promote	 fibrogenesis	 from	
fibroblastoid	cells	76.	The	induction	of	arginase‐1	(Arg‐1)	in	these	cells	may	lead	
to	 polyamine	 and	 proline	 biosynthesis,	 promoting	 cell	 growth,	 collagen	
formation,	and	tissue	repair	77.	Markers	to	 identify	this	cell	 type	 include	Arg‐1	














induce	 Th2	 adaptive	 immune	 responses	 after	 initial	 activation	 in	 a	 Th1‐type	
environment	81.	These	Mϕ	require	two	signals	for	activation.	The	first	signal	is	
the	 ligation	of	FcγRs	with	 immune	complexes.	Receptor	 ligation	also	has	to	be	
coupled	with	a	Mϕ	stimulatory	signal	to	influence	cytokine	production.	Stimuli	
included	those	that	signal	through	any	of	the	TLRs,	as	well	as	through	CD40	or	
CD44.	 The	 type	 II	 phenotypic	 switch	 following	 FcγR	 ligation	 occurs	 in	 un‐
primed	 and	 IFN‐γ‐primed	Mϕ.	 Type	 II‐activated	Mϕ	 are	 clearly	 distinct	 from	
alternatively	 activated	 Mϕ	 described	 above,	 as	 they	 do	 not	 induce	 arginase.	
Activation	also	results	in	altered	cytokine	expression	81.	Cytokines	produced	by	
classically	 activated	Mϕ,	 such	 as	 TNF‐α,	 IL‐1,	 and	 IL‐6	 are	 produced	 by	 these	
cells.	However,	production	of	IL‐12,	the	Th1‐promoting	cytokine,	is	reduced	and	
IL‐10,	 the	 anti‐inflammatory	 cytokine,	 is	 increased	 81;	 82.	 Type	 II	 Mϕ	 also	
promote	the	differentiation	of	Th2	cells	and	subsequent	IL‐4	production	83.	
It	 is	 now	 appreciated	 that	 the	 M2	 terminology	 encompasses	 a	 functionally	
diverse	 group	 of	 macrophages	 rather	 than	 a	 unique	 activation	 state.	
Accordingly,	M2	macrophages	 can	 be	 further	 divided	 into	 subsets	 specifically	
M2a,	M2b,	M2c	and	M2d	based	on	their	distinct	gene	expression	profiles	84;	 85.	









multipolar	 interplay	 between	 these	 and	 many	 other	 signals	 requires	 further	




genes	 involved	 are	 exhaustive	 and	 beyond	 the	 scope	 of	 this	 thesis.	 Recent	
reviews	 by	 Martinez	 &	 Gordon	 (2014)	 88	 and	 Foey	 (2015)	 89	 indicate	 the	
spectrum	of	macrophage	activation	and	the	differences	between	the	in	vitro	and	
in	vivo	environment.		
In	 the	context	of	 renal	disease,	 resident	 renal	Mϕ	may	participate	 in	 the	 local	
presentation	 of	 antigen	 in	 (DTH)	 reaction.	 They	 are	 also	 responsible	 for	
hypercellularity	 of	 the	 glomerular	 tuft,	 particularly	 in	 diffuse	 proliferative	 GN	
and	crescentic	GN.	Mϕ	also	play	a	central	role	in	mediating	the	development	of	
renal	 injury	 in	 animal	 models	 90;	 91;	 92	 as	 well	 as	 in	 human	 diseases.	 In	 rats	
subjected	 to	 5/6	 renal	 ablation	 (Nx),	 Mϕ	 infiltration	 begins	 1	 week	 after	
ablation	and	increases	progressively	with	time	90.		Mϕ	can	mediate	tissue	injury	
through	 different	 pathways.	 Besides	 the	 ability	 of	 producing	 proteolytic	
enzymes,	 reactive	 oxygen	 ROS	 and	 vasoactive	 substances,	 Mϕ	 synthesize	
cytokines	 and	 fibrogenic	 growth	 factors	 responsible	 for	 a	 sustained	
inflammatory	milieu.	 The	 maintenance	 of	 these	 cells	 in	 later	 phases	 of	 renal	
disease	suggest	that	Mϕ	are	also	involved	in	the	chronic	inflammatory	process	
leading	to	the	development	of	fibrotic	changes.	
The	 injurious	 role	 of	 infiltrating	 leukocytes	 has	 been	 discussed,	 however	 the	

















the	 genesis	 of	 chronic	 glomerular	 diseases.	 Injury	 to	 these	 cells	 results	 in	
proliferation	 and	 increased	 matrix	 production	 and	 deposition.	 Mesangial	
proliferation	 is	 often	 considered	 an	 initial,	 adaptive	 response	 that	 eventually	
loses	control	and	develops	 into	a	pathological	process.	 It	 is	a	common	 feature	
during	 the	 initial	 phase	 of	 many	 chronic	 glomerular	 diseases,	 including	 IgA	
nephropathy,	membranoproliferative	GN	95;	96;	97,	LN,	and	DN	98	99.	
Numerous	 experimental	 models	 of	 glomerular	 damage	 have	 reported	 that	
proliferation	of	mesangial	cells	frequently	precedes	and	is	associated	with	ECM	
deposition	 in	 the	 mesangium	 and,	 therefore,	 leads	 to	 fibrosis	 and	
glomerulosclerosis.	 Reduction	 of	 mesangial	 cell	 proliferation	 in	 glomerular	
disease	models	ameliorates	these	pathological	events	98.		








production	 in	 both	 focal	 and	 diffuse	 glomerulosclerosis	 104;	 107.	 Patients	 with	
mild	 glomerulonephritic	 damage	 show	 no	 interstitial	 collagen	 I	 and	 III	 99.	
Progressive	 renal	 damage	 correlates	 with	 increasing	 presence	 of	 collagen	 IV	
and	 VI,	 laminin	 and	 fibronectin	 in	 the	 mesangium.	 Finally,	 in	 later	 stages	 of	
glomerulonephritis,	 the	 amount	 of	 collagen	 IV,	 laminin	 and	 fibronectin	
gradually	 decreases,	 while	 focal	 expression	 of	 collagen	 I	 and	 III	 increases.	





Podocytes	 have	 progressively	 gained	 attention	 in	 glomerulopathies	 and	 are	
considered	to	have	a	central	role	in	the	pathological	process,	as	a	result	of	both	
genetic	 and	 acquired	 alterations	 96.	 Podocytes	 form	 the	 terminal	 layer	 of	 the	
glomerular	 filtration	 barrier.	 It	 is	 the	 specialised	 structure	 and	 function	 of	
podocytes	that	makes	them	particularly	attractive	targets.	
1.2.6 Podocyte	structure	and	function	
Podocytes	 are	 terminally	 differentiated	 and	 derive	 from	 embryonic	
mesenchyme.	Consisting	of	a	large	cell	body	at	the	centre	of	the	cell	lying	in	the	
urinary	 space	 and	 large	 primary	 processes	 extending	 from	 the	 cell	 body,	 the	
processes	 then	 diverge	 into	 smaller	 secondary	 processes,	 and	 terminate	 in	
tertiary	end	 foot	processes	 109	 (Fig	1.3	A).	These	are	polarised	cells;	 the	basal	
domain	 anchors	 podocytes	 to	 the	matrix	 proteins	 in	 the	 underlying	 GBM	 via	
cellular	 adhesion	 molecules	 such	 as	 α3β1	 integrin	 110	 and	 α‐	 and	 β‐
dystroglycans	111;	112.	Pedicles	of	neighbouring	podocytes	interdigitate	creating	
filtration	 slits,	 approximately	 30nm	wide,	 that	 are	mainly	 responsible	 for	 the	
size	selectivity	of	the	filter	113.	Podocytes	maintain	their	form	by	an	actin	fibre	
cytoskeleton,	 specifically	 comprising	 microfilaments,	 intermediate	 filaments	
and	microtubules,	in	addition	to	actin	binding	proteins	including	α‐actinin‐4	114	
and	 synaptopodin	 115.	 Microfilaments	 are	 the	 predominant	 cytoskeletal	
constituents	 of	 the	 foot	 process,	 and	 contain	 a	 dense	 network	 of	 filamenous‐
actin	(F‐actin)	and	myosin	(Fig	1.3	B).		
1.2.6.1 Podocyte	Slit	diaphragm	
Foot	 processes	 from	 adjacent	 podocytes	 interdigitate	 and	 connect	 via	 slit	
diaphragm	proteins	(Fig	1.3	B).	This	slit	diaphragm	consists	of	various	protein‐

















A&B	 (A)	 EM	 photomicrograph	 and	 (B)	 Diagrammatic	 representation	 of	 the	













Of	 the	 SD	proteins,	 nephrin	 is	well	 characterised	 118.	 	While	 only	 one	nephrin	
family	gene	exits	in	the	human	genome,	there	are	3	different	gene	loci	encoding	
the	 Neph	 family	 proteins	 Nephrin,	 Neph	 1,	 Neph	 2.	 Nephrin	 and	 Neph	 1	 are	
structurally	similar	transmembrane	Ig	superfamily	proteins.	Neph2	is	located	at	
the	 podocyte‐intercellular	 juncture,	 forms	 homodimers	 and	 its	 extracellular	
domain	binds	nephrin.	A	 further	member	of	 this	 complex	 exists,	 the	 stomatin	
family	member	membrane‐associated	protein	podocin119;	120.		
	
Like	 other	 stomatin	 family	 members	 it	 recruits	 its	 complex	 partners	 to	
cholesterol‐enriched	membrane	domains	at	the	podocyte	foot	process	junction	
thereby	 creating	 a	 cluster	 that	 can	 act	 as	 a	 unique	 signalling	 platform	 121;	 122.	
Consistently,	mutations	in	the	human	podocin	gene	NPHS2	were	characterized	






crucial	 protein	 and	 lipid	 substrates	 125;	 126.	 The	 adaptor	proteins	 in	podocytes	
including	ZO‐1‐	the	tight	junction	protein	expressed	at	the	cell	periphery;	CD2‐
AP127;	128,	α‐act‐4‐	a	protein	linking	F‐actin	filaments	and	others	129	130;	131;	132;	133	






apical	 membrane	 domain	 of	 podocytes	 is	 negatively	 charged	 due	 to	 surface	
anionic	proteins	podocalyxin	 137	and	podoplanin	 138.	This	causes	neighbouring	












component	 of	 the	 generation	 of	 proteinuria.	 The	mechanism	 of	 podocyte	 loss	





that	 include	 an	 early	 inflammatory	 phase.	 As	 discussed,	 resident	 glomerular	
cells	 such	 as	 mesangial	 cells	 and	 circulating	 inflammatory	 cells,	 including	
neutrophils,	platelets	and	Mϕ	mediate	and	perpetuate	inflammatory	responses	





The	 fibrogenic	 process	 is	 largely	 dependant	 on	 fibroblasts,	 which	 are	
considered	 to	 be	 the	 effector	 cells	 in	 fibrogenesis.	 Fibroblasts	 synthesize	 a	
variety	 of	 extracellular	 matrix	 components	 144;	 145;	 146.	 The	 overproduction	 of	
these	proteins	during	fibrogenesis	leads	to	excessive	collagen	accumulation	and	
fibrosis.	 Progressive	 fibrosis	 then	 leads	 to	 tissue	 scarring	with	 destruction	 of	
organ	architecture.	Fibroblasts	and	myofibroblasts	 can	be	derived	 from	either	
resident	 interstitial	 fibroblasts	 or	 from	 perivascular	 cells.	 They	 can	 also	 be	




remodelling	 involves	 tissue	 retraction	 147	 and	 	 is	 the	 result	 of	 the	 action	 of	
retractile	 fibroblasts	 derived	 from	 tubular	 cells.	 Through	 a	 process	 of	
transdifferentiation	 148	 these	 cells	 change	 their	 phenotype	 differentiating	 into	
myofibroblasts.	Myofibroblasts	can	be	recognized	by	their	expression	of	α‐SMA	
90	and	have	been	demonstrated	in	several	experimental	and	clinical	progressive	
renal	 diseases	 92;	 149.	 The	 number	 of	 myofibroblasts	 present	 in	 renal	 tissue	
correlates	 with	 the	 prognosis	 of	 the	 disease	 progression	 preceding	 the	




cells.	 Proliferation	 of	 fibroblasts	 and	 myofibroblasts	 is	 considered	 an	 active	
form	of	the	fibrogenic	response	147.		
	
As	 noted,	 the	 interstitial	wound	 in	 the	 fibrotic	 kidney	 is	 formed	 by	 excessive	
deposition	of	constituents	of	the	interstitial	matrix	(e.g.	collagen	I,	III,	V,	VII,	XV,	
fibronectin),	components	restricted	to	tubular	basement	membranes	in	normal	




proteins	 to	 accumulate	 in	 response	 to	 the	 initial	 damage.	 Fibroblasts,	
myofibroblasts,	Mϕ,	mesangial	and	 tubular	 cells	are	 sources	of	 fibronectin	 151;	
152.	 Other	 upregulated	 components	 include	 hialuronic	 acid	 153;	 154,	 secreted	
protein	 acidic	 and	 rich	 in	 cysteine	 (SPARC),	 thrombospondin	 (TSP)	 155;	 156,	
decorin	and	biglycan	157;	158.	
Certain	 types	 of	 CKD	 are	 caused	 by	 a	 marked	 alteration	 of	 renal	 collagenase	
activity	with	 little	 or	 no	 changes	 in	 collagen	 synthesis.	 Renal	 fibrosis	 in	mice	
with	 unilateral	 ureteric	 obstruction	 (UUO)	 is	 also	 the	 result	 of	 decreased	




by	 down‐regulating	 the	 expression	 of	 matrix	 metalloproteinases	 (MMP)	 and	
activating	the	expression	of	the	MMP‐inhibitor	plasminogen	activator	inhibitor	
1	 (PAI‐1)160.	 Also	 tissue	 inhibitor	 of	 matrix	 metalloproteinases	 (TIMP)‐1,	 an	
endogenous	 tissue	 inhibitor	 of	MMPs,	 is	 actively	 synthesized	 by	 renal	 cells	 in	
progressive	 CKD	 161,	 and	 its	 expression	 is	 stimulated	 by	 TGF‐β,	 TGF‐α,	
epidermal	growth	factor	(EGF),	PDGF,	TNF‐α,	IL1,	IL‐6,	oncostatin	M,	endotoxin,	
and	 thrombin82.	 However,	 its	 role	 is	 controversial	 as	 TIMP‐1	 deficient	 mice	
show	 no	 significant	 differences	 in	 interstitial	 fibrosis	 during	 induced	 renal	
damage	162;	163.	
In	wound‐healing	studies,	an	anti‐fibrotic	role	for	Mϕ	is	described,	due	to	their	




in	 experimental	 obstructive	 nephropathy	 is	 accompanied	 by	 enhanced	 renal	
interstitial	 fibrosis	 and	 pro‐fibrotic	 activity	 166.	 However,	 longer‐term	 studies	
reveal	 a	 reciprocal	 relationship	 between	 these	 two	 parameters,	 and	 raise	
questions	about	 the	 function	of	 infiltrating	cells	 167.	Thus,	Mϕ	probably	play	a	


















This	 introductory	 chapter	 summarizes	 the	 key	 pathophysiological	 events	 of	
CKDs	compromising	 renal	 excretory	 function,	 at	 the	 tissue,	 cell	 and	molecular	
levels.	CKD	may	occur	as	a	result	of	 injury	to	the	glomeruli,	 the	tubules	or	the	
renal	vessels.	Most	of	the	diseases	in	each	of	these	groups	have	specific,	but	also	
common	 pathophysiological	 characteristics	 resulting	 from	 increasingly	
understood	mechanisms	 of	 action.	Moreover,	 all	 these	 diseases,	 regardless	 of	
aetiology,	 eventually	 affect	 all	 parts	 of	 the	 nephron	 and	 enter	 an	 irreversible	
course.	As	 the	 disease	progresses,	 a	more	uniform	pathophysiological	 pattern	




in	 patients	 with	 ESRD	 remains	 10‐20	 times	 higher	 than	 that	 in	 the	 general	
population.	 There	 is	 no	 cure	 for	 CKD;	 the	 natural	 course	 of	 the	 disease	 is	 to	
progress	 towards	 ESRD	 and	 death,	 unless	 RRT	 is	 implemented.	 It	 is	 essential	
then,	that	earliest	possible	diagnosis	is	critical	for	prognosis.	The	focus	in	recent	
years	 has	 shifted	 to	 optimizing	 the	 care	 of	 these	patients	 during	 the	phase	 of	
CKD,	 and	 to	 slow	progression	with	 the	 aim	of	 avoiding	 the	 necessity	 of	 renal	
replacement	therapy	during	the	patient's	lifespan.		
Present	 treatments	 for	 CKD	 are	 only	 reasonably	 effective	 at	 slowing	
progression.	 Treatments	 are	 given	 substantially	 after	 irreversibility	 ensues,	
mostly	 because	 clear	 pathological	 signs	 only	 arise	 after	more	 than	 half	 of	 the	
nephrons	 are	 functionally	 nulled.	 In	 many	 cases,	 it	 is	 possible	 to	 slow	 the	
progression	 of	 CKD	 to	 ESRD	 if	 kidney	 disease	 is	 diagnosed	 and	 treated	 in	 its	
earlier	stages.	The	necessity	 for	aggressive	blood	pressure	control	 in	CVD	and	
CKD	 patients	 is	 undisputed.	 As	 discussed,	 current	 treatments	 for	 proteinuric	
renal	 diseases	 focus	 on	 blood	 pressure	 control	 via	 blockade	 of	 the	 renin‐
angiotensin	 system168	 primarily	 with	 RAS	 blockers	 169.	 Thus,	 early	 CKD	







Thus	 in	 chronic	 disease,	 an	 initial	 insult	 to	 the	 kidney,	 whether	 by	 injury	 or	
infection,	 is	 not	 repaired	 but	 rather	 leads	 to	 persistent,	 irreversible	
inflammation,	sclerosis	and	necrosis.	This	no‐return	point	in	the	fate	of	injured	
kidneys	probably	holds	the	key	to	a	conceptual	 therapeutic	drift	 from	slowing	
progression	 towards	 regression	 and,	 along	with	 a	 sufficiently	 early	 diagnosis,	
prevention	of	entering	the	vicious	cycle	of	deterioration.		
This	 thesis	 therefore	 aims	 to	 identify	 and	 investigate	 potential	 cellular	 and	
molecular	 targets	 and	 renoprotective	 agents	 capable	 of	 preserving	 renal	
structure	and	function	and/or	reversing	damage	and	improving	proteinuria.		
1.3.1 Protecting	the	glomerulus	from	podocyte	loss	and	effacement	
Molecular	 insights	 have	 established	 the	 podocyte	 as	 a	 key	 component	 of	 the	
glomerular	 filtration	barrier,	and	hence	have	progressively	gained	attention	in	
glomerulopathies.	 The	 specialised	 structure	 of	 podocytes	 creates	 a	 filter	 (see	
section	 1.4.1.2	 podocyte	 structure	 and	 function).	 Pathological	 podocyte	
involvement	 is	 mainly	 the	 consequence	 of	 podocytopenia	 resulting	 from	
podocyte	 apoptosis	 and	 EMT,	 or	 foot	 process	 effacement	 and	 alterations	 in	
podocyte	dynamics	96;	139;	140.		
1.3.1.1 Podcytopenia	
The	 loss	 of	 α3β1	 integrin	 anchoring	 of	 podocyte	 foot	 processes	 to	 the	 GBM,	
followed	by	podocyte	detachment	(podcytopenia)	and	shedding	into	the	urine	is	
now	recognized	as	an	early	pathologic	feature	in	the	progression	of	glomerular	
diseases	 (including	 experimental	 and	 human	 diabetes	 170;	 171)	 to	
glomerulosclerosis	172.	Loss	of	these	cells	is	believed	to	cause	the	adhesion	of	a	
glomerular	 capillary	 to	 Bowman's	 capsule	 at	 a	 podocyte	 deprived	 basement	
membrane	point.	These	adhesions	create	spaces	in	the	parietal	epithelium	that	
allow	 ectopic	 filtration	 out	 of	 Bowman's	 capsule	 into	 the	 paraglomerular,	
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interstitial	 space,	 which	 may	 be	 extended	 over	 the	 glomerulus	 and	may	 also	
initiate	 tubulo‐interstitial	 injury.	 In	 human	 diabetic	 nephropathy	 and	 IgA	
nephropathy,	 decreased	 podocyte	 number	 correlates	 significantly	 with	 poor	
prognosis	173;	174.	These	data	suggest	that	podocyte	injury	is	critical	not	only	in	
podocyte‐specific	 diseases	 such	 as	 MCNS	 and	 FSGS	 but	 also	 in	 podocyte‐
nonspecific	diseases	such	as	IgA	and	DN.	 




podocyte	 175.	 By	 delineating	 molecular	 mechanisms	 leading	 to	 these	 cellular	




flattening	of	 foot	processes	due	 to	gradual	 simplification	of	 the	 interdigitating	
foot	process;	the	whole	podocyte	appears	flattened	due	to	retraction,	widening,	
and	 shortening	 of	 the	 processes	 of	 each	 podocyte	 while	 the	 frequency	 of	
filtration	 slits	 is	 reduced,	 giving	 the	 appearance	 of	 a	 continuous	 cytoplasmic	
sheet	 covering	 the	 glomerular	 basement	 membrane.	 These	 cells	 may	 also	
become	 detached	 from	 the	 GBM	 which	 then	 forms	 a	 ‘tuft	 adhesion’	 to	 the	
parietal	 cells	of	Bowman’s	 capsule,	 leading	 to	misdirected	 filtration	of	protein	
from	 the	 denuded	 capillary	 to	 the	 periglomerular	 or	 peritubular	 space.	 This	
results	 in	degeneration	of	 the	affected	tubule,	 interstitial	 fibrosis	and	eventual	
sclerosis	176.	The	podocytes	restricted	capacity	to	replicate	and/	or	repair	may	
underlie	 the	 tendency	 for	 glomerular	 diseases	 to	 progress	 to	 scarring	
(glomerulosclerosis)	177.	
	
Effacement,	 injury	 or	 loss	 of	 cells	 results	 in	 perturbations	 in	 the	 complex	






as	 seen	 in	 thrombotic	 microangiopathy	 or	 anti‐GBM	 disease,	 respectively.		
However	in	the	majority	of	glomerular	diseases,	podocyte	loss	or	effacement	is	
a	frequent	finding.		Human	acquired	proteinuric	glomerulopathies,	such	as	DN,	






become	 an	 area	 of	 increasing	 interest	 in	 renal	 pathophysiology.	 	 There	 are	
several	 lines	 of	 evidence	 to	 demonstrate	 the	 mechanism	 by	 which	 podocyte	
effacement	occurs.	In	experimental	models,	podocytes	are	highly	susceptible	to	




target	 of	 complement‐mediated	 immune	 injury	 in	 membranous	 nephropathy	






immune	 complex–initiated	 injury	 in	 thymic	 stromal	 lymphopoietin	 transgenic	
mice	 that	 develop	 cryoglobulinemia	 and	 membranoproliferative	
glomerulonephritis.	Expression	of	mRNA	encoding	Toll‐like	receptor	(TLR)‐1,	‐




deletion	 of	 an	 inhibitory	 Fc	 receptor	 (FcRIIb).	 TLR‐4	 expression	 is	 found	 on	
podocytes	in	nephritic	glomeruli,	and	in	vitro	studies	using	immortalized	mouse	
podocytes	demonstrate	induction	of	chemokine	expression	in	response	to	lipid	




actively	 to	 recruitment	 of	 inflammatory	 cells	 and	 glomerular	 injury	 by	
upregulating	 TLR‐4	 and	 production	 of	 pro‐inflammatory	 chemokines	 in	
response	to	stimulation	by	either	endogenous	or	exogenous	TLR‐4	ligands.	
In	rat	PAN	nephropathy‐	used	as	a	model	of	idiopathic	nephrotic	syndrome,	and	
murine	 adriamycin	 (ADR)	 nephropathy,	 direct	 oxidative	 mechanisms	 induce	
podocyte	 foot	 process	 effacement183	 	 and	 apoptosis184	 leading	 to	 proteinuria,	
and	 have	 provided	 insights	 into	 the	 cellular	 and	 intracellular	 mechanisms	 of	
podocyte	 injury	 disease.	 Sustained	 proteinuria	 gives	 rise	 to	 tubulo‐interstitial	
injury,	 eventually	 leading	 to	 renal	 failure	 185. Second,	 podocyte	 injury	 impairs	
mesangial	 structure	 and	 function.	 In	 anti‐Thy‐1	 GN,	 the	 induction	 of	 minor	
podocyte	 injury	 with	 PAN	 pre‐treatment	 results	 in	 an	 irreversible	 mesangial	
alteration	186.	In	addition,	cysteine‐rich	protein	61	(Cyr61),	a	potent	angiogenic	
protein	 that	 belongs	 to	 the	 CCN	 family	 of	 matrix‐associated	 secreted	 protein	



















endocytosis	 193.	Protein	overload,	both	 in	vivo	 194	and	 in	vitro	 195;	 196,	has	been	
shown	to	 induce	podocyte	de‐differentiation	and	rearrangement	of	 the	F‐actin	
cytoskeleton,	in	addition	to	stimulating	upregulation	of	TGFβ.	
Pro‐inflammatory	 cytokines	 and	 oxidative	 stress	 are	 also	 causes	 of	 podocyte	
damage	 and	 de‐differentiation	 197;	 198;	 199.	 Stress–tension	 caused	 by	 increased	
intraglomerular	 pressure	 seen	 in	 e.g.	 systemic	 hypertension	 and	 diabetic	 and	
non‐diabetic	 nephropathy	 can	 lead	 to	 podocyte	 injury	 200;	 201.	 Various	 soluble	
factors	 such	 as	 the	 vasopressor	 Ang	 II	 have	 also	 been	 shown	 to	 induce	
alterations	or	damage	to	podocytes	by	inducing	depolarization	202,	cytoskeletal	
rearrangements	 203,	 and	 stimulation	 of	 TGFβ	 204.	 Furthermore,	 in	 murine	
podocyte	 cell	 lines	 these	 effects	 are	 paralleled	 with	 increased	 albumin	
permeability	 across	 podocyte	 monolayers205.	 For	 example,	 Ang	 II	 and	 high	
glucose	 exposure	 increase	 podocyte	 production	 of	 TGF‐β1	 206	 and	 vascular	
endothelial	growth	factor	(VEGF)	207.		
Lastly,	 endothelins	 (ETs),	 a	 family	 of	 structurally	 related	 vasoconstrictor	
peptides,	 also	 have	 implicated	 roles	 as	 both	 a	 stimulus,	 and	 a	 product	 of	








The	 endothelins	 are	 potent	 vasoconstrictor/pressor	 peptides.	 There	 are	
currently	3	known	isoforms	encoded	by	distinct	genes	(EDN1,	EDN2	and	EDN3),	
of	which	ET‐1	is	the	most	potent	and	widely	distributed	209.	ET‐1	was	originally	
characterised	 from	 the	 culture	 supernatant	 of	 porcine	 aortic	 endothelial	 cells	
and	 consists	 of	 21	 amino	 acid	 residues	 with	 two	 sets	 of	 intrachain	 disulfide	
linkages	 208.	Human	EDN1	 encodes	 the	212	amino	acid	peptide	ET1	precursor	





induced	by	 various	 stimuli	 212;	 213,	 each	 acting	 in	 certain	 cells	 and	 tissues	 and	
each	are	regulated	by	different	transcription	factors.	These	include	Ang	II,	pro‐
inflammatory	 cytokines	 (TNF‐α,	 IL‐1b),	 hypoxia,	 ROS,	 pro‐fibrotic	 cytokines	
(TGF‐β,	 PDGF)	 and	others.	Gene	 transcription	 is	 inhibited	by	prostacyclin,	NO	
and	the	natriuretic	peptides.		
EDN1	 is	under	the	transcriptional	control	of	a	TATA	box‐containing	promoter.	
Within	 the	proximal	promoter,	a	 functional	activator	protein	1	 (Ap‐1)	site	has	
been	identified,	which	can	be	bound	by	the	c‐fos	and	c‐jun	transcription	factors.	
This	 promotes	 the	 transcription	 of	 EDN1	 in	 response	 to	 various	 stimuli,	
including	 phorbol	 esters,	 thrombin,	 Ang	 II	 and	 insulin,	 which	 signal	 through	
different	 pathways, including	 protein	 kinase	 C	 (PKC)	 and	 c‐jun	 N‐terminal	
kinase	 (JNK)	 pathways	 for	 transcriptional	 control	 of	 a	 TATA	 box‐containing	
promoter.	 Other	 regulatory	 elements	 in	 the	 proximal	EDN1	 promoter	 include	
binding	 sites	 for	 GATA	 family	 transcription	 factors	 TGFβ,	 activated	 SMAD	
transcription	factors	and	hypoxia‐inducible	factor	1	(HIF‐1). 
ET‐1	 is	 produced	 by	 a	 variety	 of	 cell	 types	 including	 vascular	 smooth	muscle	
cells,	 cardiomyocytes	 and	 epicardial	 cells,	 glial	 cells	 and	pituitary	 cells	 209;	 214,	





responses	 via	 stimulation	 of	 two	 G‐protein	 coupled	 receptors	 (GPRCs);	 the	
endothelin	A	receptor	(ETAR)	and	endothelin	B	receptor	(ETBR)	216;	 217.	Tissue	
distribution	 of	 receptor	 subtypes	 varies,	 but	 both	 are	widely	 expressed.	 ETAR	
are	 found	 primarily	 on	 VSMCs	 and	 interaction	 with	 ET‐1	 causes	
vasoconstriction.	 ETBR	 are	 found	on	VSMCs	 and	ECs	where	 their	 activation	 is	
principally	 involved	 in	 vasodilatation	 via	 the	 release	 of	 NO	 and	 prostacyclin.	




accurately	 reflect	 ET‐1	 production.	 Some	ET‐1	 is	 released	 into	 the	 circulation	
and	the	ETBR	also	acts	to	clear	this	circulating	ET‐1.		
The	 result	 of	 the	 ET‐1	 ligand	 binding	 to	 ETBR	 is	 complex	 internalization	 and	
intracellular	degradation,	accounting	for	the	majority	of	clearance,	particularly	
in	the	pulmonary	219	and	renal	213;220	circulation.	Therefore,	reductions	in	ETBR	





synthesis	 221.	 Within	 the	 renal	 system,	 ETs	 are	 involved	 in	 the	 regulation	 of	
various	 functions	 including	 vasoconstriction	 222,	 natriuresis/diuresis	 223;	 224,	
inflammation	 and	 fibrosis	 225.	 	 ET‐1	 is	 produced	 by	 glomerular	 epithelial,	







and	 glomerular	 filtration	 rate	 through	 constriction	 of	 glomerular	 afferent	 and	
efferent	 arterioles.	 ETAR	 are	 predominantly	 located	 in	 cells	 of	 the	 renal	
vasculature	 throughout	 the	 cortex	 and	 medulla,	 including	 the	 large	 arcuate	
arteries,	 adjacent	 veins	 and	 arterioles,	 the	 vasa	 recta	 and	 glomeruli	 229.	
Activation	of	ETAR	leads	to	constriction	of	pre‐glomerular	arteries	and	efferent	
arterioles	 230	 and	 proliferation	 of	mesangial	 cells	 231.	 ETBR	 are	 predominantly	
located	 in	 the	 collecting	ducts	 229,	 and	 function	predominantly	 in	Na+	 and	K+	
excretion	232.		
1.3.4 Therapeutic	intervention	by	ET	receptor	blockade	
Various	 ET	 receptor	 antagonists	 are	 currently	 under	 investigation	 and	 have	
provided	further	insight	as	to	the	role	and	actions	of	ET‐1	and	the	ET	receptors.	
The	ET	receptor	antagonists	were	originally	licenced	for	and	are	used	primarily	
in	 the	 treatment	 of	 pulmonary	 arterial	 hypertension	 (PAH)	 (reviewed	 by	
Humbert	et	al.	2015	233).	PAH	patients	have	higher	plasma	and	lung	ET‐1	levels	
than	 controls.	 Excessive	 ET‐1	 could	 be	 due	 to	 increased	 production,	 reduced	
clearance	or	a	combination	of	the	two	processes	in	the	lung	vasculature	234;	235;	
236.	Furthermore,	ET‐1	levels	in	the	circulation	correspond	to	severity	of	disease	
and	 prognosis	 237;	 238;	 239.	 In	 experimental	 pulmonary	 hypertension	 the	 same	
trend	of	increased	ET‐1,	ETAR,	and	ETBR	expression	can	be	seen	240;	241;	242.		
Receptor	 antagonists	 are	 classified	 as	 either	 ETAR	 or	 ETBR	 selective,	 or	 non‐
selective	 ETA/BR	 antagonists.	 There	 is	 significant	 debate	 as	 to	 whether	 a	
selective	ETAR	or	mixed	ETA/BR	antagonist	has	most	benefit.	
1.3.4.1 ET‐1	antagonism	in	hypertension	
In	 addition	 to	 the	 observations	 in	 PAH,	 in	 humans,	 systemic	 studies	 using	
bosentan	(dual	ETA/BR	antagonist)	and	darusentan	(selective	ETAR	antagonist)	
in	hypertensive	patients	caused	significant	reduction	of	blood	pressure	(BP)	243;	
244.	 In	 a	 study	 by	 Haynes	 et	 al.	 (1996)	 245	 BQ123	 has	 been	 shown	 to	 cause	
arterial	 vasodilation	 in	 both	 healthy	 volunteers	 and	 hypertensive	 patients.	
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BQ123	 is	 a	 synthetic	 derivative	 of	 BE	 18257B,	 a	 product	 of	 Streptomyces	
misakiensisis	 and	 is	 a	 cyclic	 pentapeptide	 that	 is	 highly	 selective	 for	 the	 ETA	
receptor	 (IC50:	 ETA	 =	 7.3	 nM)	 246.	 Studies	 with	 radiolabelled	 BQ123	




In	 animal	 models	 of	 hypertension,	 selective	 ETAR	 antagonists	 BQ123	 and	
darusentan	 were	 shown	 to	 decrease	 mean	 arterial	 pressure	 (MAP).	 The	
nonselective	 ET	 antagonists	 bosentan	 and	 SB209670	 also	 lowered	 BP	 in	 the	




vasorelaxation.	 Because	 the	 two	 receptors	 have	 synergistic	 and	 alternate	




ETA	 and	 non‐selective	 ETA/B	 receptor	 blockade	 are	 variable,	 the	 relative	
beneficial	effects	of	selective	versus	non‐selective	ET	receptor	blockade	remain	
to	be	determined.			
Furthermore,	 evidence	 suggests	 that	 ET‐1	 is	 involved	 in	 the	 pathogenesis	 of	
renal	 disease.	 Urinary	 ET‐1	 reflects	 renal	 ET‐1	 production.	 In	 salt‐dependent	
models	 of	 experimental	 hypertension	 such	 as	 Deoxycorticosterone	 acetate	
(DOCA)‐salt	 hypertension	 or	 Dahl	 salt‐sensitive	 rats,	 renal	 ET	 synthesis	 is	







and	 in	 combination	 in	 healthy	 subjects	 and	 patients	with	 CKD.	 Both	 selective	
ETAR	and	 combined	ETA/BR	 antagonism	 significantly	 reduces	BP	 and	 systemic	
vascular	resistance	 in	CKD	patients	compared	healthy	subjects.	These	changes	
were	not	consistent	with	renal	vasoconstriction.	Combined	ETA/BR	antagonism	
had	no	effect	on	 renal	blood	 flow	 (RBF)	or	 renal	vascular	 resistance,	whereas	
selective	 ETAR	 antagonism	 produced	 an	 increase	 in	 RBF.	 The	 results	 of	 this	
study	showed	the	possible	renoprotective	effect	of	selective	ETAR	antagonism	as	
there	 was	 also	 reduced	 filtration	 fraction	 and	 proteinuria,	 suggesting	




and	 GN.	 The	 effects	 of	 ET	 receptor	 antagonism	 have	 been	 investigated	 in	
hypertensive	 renal	 disease,	 ETAR	 antagonism	 results	 in	 a	 reduction	 in	
proteinuria	 and	 glomerulosclerosis	 in	 a	 renal	 mass	 reduction	 rat	 model	 of	
hypertensive	nephropathy253.	Since	 these	early	studies,	many	other	preclinical	
data	 have	 emerged	 confirming	 the	 renoprotective	 effects	 of	 both	 ETAR	 and	
ETA/BR	 antagonism	 in	 several	 forms	 of	 experimental	 hypertension	 and	 have	
been	 reviewed	 elsewhere	 254.	 Opocensky	 et	 al.	 255	 demonstrated	 that	
hypertensive	 rats	 also	 developed	 podocyte	 injury,	 an	 effect	 observed	 prior	 to	
the	 development	 of	 proteinuria.	 Treatment	 with	 atrasentan	 (selective	 ETAR	
antagonist)	 prevented	 podocyte	 injury	 and	 reduced	 proteinuria	 whilst	
hypertension	 persisted	 255,	 an	 effect	 not	 seen	 with	 bosentan	 (mixed	 ETA/BR	







In	 models	 of	 DN	 mixed	 ETA/BR	 antagonists	 showed	 reduced	 proteinuria,	
glomerular	 injury	 and	 hypertension	 258;	 259.	 When	 comparing	 ET	 receptor	
antagonists	to	ACE	inhibitors,	ET	receptor	antagonists	were	not	superior	to	ACE	
inhibitors	when	measuring	proteinuria	 as	 an	endpoint,	 however	 some	 studies	
demonstrated	 equal	 efficacy	 260;	 261.	 Overall,	 ACE	 inhibitors	 were	 superior	 in	
efficacy	 262,	 however	 the	 combination	 of	 ACE	 inhibition	 with	 ET	 receptor	
antagonism	is	additive	260.	ET	receptor	antagonists	also	affect	glomerular	injury	
and	 inflammation	 in	 models	 of	 DN.	 In	 streptozocin‐induced	 DN,	 ETAR	
antagonism	 resulted	 in	 reduced	 expression	 of	 ICAM‐1	 and	 monocyte	 chemo‐
attractant	 protein	 (MCP‐1),	 whilst	 preserving	 expression	 of	 nephrin	 263.	
Furthermore,	 the	 selective	 ETAR	 antagonist	 sitaxentan	 reduced	 renal	 Mϕ	
infiltration	and	expression	of	pro‐inflammatory	cytokines	in	different	models	of	
DN262;	 264.	 These	 BP‐independent,	 anti‐inflammatory	 and	 podocyte	 protective	
effects	of	ET	receptor	antagonism	may	provide	additional	longer‐term	benefits	
in	DN.	
As	 noted,	 studies	 investigating	 ET	 receptor	 antagonism	 have	 largely	 been	
performed	 in	animal	models	of	either	hypertension	or	DN,	and	 there	are	very	
few	 studies	 in	 inflammatory	 GN.	 The	 following	 studies	 in	 rats	 demonstrated	
similar	effects	of	ET	receptor	antagonism.	Studies	in	immune	complex	GN	using	
a	mixed	 ETA/BR	 antagonist	 demonstrated	 reduced	 proteinuria	 and	 glomerular	
injury265.	In	Anti‐Thy1	nephritis	using	a	selective	ETAR	antagonist	demonstrated	
reduced	 glomerular	 cell	 proliferation231.	 Similarly,	 studies	 in	 membranous	
nephropathy	 using	 an	 ACE	 inhibitor	 and	 ETAR	 antagonist,	 alone	 and	 in	
combination	 demonstrated	 reduced	 proteinuria,	 lower	 serum	 creatinine	 and	
less	glomerular	and	tubulointerstitial	injury.	Combination	therapy	was	found	to	
be	 more	 effective	 to	 either	 intervention	 alone266.	 Finally,	 studies	 examining	
Heymann	 nephritis	 using	 an	 ACE	 inhibitor,	 an	 ARB,	 and	 an	 ETAR	 antagonist	
alone	 and	 in	 combination,	 demonstrated	 a	 similar	 reduction	 in	 BP.	 The	 ACE	
inhibitor	 was	 more	 effective	 in	 reducing	 proteinuria	 and	 glomerulosclerosis.	
ETAR	antagonism	had	an	additive	effect	when	used	 in	 conjunction	with	either	
the	ACE	 inhibitor	or	 the	ARB	267.	Whether	ET	receptor	antagonists	are	able	 to	
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alter	 Mϕ	 infiltration	 and	 function	 and	 podocyte	 biology	 in	 GN	 has	 not	 been	
assessed.	 Finally,	 a	 single	 study	 to	 assess	 renal	 inflammation	 by	 ETR	
antagonism	 exists	 in	 the	 context	 of	 lupus	 nephritis.	 This	 study	 shows	 that	
urinary	ET‐1	as	a	reflection	of	renal	ET‐1	synthesis	268	269	is	increased	in	those	
with	 renal	 inflammation.	 Urinary	 ET‐1	 levels	 decreased	 following	 successful	
treatment	of	the	inflammation.		
1.3.4.3 ET‐1	antagonism	in	podocytes	
Podocytes	 have	 been	 shown	 to	 express	 both	 ETAR195	 and	 ETBR270	 in	 rodents.	




an	 albumin	 (or	 IgG)	 load	 leads	 to	 disruption	 of	 the	 actin	 cytoskeleton	 and	
activation	 of	 focal	 adhesion	 kinase	 (FAK).	 This	 activates	 transcription	 of	 pre‐




CD2AP	 and	 synaptopodin.	 Of	 these,	 nephrin	 particularly	 is	 often	 used	 in	
experimental	 models	 as	 a	 marker	 of	 podocyte	 injury.	 In	 vitro	 studies	
demonstrate	 that	 glomerular	 endothelial	 cells	 incubated	 with	 pre‐eclamptic	
sera	 induced	 ET‐1	 production.	 Treatment	 of	 murine	 podocytes	 with	 this	
conditioned	sera	induced	shedding	of	nephrin	272.	Furthermore,	infusion	of	ET‐1	
into	 rats	 caused	 nephrin	 excretion	 into	 the	 urine	 263.	 In	 both	 instances	 these	
effects	were	inhibited	by	ETA	receptor	antagonism.	
In	 addition	 to	 the	 studies	 previously	 mentioned	 (section	 1.3.4.2	 ET‐1	
antagonism	 in	CKD),	 there	 is	 further	evidence	 that	 the	beneficial	 effects	of	ET	
antagonists	 may	 be,	 in	 part,	 due	 to	 protection	 of	 podocyte	 structure	 and	







ET‐1	 is	 known	 to	 be	 involved	 in	 the	 regulation	 of	 various	 functions	 including	
vasoconstriction222,	 natriuresis	 and	 	 diuresis	 223;	 224	 and	 importantly	 in	
inflammation	and	fibrosis	225.	Mϕ	infiltration	is	a	near	universal	feature	of	renal	
disease	 and	 is	 involved	 in	 both	 progression	 and	 resolution	 of	 renal	 injury.	
Although	the	data	 is	 limited,	Mϕ	are	believed	to	have	an	ET‐1	system.	Human	
Mϕ	 have	 been	 shown	 to	 express	 ETBR,	 but	 there	 is	 currently	 no	 data	
demonstrating	 the	 presence	 of	 the	 ETAR	 276.	 In	 human	 and	 animal	 studies	
activated	Mϕ	have	been	shown	to	synthesise	ET‐1	in	response	to	LPS,	phorbol	




in	 instances	 of	 chronic	 inflammation,	 ET‐1	 promotes	 the	 pro‐inflammatory	





















ETA	and	ETB	 receptors	are	present	on	 the	surface	of	podocyte	cells	 in	humans	
and	 in	 animals	 270;	 273.	 Inflammatory	 cytokines	 and	proteinuria	 augment	 renal	
ET‐1	 production	 286.	 ET‐1	may	 therefore	 cause	 podocyte	 effacement	 by	 direct	
interaction	 with	 the	 cells,	 and	 a	 resultant	 increase	 in	 ET‐1	 production.	
Furthermore,	activated	Mϕ	have	been	shown	to	synthesize	ET‐1,	and	ET‐1	may	
activate	and	be	chemotactic	for	Mϕ/monocytes	277	280.	The	pathophysiology	of	
the	 ET	 system	 in	 renal	 disease	 is	 not	 yet	 fully	 understood,	 there	 is	 a	 body	 of	



















derived	Mϕ.	We	hypothesise	 that	 ET‐1	will	mediate	 podocyte	 effacement	 and	
macrophage	 inflammation.	 We	 further	 aim	 to	 investigate	 the	 mechanism	 by	



















































All	 experiments	 in	 this	 study	 utilise	 a	 conditionally	 immortalized	 human	
podocyte	 cell	 line	 initially	 described	 by	 Saleem	 et	 al.	 (2002)287.	 Briefly,	 cells	
were	cultured	under	growth‐permissive	conditions	to	promote	cell	propagation	
as	 a	 cobblestone	 phenotype	 (undifferentiated)	 in	 uncoated	 75‐cm2	 flasks	
(Falcon;	BD	Biosciences,	Bedford,	MA)	at	33°C	(5%	CO2)	in	RPMI	1640	medium	
supplemented	 with	 10%	 foetal	 bovine	 serum	 (FBS),	 insulin,	 transferrin,	
selenium	(Sigma	Chemicals,	Dorset,	UK),	L‐glutamine,	100	µl/ml	penicillin	and	
0.1	mg/ml	 streptomycin	 (P/S).	 Cells	were	 grown	 to	 70‐80%	 confluence,	 then	
trypsinized	for	5	min	and	re‐suspended	in	supplemented	media.	The	cells	were	
then	 centrifuged	 300	 x	g,	 supernatant	 removed,	 and	 cell	 pellet	 re‐suspended.	
The	 cells	 were	 seeded	 into	 fresh	 flasks	 at	 a	 dilution	 of	 between	 1:3	 and	 1:5,	
and/or	 seeded	 to	 varying	 sizes	 (depending	 on	 the	 assay)	 of	 uncoated	 tissue	
culture	 plates.	 	 Cells	 were	 seeded	 onto	 type	 I	 rat	 tail	 collagen	 coated	 glass	
coverslips	for	immunofluorescence	studies.	To	induce	differentiation,	podocytes	
were	maintained	 in	non‐permissive	 conditions	 at	 37°C	 (5%	CO2)	 to	 inactivate	
the	temperature	sensitive	SV40	T	antigen.	Experiments	were	conducted	on	day	
14	 of	 differentiation.	 In	 this	 culture	 condition,	 cells	 were	 identified	 as	
differentiated	podocytes	by	their	arborized	morphology	under	light	microscopy	








All	 experiments	 with	 Mϕ	 were	 of	 human	 peripheral	 blood	 mononuclear	 cell	
(hPBMC)	 origin.	 Blood	 was	 taken	 under	 the	 remit	 of	 an	 on‐going	 clinical	
research	 trial	 for	which	ethical	approval	was	obtained.	Blood	was	drawn	by	a	
qualified	phlebotomist	 also	 registered	 in	 the	 trial.	 Consent	was	obtained	 from	
healthy	 volunteers	 in	 each	 case.	 For	 each	 experiment	 160ml	 of	 peripheral	
venous	blood	was	drawn	from	a	single	volunteer.	Sodium	citrate	(0.31%)	was	
used	as	an	anti‐coagulant.	Blood	was	centrifuged	at	350	x	g	for	20	min	at	room	
temperature.	 The	 top	 layer	 of	 platelet	 rich	 plasma	 (PRP)	 was	 removed.	






and	 the	 upper	 layer	 containing	 monocytes	 was	 obtained	 following	
centrifugation	at	720	x	g	for	20	min.	Cells	were	re‐suspended	in	1	x	PBS	(‐)	and	
centrifuged	at	230	x	g	 for	6	min.	Cells	were	counted	using	a	haemocytometer	
with	 trypan	 blue	 exclusion.	 Cells	 were	 re‐suspended	 in	 serum	 free	 Iscove’s	
modified	Dulbecco’s	medium	(IMDM)	(4x106/well)	and	purified	by	adhesion	in	
culture	flasks	for	90	min	at	37°C.	Non‐adherent	cells	were	removed	and	medium	
replaced	by	 fresh	 IMDM	containing	10%	autologous	 serum.	 Serum	 containing	
medium	 was	 changed	 every	 2–3	 days.	 After	 4‐6	 days	 of	 culture,	 monocytes	
acquired	a	Mϕ	phenotype	288.	Cells	were	used	on	d7	for	all	experiments.		
2.1.2 ET‐1	stimulation	assay	
To	 investigate	 the	 effect	 of	 exogenous	 ET‐1	 administration	 on	 podocytes	 and	
Mϕ,	 confluent	 differentiated	 cells	 were	 exposed	 for	 2‐48	 hours	 to	 medium	
alone,	or	 in	 the	presence	of	5‐50,000	pg/ml	of	ET‐1	depending	on	 the	specific	
assay.		The	cell	supernatant	was	then	removed	and	centrifuged	at	13,000	x	g	for	








ET‐1	 in	 supplemented	media	was	measured	at	0h	and	after	48h	 incubation	at	
37°C	(5%	CO2)	standard	culture	conditions.		
2.1.4 ET‐1	quantification	
ET‐1	 protein	 from	 cell	 supernatants	 was	 assessed	 by	 standard	
radioimmunoassay	(RIA)	(Peninsula	Laboratories	Europe,	St	Helens,	UK)	using	
125I	radiolabelling	252;	 289;	 290.	Either	standard	compounds	or	unknown	samples	
(100µl)	 were	 added	 to	 100µl	 of	 antiserum	 (Peninsula	 Laboratories	 Inc.,	
Belmont,	CA)	diluted	in	phosphate	buffer,	pH	7.2	(RIA	buffer),	at	a	final	dilution	




anti‐rabbit	 IgG	 and	 polyethylene	 glycol)	 for	 30	 min	 at	 room	 temperature.	
Finally,	 500µl	 of	 RIA	 buffer	 was	 added	 to	 the	 stop	 reaction,	 and	 the	
immunoprecipitates	 were	 centrifuged	 at	 5000	 x	 g	 for	 30	 min.	 Supernatants	
were	discarded,	and	pellet	radioactivity	detected	by	γ‐counter	(Beckman,	Irvine,	
CA).	 Results	were	 expressed	 as	 pg/ml	 quantities.	 The	 sensitivity	 of	 the	 assay	
was	1	fmol/tube	with	inter‐	and	intra‐assay	coefficients	of	variation	of	13%	and	
9%,	 respectively.	 Cross‐reactivity	 with	 endothelin‐3	 and	 non‐endothelin	
peptides	was	less	than	1%.	
2.1.5 Enzyme‐linked	immunosorbent	assay	(ELISA)		
The	 detection	 of	 cytokines	 were	 performed	 by	 capture	 ELISA	 according	 to	
manufacturers	 protocol	 (ELISA	 Duoset,	 R&D	 Systems).	 Briefly,	 96	 well	 ELISA	




and	 incubated	overnight	at	 room	 temperature.	Wells	were	 then	aspirated	and	
washed	 with	 wash	 buffer	 (x3).	 Antibodies	 were	 then	 blocked	 by	 addition	 of	
300μL	 reagent	 diluent	 to	 each	well	 and	 incubated	 at	 room	 temperature	 for	 a	
minimum	of	1	hour.		Plates	were	then	washed	(x2)	with	wash	buffer	and	100μL	
of	sample	or	standards	in	reagent	diluent	were	added	per	well.	Plates	were	re‐
sealed	 and	 incubated	 for	 2	 hours	 at	 room	 temperature.	 Following	 sample	
incubation	plates	were	washed	(x2)	in	wash	buffer	then	100μL	of	the	detection	
antibody	diluted	in	reagent	diluent	was	added.	Plates	were	incubated	for	2h	at	
RT.	 Plates	 were	 washed	 (x2)	 with	 wash	 buffer	 then	 100μL	 of	 the	 working	
dilution	of	Streptavidin‐HRP	was	added	to	each	well.	Plates	were	re‐sealed	and	
incubated	 for	 20	min	 at	 RT.	 Plates	 were	 washed	 (x2)	 with	 wash	 buffer	 then	
100μL	of	Substrate	Solution	was	added	to	each	well	and	incubate	for	20	min	at	
RT.	 Finally,	 50μL	 of	 Stop	 Solution	 was	 added	 to	 each	 well.	 Samples	 were	
quantified	 by	 optical	 densitometry	 at	 450nm	 (Molecular	 device	 spectra	 340	
microplate	 reader,	 USA)	 and	 GEN5	 software,	 and	 standard	 curve	 generated	
using	 Microsoft	 Excel	 software.	 Cytokines	 measured	 were	 IL‐6	 (9.38‐600	




receptor	 antagonism	 on	 ET‐1	 induced	 ET‐1	 and	 cytokine	 protein	 production	
were	 conducted	using	 the	 selective	ETAR	antagonist	BQ‐123	 	 (IC50:	ETA	=	7.3	
nM)	 246	 (1µM)	 (Merck	 Biosciences,	 Beeston,	 Nottingham),	 246;	 252	 and	 BQ‐788	
(0.1µM)	 (IC50:	 ETB	 =	 18	M)	 246	 (Merck	Biosciences,	 Beeston,	Nottingham),	 a	
selective	 ETBR	 antagonist.	 The	 doses	 used	were	 based	 on	 previous	 studies	 as	
















in	 PBS	 	 (‐)	 for	 10	 min.	 Non‐specific	 binding	 sites	 were	 blocked	 with	 block	
solution	(4%	FBS	+	2%	bovine	serum	albumin	(BSA)	+	0.1%	Tween	x	20	(Sigma)	
in	 PBS	 (‐))	 for	 30	 min.	 Coverslips	 were	 washed	 x1	 in	 PBS	 (‐).	 Primary	
antibodies:	polyclonal	mouse	α	human	ETA	and	ETB	 receptor	 (Sigma)	 (1:200),	
polycolonal	mouse	α	human	nephrin	(Sigma)	(1:200),	rabbit	α	human	podocin	
(Santa	 Cruz)	 (1:200),	 polyclonal	 goat	 α	 human	 Synaptopodin	 (1:200)	
Rhodamine	 conjugated	 Phalloidin	 (Biotium)	 (5units/	 300µl),	 and	 isotype	





Nuclei	 were	 stained	 for	 5	 sec	 with	 methanolic	 4',6‐diamidino‐2‐phenylindole	
(DAPI).	Coverslips	were	washed	x3	 in	dH2O	and	mounted	on	glass	 slides	with	
VECTASHIELD	(Vector	Labs)	mounting	medium	for	 fluorescence.	 Images	were	







cell	 lysis	 buffer	 (1%	 saponin	 (Sigma),	 75	 mM	 NaCl,	 5	 mM	
ethylenediaminetetraacetic	 acid	 (EDTA),	 50	 mM	 Tris	 (pH	 7.6),	 1	 mM	
phenylmethylsulfonyl	fluoride	(PMSF),	1	µg/ml	aprotinin,	1	µg/ml	leupeptin,	1	
µg/ml	pepstatin,	1	mM	Na	Orthovanadate)	at	4°C	for	20	min.	Cells	were	scraped	







was	 determined	 colorimetrically	 at	 720nm	 (Molecular	 device	 spectra	 340	
microplate	reader,	USA).		
2.1.10 SDS‐PAGE	and	Western	blot		
Following	 whole	 protein	 content	 quantification	 samples	 were	 diluted	 to	 1µg	
total	 protein/	 µl,	 and	 Laemmli	 Buffer	 (LB)	 added	 (1:5)	 and	 denatured	 by	
heating	to	95C.	25µl	(20µg	total	protein)	was	loaded	onto	9%	sodium	dodecyl	
sulfate–polyacrylamide	 gels	 and	 electrophoresed	 (SDS‐PAGE)	 under	 standard	
conditions	 (120V,	 1h).	 Following	 running,	 gels	 were	 equilibrated	 in	 transfer	




and	 ETBR	 (Sigma;	 1:200;	 each	 50kDa),	 rabbit	 α‐	 human	 podocin	 (Santa	 Cruz;	
1:200;	42kDa)	and	mouse	α‐β‐actin	(Sigma,	1:10,000;	50kDa).	Membranes	were	









manufacturers	 instructions.	 Briefly,	 cells	 were	 lifted	 using	 trypsin	 and	
centrifuged	13,000	x	g.	The	cell	pellet	was	then	washed	(x2)	with	PBS	(‐).		The	




ethanol	 (70%)	 and	 vortexing.	 Precipitated	 RNA	 was	 then	 loaded	 onto	
Nucleospin	silica	membrane	columns	and	centrifuged	at	11,000	x	g	for	30s.	Salt	
residues	 on	 silica	 membranes	 containing	 bound	 RNA	 were	 then	 removed	 by	
incubation	(1min)	with	membrane	desalting	buffer	(MDB)	and	centrifugation	at	
11,000	x	g	for	30s.	DNA	was	then	digested	by	addition	of	95μl	of	reconstituted	
DNAse	 to	 the	 membrane	 for	 15	 min	 at	 room	 temperature.	 Following	 DNA	




was	 determined	 by	 A260/A280	 values	 being	 1.7‐2.0.	 Similarly,	 A260/A230	
values	between	1.3‐1.7.	RNA	was	then	diluted	to	100ng/µl	in	nuclease‐free	H2O.	
1µg	 total	 RNA	 was	 reverse	 transcribed	 using	 MultiScribe	 RT	 Kit	 (Promega)	
according	 to	 manufacturers	 instructions.	 Briefly	 10μl	 (100ng/µl)	 RNA	 was	
added	 to	 10µl	 2X	RT	Mix	 containing	 2	 µl	 10X	RT	 buffer,	 0.8µl	 25X	 dNTP	Mix	
(100mM),	2µl	10X	RT	Random	Primers,	1µl	MultiScribe	RT,	1µl	RNAse	Inhibitor	






	In	each	PCR	reaction,	2µl	 cDNA	 template	was	added	 to	12.5µl	2X	PCR	master	
mix	 containing	 Taq	 DNA	 polymerase	 (pH	 8.5),	 400μM	 of	 each	 dATP,	 dGTP,	
dCTP,	dTTP	and	3mM	MgCl2.	Additionally,	1μl	sense	and	1μl	antisense	primers,	
and	 8.5μl	 nuclease‐free	 H2O	were	 added.	 Amplification	was	 carried	 out	 using	
the	following	PCR	program:	Denaturation‐	94ºC	for	5	minutes	Annealing‐	94ºC	
for	30	sec,	56ºC	for	30	sec,	72ºC	for	30s	(35	cycles)	Extension‐	72ºC	for	5min	




loaded	 in	 to	 the	 first	 lane.	 The	 samples	 were	 electrophoresed	 at	 120V	 for	
approx.	 30mins,	 and	 visualised	 under	 UV	 light.	 The	 product	 sizes	 are	 ETAR‐















































medium	 (IMDM	 +	 10%	 autologous	 serum	 +	 1%	 P/S),	 counted	 using	 a	
haemocytometer,	 centrifuged	at	350	x	g	 for	5	min,	 supernatant	discarded	and	
cell	pellet	re‐suspended	in	at	1x106/ml.	100μl	(100,000	cells)	of	cell	suspension	





was	 removed	and	 cells	were	washed	 x2	 in	dH2O	and	visualised	under	 a	Zeiss	
inverted	 fluorescence	 microscope.	 Low	 power	 images	 were	 captured	 using	




Mature	 Mϕ	 were	 treated	 with	 dexamethosone	 (DEX)	 (100ng/ml)	 as	 positive	
control,	 ET‐1	 (10‐1000	 pg/ml)	 or	 media	 alone	 for	 24h	 in	 assay	 medium	















to	 addition	 of	 ET‐1	 (30‐30,000	 pg/ml)	 for	 2h	 and	 24h	 in	 assay	 medium	
containing	 (IMDM	 +	 10%	 autologous	 serum	 +	 1%	 P/S).	 CQ	 or	 NZ	 plus	 ET‐1	
(3000	pg/ml)	alone	(no	Mϕ)	were	also	incubated	as	internal	controls.	
2.1.15 Mϕ	protease	inhibitor	assay	
Mature	Mϕ	were	 treated	with	 protease	 inhibitors	 (PI)	 (1	 tablet/50ml;	 Roche	
Diagnostics	Ltd,	Welwyn	Garden	City,	UK)	2h	prior	to	addition	of	ET‐1	(30‐3000	



















serum	 (NTS)‐induced	nephritis	 in	 rats	 292.	 This	 is	 a	 basic	 experimental	model	
first	 described	 by	 Masugi	 and	 colleagues293,	 that	 resembles	 human	 diffuse	
glomerulonephritis	 (GN).	 Briefly,	 in	 this	 model	 the	 GN	 is	 induced	 by	 the	
injection	 of	 a	 rabbit	 antibody	 raised	 against	 rat	 GBM.	Within	 hours	 from	 the	
injection	 of	 the	 anti‐GBM	 antibody,	 the	 initial	 heterologous	 phase	 of	 the	
nephritis	takes	place.	It	is	mediated	by	the	binding	of	the	heterologous	antibody	
to	the	rat	GBM.	Proteinuria	also	occurs	in	this	heterologous	phase	and	coincides	
with	 the	 binding	 of	 rabbit	 antibody	 to	 the	 GBM	 294;	 295;	 296.	 Furthermore,	 a	
complement‐dependent	 attraction	 of	 polymorphonuclear	 leucocytes	 to	 the	
glomeruli	also	occurs	297.		
Schreiner	 et	 al.	 298,	 In	 a	 model	 of	 nephrotoxic	 nephritis	 resembling	 the	




The	 nephritic	 effects	 of	 NTS	 in	 different	 species	 and	 strains	 can	 vary	
significantly	 its	ability	 to	 induce	proteinuria,	hypertension,	crescent	 formation	
etc	299.	These	experiments	were	conducted	in	Sprague‐Dawley	rats	to	determine	
whether	 a	 selective	 ETAR	 antagonist	 sitaxsentan	 (STX),	 would	 ameliorate	
proteinuria,	hypertension,	and	renal	inflammation	and	fibrosis.	









with	1mg	of	 rabbit	 IgG.	NTN	was	 induced	by	 single	 i.v.	 injection	 of	 1ml/200g	
nephrotoxic	 serum	 (NTS)	 containing	 rabbit	 anti‐rat	 glomerulus	 antibodies	
under	 halothane	 anesthesia	 (Zeneca,	 Macclesfield,	 UK).	 Three	 days	 prior	 to	
induction	 of	 NTN	 animals	were	 treated	with	 either	 selective	 ETAR	 antagonist	
STX	 (30mg/kg)	 or	 placebo	 by	 gavage,	 and	 every	 day	 thereafter	 for	 17d.	 This	
work	 was	 carried	 out	 under	 the	 supervision	 of	 David	 Kluth	 and	 William	
Mungall.		
2.2.1.2 	Production	of	nephrotoxic	serum	
Nephrotoxic	 serum	 contains	 high	 titres	 of	 anti‐rat	 GBM	 antibodies	 and	 was	
produced	 by	 immunisation	 of	 rabbits	with	 homogenate	 of	 rat	 glomeruli.	 	 Rat	
GBM	antigen	was	prepared	 from	 frozen	kidneys	of	 Sprague‐Dawley	 rats.	 	 The	
capsules	were	 removed	 from	 the	 kidney	 and	 the	 renal	 cortex	dissected	 away.		
The	glomeruli	were	purified	from	the	renal	cortex	by	sieving	through	meshes	of	
250m,	 150m	 and	 63m	 diameter	 with	 the	 glomeruli	 caught	 by	 the	 63m	
sieve.	 	Glomeruli	were	recovered	into	ice	cold	PBS	and	the	suspension	spun	at	
500	rpm	for	5	minutes	 in	a	 Jouan	CR	312	centrifuge.	 	This	washing	procedure	
was	repeated	on	2	more	occasions.	 	The	glomeruli	were	 then	sonicated	on	 ice	
for	 3‐5	 minutes	 until	 complete	 disruption	 of	 glomeruli	 was	 confirmed	 by	
microscopic	examination.	 	The	sonicated	glomeruli	were	washed	x2	 in	PBS	(‐)	
followed	 by	 centrifugation	 at	 (1000	 rpm,	 5	 min).	 	 The	 GBM	 pellet	 was	
lyophilised	and	stored	at	–20C	until	use.		
	
Nephrotoxic	 serum	 was	 raised	 in	 New	 Zealand	 white	 rabbits.	 	 They	 were	
initially	 immunised	with	 subcutaneous	 injection	 of	 1	mg	 of	 prepared	 GBM	 in	
1ml	 of	 Freund’s	 complete	 adjuvant	 (Sigma,	 Poole,	 Dorset,	 UK)	 and	 then	 at	 2	
weekly	intervals	the	rabbits	were	boosted	with	1mg	of	GBM	in	1ml	of	Freund’s	




This	 was	 assessed	 by	 determining	 the	 binding	 of	 dilutions	 of	 the	 serum	 to	
cryostat	sections	of	normal	rat	kidney	followed	by	staining	with	anti‐rabbit	IgG	
FITC	(Sigma,	Poole,	Dorset,	UK).	 	A	titre	of	at	 least	1:1000	was	required	and	if	
this	 level	 was	 obtained	 the	 animals	 were	 boosted	 on	 one	 further	 occasion	 2	
weeks	 later	 and	 the	 rabbits	 the	 sacrificed	 by	 cardiac	 puncture	 under	
anaesthesia.	 	The	blood	was	centrifuged	at	2500	rpm	in	Jouan	CR	312	and	the	
serum	removed.		Complement	within	the	serum	was	heat	inactivated	by	heating	
to	 56C	 for	 30	minutes.	 	 The	 serum	was	 then	 absorbed	 against	 rat	 red	 blood	
cells	at	4C	overnight	and	then	repeated	for	1	hour	at	room	temperature.	 	The	









3‐5	 days.	 14d	 after	 treatment,	 the	 animals	 were	 sacrificed	 by	 cervical	
dislocation.	Prior	to	sacrifice,	a	minimum	of	1ml	of	blood	from	the	tail	vein	was	
collected	 into	 sodium	citrate.	Blood	was	 centrifuged	 (300	x	g)	 for	10	min	and	
the	serum	removed	and	stored.	The	urinary	and	serum	albumin	and	creatinine	
concentrations	 were	 determined.	 Albuminuria	 was	 expressed	 as	 an	 albumin	











measurements	 were	 performed	 by	 Forbes	 Howie.	 Measurement	 of	 serum	
albumin	 was	 based	 on	 its	 quantitative	 binding	 to	 bromocresol	 green	 (BCG).	
Albumin‐BCG‐complex	 absorbs	 maximally	 at	 578nm,	 the	 absorbance	 being	
directly	proportional	 to	 the	concentration	 in	 the	sample.	Within	 run	precision	
was	CV	<	2.5%	while	intra‐batch	precision	was	CV	<	4%.	
	
Serum	 creatinine	 was	 determined	 using	 the	 creatininase/creatinase	 specific	






Rats	were	pre‐	heated	 in	a	 chamber	at	35	 °C	 for	5	min,	 then	placed	on	a	heat	
blanket.	A	cuff	with	a	pneumatic	pulse	sensor	was	attached	to	the	tail.	Rats	were	
allowed	to	habituate	to	this	procedure	for	7d	prior	to	experiments.	BP	and	HR	
values	 were	 recorded	 on	 a	 Model	 MK‐2000	 with	 heating	 and	 were	 averaged	
from	three	consecutive	readings	obtained	from	each	rat.		
2.2.1.6 Mϕ	infiltration	immunohistochemistry	
Glomerular	 Mϕ	 infiltration	 in	 NTN	 animals	 was	 assessed	 by	
immunohistochemical	(IHC)	staining	for	ED‐1	(CD68)	a	rat	Mϕ	marker.	Kidneys	






5	 min.	 IHC	 staining	 was	 performed	 using	 the	 streptavidin–biotin–peroxidase	
method	 using	 the	 Vectastain	 Avidin‐Biotin	 Complex	 (ABC)	 kit	 for	 peroxidase	
(rabbit	 IgG)	 (Vector	 Laboratories,	 Burlingame,	 USA)	 according	 to	 the	
manufacturer's	 protocol.	 Briefly,	 antigen	 was	 retrieved	 by	 citrate	 treatment	







counterstained	 with	 haematoxylin,	 cleared	 through	 to	 xylene,	 and	 mounted	
using	 DPX	 mounting	 medium.	 Slides	 were	 viewed	 under	 LM.	 Images	 (50	
glomeruli	identified	morphologically	per	slide)	were	taken	using	a	Spot	2	slider	
digital	 camera	 (Diagnostic	 Instruments	 Inc.,	 Sterling	 Hts.	 MI),	 and	 analysed	
using	 Image	 J	 software.	 ED‐1	 positive	 cells/glomerulus	 were	 counted,	 and	
glomerluar	 areas	 measured.	 Data	 are	 expressed	 as	 ED‐1	 positive	
cells/glomerular	area	(100μm2).	
2.2.1.7 Glomerular	sclerosis‐	Picrosirius	Red	staining	
Glomerular	 sclerosis	 in	 NTN	 animals	 was	 assessed	 by	 picrosirius	 red	
histological	stain	for	collagen	fibres.	Kidneys	from	STX	and	placebo	treated	rats	












LM.	 Images	 were	 taken	 using	 a	 Spot	 2	 slider	 digital	 camera	 (Diagnostic	
Instruments	 Inc.,	 Sterling	Hts.	MI),	 and	analysed	using	 semi‐quantitave	 colour	
image	analysis	in	photoshop.	Briefly,	a	range	of	red	pantones	were	determined.	
This	colour	spectrum	was	 identified	 in	each	 image	and	recorded	as	red	pixels.		
The	 relative	 red	pixel	number	 to	 total	 pixel	 number	was	 then	determined	 for	
each	image.	 	10	 images	from	random	fields	were	taken	per	slide.	The	data	are	



























receptor	 (DTR)	 under	 the	 control	 of	 the	 CD11b	 promoter	 on	 an	 FVB	






Diptheria	 toxin	 (DT) (1.0mg)	 (List	Biological	Laboratories,	Campbell,	CA)	was	
reconstituted	with	 1.0ml	 sterile	 distilled	water	 and	 then	 diluted	 to	 2ng/ml	 in	
sterile	PBS.	DT	(20ng/g	i.p)	was	administered	to	mice	to	induce	monocyte/	Mϕ	
depletion	 in	CD11b‐DTR	transgenic	mice	and	FVB	strain	controls	24h	prior	 to	
experiments.	 This	 dose	 of	 DT	 was	 chosen	 based	 on	 previous	 studies.	 The	
original	 studies	 by	 Duffield	 et	 al.	 302	 using	 this	 model	 in	 the	 context	 of	 liver	
fibrosis	used	does	of	DT	between	10ng/g	and	25ng/g.	Further	studies	from	the	
Duffield	 lab	 by	 Guo	 et	 al.	 303	 used	 mice	 transgenic	 for	 thymic	 stromal	
lymphopoietin	 (TSLP),	 under	 regulation	 of	 the	 lymphocyte‐specific	 promoter	
Lck.	These	Lck‐TSLP	transgenic	mice	also	expressed	the	human	diphtheria	toxin	
receptor	 (DTR)	 under	 control	 of	 the	monocyte/macrophage‐restricted	 CD11b	
promoter	 (Lck‐TSLP;CD11b‐DTR).	 Treatment	 with	 20ng/g	 DT	 resulted	 in	 a	
marked	 reduction	of	monocytes/macrophages	 in	 the	peritoneal	 cavity	of	both	















Whole	 mouse	 blood	 was	 assessed	 by	 flow	 cytometry.	 Briefly,	 to	 avoid	
coagulation	30l	of	3.9%	sodium	citrate	was	taken	up	into	a	p100	pipette	set	at	
60l.	Mouse	tails	were	nicked	using	a	scalpel.	A	further	30l	of	blood	was	then	
taken	 up	 into	 the	 pipette	 to	 give	 a	 total	 volume	 of	 blood	 and	 citrate	 of	 60l.	
Citrate	anticoagulated	blood	was	aliquoted	(20l)	 into	FACS	staining	tubes.	To	
allow	 careful	 characterisation	 of	 inflammatory	 and	 resident	 monocytes	 a	
combination	 of	 lymphocyte	 antigen	 6C	 (Ly6C)	 to	 represent	 inflammatory	
monocytes,	Ly6G	to	represent	neutrophils,	CD115	to	represent	total	monocytes	
and	CD11b	to	represent	total	leukocytes	is	used	(table	2.2).	Antibodies	to	stain	
mouse	 blood	 were	 prepared	 into	 a	 mastermix	 depending	 of	 the	 number	 of	





5min	 at	 4C.	 The	 supernatant	 fraction	 was	 then	 discarded	 and	 cells	 were	


































Initially,	 polymorphonuclear	 cells	 (PMC)	 were	 gated	 on	 the	 basis	 of	 size	 or	
forward	 scatter	 (FSC)	 and	 granularity	 or	 side	 scatter	 (SSC)	 profiles.	 The	 un‐
gated	 population	 represents	 small	 less	 granular	 lymphocytes	 (Fig	 2.1A).	 This	
‘PMN’	population	was	 then	plotted	against	CD11b	and	Ly6G.	 	Co‐positive	cells	
are	 inversely	 gated	 out	 and	 labelled	 as	 neutrophils	 (Fig	 2.1B).	 CD11b	 single	
positive	 Ly6G	 negative	 populations	 were	 labelled	 CD11b+	 (Fig	 2.1C).	 Both	
‘Neutrophil’	 and	 CD11b+	 populations	were	 then	 displayed	 on	 FSC	 SSC	 plot	 of	
the	 entire	 blood	 sample,	 to	 ensure	 they	were	 represented	 in	 the	 appropriate	
place	(Fig	2.1D).	Neutrophils	(blue)	are	approximately	the	same	size	but	more	
granular	 than	 the	 CD11b+	 cells	 (orange).	 This	 was	 to	 be	 expected	 and	 the	
analysis	 continued.	 The	 remaining	 CD11b+	 cells	 are	 expected	 to	 represent	
monocytes.	 This	 was	 ensured	 by	 plotting	 CD115	 against	 Ly6C‐	 a	 monocyte	
specific	marker	 (Fig	2.1E)	Co‐positive	 cells	 are	 considered	Ly6C	+	monocytes.	
The	 profile	 is	 expected	 to	 show	 3	 distinct	 monocyte	 populations	 1)	 Ly6C	 hi	
CD115	hi	2)	Ly6	intermediate	CD	115	low	and	3)	Ly6C	lo	CD115	hi.	The	blood	
sample	 in	 these	 experiments	 always	 showed	 an	 anomalous	 population	 (gated	
population	in	Fig	2.1E).	When	this	population	was	shown	on	the	FSC	SSC	profile	
of	 the	whole	 blood	 sample,	 these	 cells	 appeared	where	 neutrophils	would	 be	
expected	(Fig	2.1F).	These	cells	were	labelled	as	Ly6C+	neutrophils	(blue)	with	
the	 likelihood	 of	 the	 Ly6C	 antibody	 cross	 reacticting	 with	 Ly6G	 (neutrophil	
marker)	 antibody.	 This	 population	 was	 then	 gated	 out,	 and	 the	 remaining	
ungated	population	were	labelled	Ly6	C+	neutrophil	‐	(orange).	This	population	
were	CD11b+,	CD115+,	Ly6C+	and	 therefore	 represented	monocyte	 cells.	This	
remaining	population	was	gated	into	1)	Ly6C	hi,	CD115	hi	2)	Ly6	intermediate,	


















A‐C	FACS	plots	of	 stained	whole	mouse	blood.	 (A)	PMNs	 initially	gated	on	 the	






















D	 FACS	 plots	 of	 stained	 whole	 mouse	 blood.	 (D)	 ‘CD	 11b+’	 (orange)	 and	

























plotted	 against	 CD115	 and	 Ly6C.	 An	 anomalous	 population	 appeared	 (gated	
population).	 (F)	 The	 anomalous	 (gated)	 population	 visualised	 on	 FSC	 SSC	 of	
whole	blood	sample.	The	size	and	granularity	of	 this	population	suggests	 they	
are	 neutrophils	 not	 monocytes.	 This	 population	 was	 gated	 out	 and	 labelled	
Ly6C+	 neutrophil+	 (blue).	 The	 remaining	 population	 was	 labelled	 Ly6C+	




























G	 FACS	 plot	 of	 stained	 whole	 mouse	 blood	 showing	 (G)	 The	 pure	 monocyte	
population	 labelled	 Ly6C	 +	 neut	 ‐	 plotted	 against	 CD115	 and	 Ly6C	 and	 gated	








assessed	 by	 immunohistochemical	 (IHC)	 staining	 for	 F4/80	 a	 murine	 Mϕ	
marker.	 Organs	 from	 DT	 and	 placebo	 treated	 mice	 were	 removed	 24h	 post	
DT/saline	 injection,	 formalin	 fixed	 and	 paraffin	 wax	 embedded.	 4μm	 serial	
sections	 were	 cut	 and	mounted	 onto	 poly‐l‐lysine	 coated	 slides.	 IHC	 staining	
was	 performed	 using	 the	 streptavidin–biotin–peroxidase	 method	 using	 the	
Vectastain	Avidin‐Biotin	Complex	(ABC)	kit	for	peroxidase	(rabbit	IgG)	(Vector	
Laboratories,	 Burlingame,	USA)	 according	 to	 the	manufacturer's	 protocol	 (see	
section	 2.2.1.6).	 Primary	 antibody	 (F4/80;	 Santa	 Cruz	 Biotechnology)	 was	




Mice	 were	 initially	 anaesthetized	 with	 Thiobutabarbital	 (100mg/kg	 i.p.).	
Following	 this	a	 tracheotomy	was	performed	and	 the	 jugular	vein	and	carotid	
artery	were	cannulated	for	administration	of	drugs	and	bp	measurement.	
Briefly,	 a	 small	 incision	 (1.5–2	 cm)	 was	 made	 in	 the	 neck	 of	 the	 mouse	 for	
tracheostomy.	 A	 slit	 incision	was	 then	made	 in	 the	mouse	 platysma	muscles.	
The	trachea	was	then	identified	and	a	small	incision	was	made	on	the	cartilage	












with	 along	 with	 the	 catheter	 304.	 After	 cannulation,	 the	 cannulation	 line	 is	
flushed	with	normal	saline	(0.1	ml)	to	prevent	thrombosis	305;	306	






filled	 with	 heparinized	 normal	 saline	 (0.5	 IU/ml).	 The	 opposing	 end	 of	 the	
cannula	was	connected	to	a	three‐way	stopcock/saline	filled	tuberculin	syringe.	
Then	 the	 carotid	 artery	 cannulation	 site	 was	 tied.	 After	 cannulation,	 the	 tied	
suture	at	the	cardiac	end	of	the	blood	vessel	was	released	slowly,	ensuring	that	
there	was	no	bleeding	at	the	cannulation	site.		
The	 three‐way	 stopcock	 was	 connected	 to	 the	 pressure	 transducer	 and	 a	
syringe	filled	with	heparinized	saline.	The	heparinized	saline	aids	in	application	
of	 a	 positive	 pressure	 to	 maintain	 it	 at	 the	 baseline	 value.	 The	 three‐way	
stopcock	 works	 as	 a	 bridge	 connecting	 the	 carotid	 cannula	 and	 the	 pressure	
transducer.	 During	 the	 experiment,	 the	 positive	 pressure	 is	 to	 be	 blocked	 to	
avoid	 transmission	 of	 BP	 to	 the	 syringe.	 The	 pressure	 transducer	 unit	 of	 the	
student	 physiograph/data	 acquisition	 system	 (AD	 instruments)	 converts	 BP	
into	 an	 electrical	 signal.	 The	 animals	 are	 allowed	 to	 stabilize	 for	 10–20	min,	
during	 this	 time	 the	 animals	 are	 also	 monitored	 for	 any	 bleeding	 and	
respiratory	 problems.	 Following	 this	 stabilisation,	 baseline	 recordings	 are	







30	minutes	 after	 surgery	 the	 effect,	 duration	 of	 the	 action	 of	 the	 drugs	were	
observed	 and	 recorded.	 First,	 The	 lowest	 dose	 of	 ET‐1	 (0.01	 nmol/kg)	 is	
injected	i.v.	and	b.p	is	recorded	over	a	20‐minute	period.	The	second	dose	(0.1	
nmol/kg)	is	injected,	followed	20	minutes	later	by	the	highest	dose	(1nmol/kg).	
The	 final	 drug	 to	 be	 administered	 was	 ang	 II	 (1nmol/kg).	 After	 each	 drug	
administration,	 the	 BP	 of	 the	 animal	 was	 allowed	 to	 return	 to	 the	 normal	
baseline	value.	Following	these	experiments	the	animals	were	then	sacrificed	by	
cervical	dislocation,	and	tissues	were	harvested	for	further	analysis.	This	work	






























Representative	 traces	 of	 BP	 response	 to	 ET‐1	 at	 1nmol/kg.	 Following	 ET‐1	
administration	(Arrow)	a	classic	dip	in	ET‐1	is	observed.	Following	this,	a	rapid	









Students	 T‐test,	 1‐way	 analysis	 of	 variance	 (ANOVA)	 with	 post‐hoc	 Dunnetts	
comparisons,	or	2‐way	ANOVA	with	pairwise	comparisons	using	bonferroni	or	































































Various	 ET	 receptor	 antagonists	 are	 currently	 under	 investigation	 and	 have	
provided	further	insight	as	to	the	role	and	actions	of	ET‐1	and	the	ET	receptors.	
Receptor	 antagonists	 are	 classified	 as	 either	 ETAR	 or	 ETBR	 selective,	 or	
nonselective	ETA/BR	antagonists.	The	majority	of	studies	using	ETR	antagonists	
are	 performed	 in	 models	 of	 hypertensive	 nephropathy	 and	 diabetic	
nephropathy	with	few	in	models	of	GN.	This	chapter	will	investigate	the	use	of	a	
selective	ETAR	antagonist	sitaxsentan	(STX)	as	a	renoprotective	agent	in	vivo	in	
a	 telescoped	 model	 of	 rat	 NTN.	 The	 immediate	 or	 heterologous	 phase	 of	
nephrotoxic	nephritis	 is	 characterised	by	 the	accumulation	of	PMCs,	primarily	
neutrophils	within	the	glomeruli,	hypertension	and	overt	proteinuria	307;	308;	309.	
Proteinuria	 then	 rapidly	 declines	 and	 the	 autologous	 phase	 commences,	
whereby	 less	 obvious	 glomerular	 polymorph	 accumulation	 also	 occurs,	 and	




We	 hypothesise	 that	 STX	 treatment	 will	 reduce	 BP	 in	 STX	 treated	 animals.	







I. Rats	were	pre‐	 immunised	with	s.c.	 injection	7d	prior	to	 induction	of	NTN	
with	1mg	of	rabbit	IgG.		
II. Three	 days	 prior	 to	 induction	 of	 NTN	 animals	 were	 treated	 with	 either	
selective	ETA	antagonist	sitaxsentan	(30mg/kg)	or	placebo	(n=5	per	group)	
(gavage)	and	every	day	thereafter	for	17d.	
III. NTN	was	 induced	 by	 single	 i.v.	 injection	 of	 1ml/200g	 nephrotoxic	 serum	
(NTS)	 containing	 rabbit	 anti‐rat	 glomerulus	 antibodies	 under	 halothane	
anaesthesia	(AstraZeneca,	Macclesfield,	UK).		
IV. Rats	were	weighed	 daily	 and	 housed	 in	metabolic	 cages	 and	 timed	 urine	
collections	were	made	every	2‐3	days.	
V. Blood	 pressure	 was	 recorded	 by	 tail	 cuff	 plethysmography	 prior	 to	 STX	
treatment	and	thereafter	every	3‐4	days.	Rats	were	allowed	to	habituate	to	
this	measurement	procedure	for	3d	prior	to	experiments	to	ensure	accurate	
BP	not	 related	 to	 stress	 responses.	BP	and	HR	values	were	 recorded	on	a	
Model	MK‐2000	and	were	averaged	from	three	consecutive	readings.		
VI. 14	days	after	NTN	 induction,	animals	were	culled,	and	blood	collected	 for	
analysis.	 The	 final	 urine	 sample	 was	 collected	 and	 kidneys	 removed	 for	
analysis.	Urinary	and	serum	albumin	and	creatinine	were	analysed.	
VII. Kidneys	were	 formaldehyde	 (FA)	 fixed	 and	 paraffin	wax	 embedded.	 4μm	
serial	sections	were	cut	and	mounted	onto	poly‐l‐lysine	coated	slides.		
VIII. Renal	 inflammation	was	determined	by	glomerular	Mϕ	 infiltration	by	 IHC	
for	 CD68	 (rat	 Mϕ	 marker),	 and	 determined	 as	 Mϕ	 n/glomeruli	 from	 50	
glomeruli	from	a	representative	section.		
IX. Glomerular	 sclerosis	was	assessed	by	picrosirius	 red	 staining	 for	 collagen	
accumulation.	 Picrosirius	 red	 was	 analysed	 using	 semiquantitave	 colour	
image	 analysis	 using	 Photoshop	 software.	 10	 images	 from	 random	 fields	
were	 taken	per	 slide.	Data	were	 converted	 to	percentage	 red	 staining	per	
image	with	the	mean	of	10	images	calculated.	















































determine	 the	 efficacy	 of	 the	 NTS	 (1ml/200g)	 and	 tolerability	 of	 STX	
(30mg/kg).		
3.3.1 NTS	treated	animals	develop	progressive	glomerulonephritis	
NTN	control	 animals	gained	weight	over	 the	 course	of	 the	experiment	 (d‐3	vs	
d14;	253.2	±	15.7g	vs	301.4	±	20.5g)	(Fig	3.2	A).	On	d1	following	NTS	treatment,	
a	slight	reduction	 in	body	weight	was	observed	along	with	a	rapid	 increase	 in	
urinary	albumin	excretion	(Fig	3.2	B),	consistent	with	the	heterologous	phase	of	
NTN.	 	 Proteinuria	 then	 rapidly	decreases	on	d2.	 From	d3	 and	 thereafter	until	
d14	 the	 animals	progressively	develop	proteinuria	 throughout	 the	 autologous	
phase	of	disease	(d0	vs	d14;	13.7	±	13.4	mg/mmol	vs	350.0	±	403.5	mg/mmol)	
(Fig	 3.2	 B).	 Over	 the	 course	 of	 the	 experiment	 a	 significantly	 increased	BP	 in	
NTS	treated	control	animals	was	also	apparent	(d0	vs	d14;	135	±	14.9	mmHg	vs	
172.4	 ±	 23.8	 mmHg)	 (Fig	 3.2	 D).	 Lastly,	 evidence	 of	 Mϕ	 infiltration	 in	 NTN	
treated	rats	was	apparent	on	d14	(Fig	3.3	A).	
3.3.2 Sitaxsentan	improves	renal	function	and	glomerular	inflammation	
NTN	 animals	 treated	 with	 STX	 also	 gained	 weight	 normally	 throughout	 the	
study	(d‐3	vs	d14;	273.8	±	26.1g	vs	328.8	±	34.0g)	(Fig	3.2	A).	On	d1	following	
NTS	treatment,	a	reduction	in	body	weight	was	also	observed	accompanied	by	a	
less	prominent	 increase	 in	urinary	albumin	excretion	 (Fig	3.2	B)	 compared	 to	
control.	 	As	in	control	animals,	proteinuria	then	rapidly	decreases	on	d2.	From	
d3	and	thereafter	until	d14	the	animals	develop	proteinuria	(d0	vs	d14;	7.2	±	9.5	
mg/mmol	 vs	 210.8	 ±	 118.3	mg/mmol)	 (Fig	 3.2	 B).	 Proteinuria	 appears	 to	 be	
decreased	 compared	 to	 control,	 however	 this	 trend	 was	 not	 statistically	
significant.	 Renal	 function	 measured	 by	 serum	 creatinine	 was	 significantly	
reduced	 in	STX	 treated	animals	compared	 to	control	 (d14	NTN	vs	STX;	73.2	±	
13.2	µmol/l	vs	51.8	±	9.8	µmol/l)	(Fig	3.2	C).	In	these	preliminary	experiments,	
BP	was	unaffected	by	STX	treatment	by	d14	(NTN	Control	vs	NTN	STX;	172.4	±	
23.9	 mmHg	 vs	 164.8	 ±	 21.2	 mmHg)	 (Fig	 3.2	 D).	 Furthermore,	 glomerular	


















































A‐D	Body	weight	 and	measures	 of	 GN.	 (A)	 Control	 animals	 treated	with	NTN	
and	 animals	 treated	 with	 STX	 gained	 weight	 normally	 over	 14	 d	 (B)	 NTS	
treatment	 induces	 progressive	 albuminuria.	 Treatment	 with	 STX	 prevents	
severe	 development	 of	 albuminuria	 over	 14d.	 (C)	 Serum	 creatinine	 (d14)	 is	
significantly	 reduced	 by	 STX	 treatment	 compared	 to	 control.	 (D)	 NTS	 treated	
controls	develop	an	increase	in	BP	in	the	latter	stages	of	disease.	STX	treatment	
did	 not	 significantly	 lower	 blood	 pressure	 by	 d14.	 Serum	 creatinine	 data	 are	
analysed	 by	 Students	 T‐test.	 Data	 are	 mean	 ±	 SD	 (n=5/group)	 Symbols	
displayed	above	bars	represent	significance	compared	to	respective	control	*	p	<	




















































































































(B)	 animals	 treated	 with	 STX	 contained	 demonstrated	 glomerular	 Mϕ	
infiltration	by	ED‐1	staining.	(C)	Mϕ	numbers	in	the	glomeruli	are	significantly	
reduced	by	STX	treatment.	Data	analysed	by	Students’	T‐test.	Data	are	mean	±	




































similar	 findings	with	 additional	measures.	 In	 our	 interim	 experiments	we	 did	
not	detect	a	reduction	in	BP	as	anticipated.	Therefore,	in	these	experiments	we	
acclimatised	the	animals	to	the	tail‐cuff	BP	measurement	procedure	for	7	days	
prior	 to	 the	 first	 measurement	 to	 ensure	 greater	 accuracy	 of	 readings.	









458.9	 ±	 340.4	 mg/mmol).	 Over	 the	 course	 of	 the	 experiment	 a	 significant	
increase	in	BP	in	NTN	controls	was	detected	(d‐1	vs	d14;	156.7	±	8.9	mmHg	vs	





animals	 showed	 no	 significant	 increase	 in	 proteinuria	 and	 no	 body	 weight	
reduction	 on	 d1	 following	 NTS	 treatment	 (Fig	 3.4	 B).	 In	 this	 study	 STX	











In	 addition	 to	 a	 reduction	 in	 blood	 pressure,	 STX	 also	 significantly	 reduced	








































gained	 weight	 normally	 over	 14	 d	 (B)	 NTS	 treatment	 induces	 progressive	
proteinuria.	STX	treatment	does	not	affect	development	of	proteinuria	over	14d.	
(C)	Serum	creatinine	is	not	affected	by	STX	treatment	compared	to	control.	(D)	
NTN	 Control	 animals	 develop	 hypertension.	 Over	 14	 d	 STX	 treatment	
significantly	reduces	BP.	Serum	creatinine	data	are	analysed	by	Students	T‐test.	
Data	 are	 mean	 ±	 SD	 (n=5/group)	 Symbols	 displayed	 above	 bars	 represent	
significance	compared	to	respective	control	*	p	<	0.05,	****	p	<	0.001.	All	Other	data	































































































































































A‐F	Photomicrographs	of	ED‐1	 and	picrosirius	 red	 staining	 for	 (A&D)	Control	
animals	 treated	with	NTN	and	 (B&E)	 animals	 treated	with	 STX	demonstrated	
glomerular	 Mϕ	 infiltration	 by	 ED‐1	 staining.	 (C&F)	 Mϕ	 numbers	 in	 the	
glomeruli	 and	 picrosirius	 red	 staining	 in	 the	 glomerular	 and	 interstitial	
compartments	 are	 significantly	 reduced	 by	 STX	 treatment.	 Data	 analysed	 by	









































































findings	 however,	 we	 were	 unable	 to	 detect	 a	 reduction	 in	 proteinuria	 and	
serum	creatinine.	In	this	last	study	more	severe	disease	developed.	The	animal	
groups	were	 not	 comparable	 to	 the	 previous	 experiments	 and	 have	 therefore	
remained	separated.	
3.5.1 NTS	treated	animals	develop	progressive	proteinuria	
NTN	 control	 animals	 gained	 weight	 over	 the	 course	 of	 the	 treatment	 (d‐3	 vs	
d14;	283.5	21.27g	vs	308	±	25.4g)	(Fig	3.5	A).	On	d1	following	NTS	treatment,	a	
significant	reduction	in	body	weight	was	observed	along	with	a	rapid	increase	
in	 urinary	 albumin	 excretion	 (Fig	 3.5	 B).	 In	 the	 previous	 experiment	 this	
heterologous	phase	was	not	observed.		Proteinuria	then	rapidly	reduces	on	d2.	
From	d3	and	until	d14	the	animals	progressively	develop	severe	proteinuria	(d‐








following	 NTS	 treatment	 (Fig	 3.5	 B).	 The	 animals	 progressively	 developed	




reduced	 compared	 to	NTN	control	 animals	on	days	9	 and	13.	 In	 addition	 to	a	
reduction	 in	 blood	 pressure,	 Mϕ	 infiltration	 in	 STX	 treated	 animals	 was	
significantly	reduced	compared	to	control	(NTN	control	vs	STX	NTN	d14;	39.9	±	
3.4	Mϕ/glom	vs	17.7	±	2.6	Mϕ/glom)	(Fig	3.6	A‐C).	Renal	function	measured	by	























































gained	 weight	 normally	 over	 14	 d	 (B)	 NTS	 treatment	 induces	 progressive	
proteinuria.	STX	treatment	results	in	a	trend	towards	reduced	proteinuria	over	
14d.	(C)	Serum	creatinine	is	not	affected	by	STX	treatment	compared	to	control.	
(D)	 NTN	 Control	 animals	 develop	 hypertension.	 Over	 14	 d	 STX	 treatment	
significantly	reduces	BP.	Serum	creatinine	data	are	analysed	by	Students	T‐test.	
Data	 are	mean	 ±	 SD	 (n=4‐5/group).	 Symbols	 displayed	 above	 bars	 represent	
significance	compared	to	respective	control	*	p	<	0.05,	**	p	<	0.01,	***	p	<	0.005.	All	
other	 data	 analysed	 by	 2‐way	 ANOVA.	 Dotted	 line	 in	 (C)	 represents	 normal	
serum	creatinine.	

















































































































A‐F	Photomicrographs	of	ED‐1	 and	picrosirius	 red	 staining	 for	 (A&D)	Control	
animals	 treated	with	NTN	and	 (B&E)	 animals	 treated	with	 STX	demonstrated	
glomerular	Mϕ	infiltration	by	ED‐1	staining.	(C)	Mϕ	numbers	 in	 the	glomeruli	
are	 significantly	 reduced	by	 STX	 treatment.	 (F)	 STX	 treatment	 does	 not	 affect	
collagen	 deposition	 in	 the	 glomerular	 and	 interstitial	 compartments	 Data	













































































Further	 experiments	 aimed	 to	 reproduce	 the	 pilot	 study	 and	 to	 accurately	
measure	 BP	 by	 acclimatising	 the	 animals	 to	 the	 tail	 cuff	 procedure.	 These	
animals	demonstrated:‐	
 Reduced	hypertension	and	glomerular	Mϕ	infiltration	
 Unable	 to	 detect	 a	 reduction	 in	 proteinuria	 and	 serum	 creatinine	 in	
response	to	STX	treatment.		







The	 results	 of	 these	 experiments	 investigating	 the	 use	 of	 a	 selective	 ETAR	
antagonist	have	suggested	a	role	for	selective	ETAR	antagonism	in	GN	however	
these	 data	 demonstrated	 some	 conflicting	 evidence.	 A	 consistent	 finding	 in	
these	experiments	was	reduced	glomerular	macrophage	 infiltration.	There	are	







ET‐1	 contributes	 to	 hypertension	 and	 CKD.	 In	 experimental	 hypertension	 249	





majority	 of	 the	 pathological	 effects	 of	 ET‐1,	 at	 least	 within	 the	 kidney,	 are	
mediated	via	the	ETAR	229;	230;	231,	with	the	ETBR	functioning	to	clear	circulating	







Hypertension	and	DN	are	 the	 leading	causes	of	CKD,	and	studies	 investigating	
ET	receptor	antagonism	have	largely	been	performed	in	animal	models	of	these	
diseases,	with	very	 few	studies	 in	 inflammatory	GN	 265;231;266;267.	We	 therefore	
utilised	an	in	vivo	model	of	GN,	the	NTN	model	(described	in	Chapter	2	section	
2.1.1)	and	 its	 subsequent	use	 to	study	 the	effect	of	 selective	ETAR	antagonism	
using	 sitaxsentan.	 NTN	 was	 achieved	 by	 administering	 nephrotoxic	 serum	
(containing	 anti‐GBM	 antibodies)	 to	 rats	 pre‐immunised	 with	 rabbit	 IgG.	 In	






Animals	 develop	 hypertension,	 progressive	 proteinuria,	 elevated	 serum	
creatinine,	glomerular	inflammation,	and	glomerular	and	interstitial	fibrosis.	
Initial	 pilot	 studies	 demonstrated	 promising	 results	 with	 the	 selective	 ETAR	
antagonist,	 showing	 a	 significant	 improvement	 in	 renal	 function	 (assessed	 by	
measurement	of	serum	creatinine	levels),	significant	albuminuria	reduction	and	
attenuation	of	glomerular	Mϕ	infiltration.		
3.7.3 Sitaxsentan	 reduces	 hypertension	 and	macrophage	 infiltration	 in	
experimental	nephrotoxic	nephritis	
Hypertension	is	a	hallmark	of	GN	and	is	apparent	in	experimental	NTN.	In	our	
pilot	 studies,	 we	were	 unable	 to	 detect	 a	 reduction	 in	 BP	 in	 response	 to	 the	
ETAR	 antagonist,	 leading	 us	 to	 conclude	 that	 the	 animals	 required	
acclimatisation	 to	 the	 tail	 cuff	 procedure.	 Further	 experiments	 aimed	 to	
reproduce	 the	 pilot	 study	 and	 to	 accurately	measure	 BP	 by	 acclimatising	 the	
animals	to	the	tail	cuff	procedure.	These	animals	also	demonstrated	a	reduction	
in	hypertension	and	glomerular	Mϕ	infiltration.	The	method	of	drug	delivery	in	
this	model	was	 by	 oral	 gavage.	 This	was	 used	 in	 favour	 of	 administration	 via	
drinking	water,	to	better	account	for	the	dose	received	by	each	animal.	Despite	
using	this	technique,	our	 in	vivo	studies	did	not	yield	a	significant	reduction	in	
proteinuria	 and	 renal	 function	 (assessed	 by	 serum	 creatinine)	 in	 response	 to	
STX	 treatment.	 These	 findings	 were	 largely	 unexpected	 and	 have	 been	










to	 quantify	 podocyte	 number,	 we	 used	 a	 monoclonal	 murine	 anti‐	 Wilms’	
tumour‐1	 (WT‐1)	 antibody	 on	 sections	 of	 rat	 kidney.	 This	 antibody	 was	
reported	 to	 cross‐react	with	 rat	WT‐1,	 however	 despite	 using	 several	 antigen	
retrieval	 techniques	 (Sodium	 Citrate	 and	 Borg	 decloaking),	 and	 alternative	
fixatives	 (4%	FA	and	Methylcarnoys),	we	were	unable	 to	detect	nuclear	WT‐1	
staining	 the	 podocytes	 of	 these	 glomeruli,	 with	 only	 weak	 non‐specific	
cytoplasmic	 staining	 apparent.	 Furthermore,	 kidneys	 were	 also	 fixed	 in	
glutaryaldehyde	for	transmission	electron	microscopic	examination	of	podocyte	
structural	abnormalities,	however	 this	EM	service	was	unavailable	at	 the	 time	
when	required,	and	these	studies	were	not	carried	out.	
3.7.5 Glomerular	inflammation	is	reduced	in	STX	treated	NTN	animals	
A	 consistent	 finding	 in	 these	 studies	was	 reduced	 glomerular	Mϕ	numbers	 in	
STX	treated	animals.	These	findings	are	consistent	with	the	literature,	however,	
the	mechanisms	by	which	ETAR	antagonists	 improve	glomerular	 inflammation	
are	 likely	 multifactorial	 and	 investigations	 into	 the	 role	 of	 ET‐1	 and	 ETR	
antagonism	 in	 macrophages	 and	 podocytes	 is	 discussed	 in	 the	 following	
sections.	
3.7.6 Further	Work	
As	 noted,	 studies	 investigating	 ET	 receptor	 antagonism	 have	 largely	 been	
performed	 in	animal	models	of	either	hypertension	or	DN,	and	 there	are	very	
few	 studies	 in	 inflammatory	 GN.	 In	 models	 of	 DN	 mixed	 ETA/BR	 antagonists	
showed	 reduced	 proteinuria,	 glomerular	 injury	 and	 hypertension	 258;	 259.	 ET	
receptor	antagonists	also	affect	glomerular	 injury	and	 inflammation	 in	models	
of	DN.		
In	 a	 previous	 study	 using	 immune	 complex	 GN,	 a	 mixed	 ETA/BR	 antagonist	
demonstrated	 reduced	 proteinuria	 and	 glomerular	 injury265.	 	 Our	 studies	





This	 NTN	 model	 has	 been	 used	 as	 a	 tool	 to	 study	 glomerulonephritis	 292	 is	
notorious	for	its	inconsistency	in	generation	of	disease	severity	and	associated	
mortality.	 This	 is	 most	 likely	 due	 to	 the	 differing	 titres	 of	 anti‐glomerular	
basement	membrane	antibody	between	batches	of	nephrotoxic	serum,	and	that	
the	 titre	 is	 not	 measured.	 The	 nature	 of	 the	 disease	 course,	 from	 an	 acute	
inflammatory	 phase,	 to	 a	 progressive	 phase	 also	 means	 that	 a	 considerable	
degree	of	variability	will	be	apparent	by	the	end	of	the	experiment.	Our	results	
demonstrated	 significant	 variability	 in	 generation	of	disease	 severity.	 Initially,	
an	n	of	six	was	chosen	based	on	preliminary	work	by	our	lab.	Furthermore,	only	
five	 of	 the	 six	 animals	 in	 each	 group	 survived	 the	 experiment.	 While	 these	
studies	were	 deemed	 appropriately	 powered	 at	 the	 outset,	 the	 variability	 has	
shown	that	these	studies	should	be	repeated	with	an	increased	n	to	account	for	
this	variability	and	mortality.		
Future	 studies	 using	 this	 NTN	 model	 would	 benefit	 from	 determination	 of	
urinary	ET‐1	 concentrations,	 to	detect	 the	 effect	 of	ETAR	antagonism	on	 renal	
ET‐1	 production.	 Furthermore,	 an	 additional	 experimental	 group	 using	 a	
calcium	 channel	 blocker	 (Nifedipine,	 Efonidipine,	 Amlodipine)	 as	 an	 active	
blood	pressure	control	should	be	pursued.	This	would	allow	for	comparison	of	
blood	pressure	effects	against	a	known	standard	agent	used	in	the	management	
of	 CKD.	 Expansion	 of	 these	 experiments	would	 also	 include	 a	 Sham	 operated	
group.	 Sham	 controls	 were	 not	 performed	 in	 this	 instance,	 as	 these	 were	
preliminary	experiments	to	determine	the	efficacy	of	Sitaxsentan	in	this	disease	
context,	thus	time	and	funding	constraints	would	not	allow	for	further	analysis.		
As	 proteinuric	 diseases	 vary	 in	 their	 degree	 of	 proteinuria	 and	 associated	
glomerulosclerosis,	 an	 alternative	 in	 vivo	 model	 of	 glomerular	 disease	 using	
ADR	 (doxorubicin)	 nephropathy,	 a	 rodent	 model	 of	 FSGS	 319;	 320	 would	 be	
advantageous.	It	is	characterized	by	rapid	onset	of	glomerular	podocyte	damage	
and	 proteinuria,	 which	 progresses	 to	 segmental	 glomerular	 sclerosis.	
Accompanying	 this	 there	 is	 early	 tubulo‐interstitial	 damage	 with	 subsequent	
tubular	atrophy,	accumulation	of	myofibroblasts	around	damaged	tubules,	and	
interstitial	 fibrosis.	 It	 is	 of	 particular	 interest	 as	 it	 is	 thought	 to	 provide	 an	
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animal	 model	 of	 the	 way	 in	 which	 glomerular	 proteinuria	 is	 associated	 with	
progressive	 tubulo‐interstitial	 scarring	 and	 inflammation.	 This	 model	 would	
allow	for	the	investigation	of	the	effects	of	selective	ETAR	antagonism	on	other	
aspects	of	glomerular	injury	in	addition	to	hypertension	and	proteinuria.		
Histological	 analysis	 of	 podocyte	 number	 is	 desirable	 in	 the	 context	 of	 these	
studies,	however	there	remains	no	rat	equivalent	commercially	available	WT‐1	
antibody.	An	antibody	generated	 in	house	may	be	necessary	 to	perform	 these	
analyses.	 Staining	 of	 podocytes	 for	 SD	 proteins	may	 be	 of	 use,	 but	would	 not	
determine	discrete	cells.	These	would	have	 to	be	semi‐quantitatively	assessed	
by	image	analysis	for	degree	of	expression.	EM	analysis	of	podocyte	structure	in	








of	 tissue	 sections	 to	determine	 the	distinct	 sub	populations	of	 glomerular	Mϕ	
origin	325.	
The	role	of	the	ET	system	in	Mϕ	is	not	well	defined.	The	second	chapter	of	this	
thesis	 investigated	 human	 blood	 monocyte	 derived	 Mϕ	 ET	 system	 biology,	
using	exogenous	ET‐1	administration	in	vitro.	In	human	and	animal	studies	Mϕ	
have	 also	been	 shown	 to	 synthesise	ET‐1	 227;	 279.	 	 Additionally,	 ET‐1	has	been	
shown	 to	 stimulate	 the	 biosynthesis	 of	 pro‐inflammatory	 cytokines	 such	 as	
TNFα	 from	 Mϕ	 282.	 ET‐1	 is	 a	 potent	 mitogen,	 and	 partly	 mediates	 the	
proliferative	effects	of	several	cytokines	283;	 284;	 285.	 It	 is	 thus	suggested	 that	 in	





























ET‐1	 is	 known	 to	 be	 involved	 in	 the	 regulation	 of	 various	 functions	 including	
vasoconstriction222,	 natriuresis	 and	 	 diuresis	 223;	 224	 and	 importantly	 in	
inflammation	and	fibrosis	225.	Mϕ	infiltration	is	a	near	universal	feature	of	renal	
disease	 and	 is	 involved	 in	 both	 progression	 and	 resolution	 of	 renal	 injury.	
Although	the	data	is	 limited,	Mϕ	are	believed	to	have	an	ET‐1	system.	Rat	Mϕ	
have	been	shown	to	express	ETBR	but	not	the	ETAR	276	and	there	is	currently	no	
data	demonstrating	 the	presence	of	 either	 receptor	 in	humans.	 In	human	and	
animal	studies	activated	Mϕ	have	been	shown	to	synthesize	ET‐1	in	response	to	
LPS,	phorbol	myristate	acetate	(PMA)	and	low‐density	lipoprotein	(LDL)277;	278;	

















The	 experiments	 described	 in	 this	 chapter	 were	 designed	 to	 investigate	 the	
hypothesis	 that	 ET‐1	 activates	 Mϕ.	 Specifically,	 in	 human	 Mϕ	 ET‐1	 will	 –	 1)	






 Determine	 whether	 ET‐1	 administration	 would	 induce	 Mϕ	 IL‐6,	 IL‐8,	
TNFα	and	IL‐10	up‐regulation.	
 Investigate	whether	ET‐1	will	induce	ET‐1	production	
 Using	 a	 transwell	 assay	 system,	 determine	 whether	 ET‐1	 induces	
chemotaxis.	
 Where	 ET‐1	 effects	 are	 observed,	 determine	 whether	 the	 effects	 are	






In	 the	 absence	 of	 ET‐1	 effects	 on	 macrophages,	 we	 aimed	 to	 investigate	 the	
mechanism	by	which	ET‐1	is	handled	by	Mϕ	in	vitro.		









lysosomotropic	 agent	 chloroquine	 (CQ)	 and	 an	 inhibitor	 of	 microtubule	
formation	Nocodazole	(NZ).		
To	 study	 the	 effect	 of	 proteases	 on	 ET‐1	 degradation,	 we	 used	 a	 protease	
inhibitor	 cocktail	 (Roche	 complete)	 that	 inhibits	 a	 broad	 spectrum	 of	 serine,	
cysteine	and	metalloproteases	as	well	as	calpains.		
Furthermore,	 the	 role	 of	 ETAR	 and	 ETBR	 in	 Mϕ	 mediated	 ET‐1	 uptake	 was	


















I. Mϕ	were	cultured	(4x106/well)	 in	 IMDM	in	75cm2	flasks	(37°C,	5%	CO2)	
and	 purified	 by	 adhesion	 in	 culture	 flasks	 for	 90	 min	 at	 37°C.	 Non‐










VII. Mϕ	phagocytosis	 in	 response	 to	ET‐1	was	assessed	by	 semi‐quantitative	
analysis	of	ingestion	of	GFP	tagged	e.	coli.	
VIII. Where	 ET‐1	 effects	 were	 observed,	 Mϕ	 were	 incubated	 with	 selective	










































IX. All	 samples	 not	 requiring	 incubation	 with	 cells	 (baseline	 and	 internal	




X. For	 each	 experiment,	 cells	 were	 incubated	 in	 either	 0.5ml	 chloroquine	
(CQ)	(100μg/ml),	0.5ml	PI	(1	tablet/50ml)	or	0.5ml	BQ123,	BQ788	or	No	
antagonist	for	2h	prior	to	addition	of	ET‐1	
























All	 experiments	 in	 this	 study	utilise	human	PBMC.	 Immature	monocytes	were	
cultured	 under	 growth‐permissive	 conditions	 (37°C)	 in	 uncoated	 standard	
tissue	 culture	 flasks	 for	 7	 days	 to	 differentiate	 into	 mature	 Mϕ.	 The	
characteristics	 of	 the	 mature	 Mϕ	 phenotype	 were	 identified	 morphologically	
under	LM	(Fig	4.1	A&B).	
4.4 Mϕ	express	ETA	and	ETB	receptors	
Mϕ	have	 previously	 been	 shown	 to	 express	 the	 ETB	 326,	 but	 not	 ETA	 receptor	
















































A&B	 Differing	 Mϕ	 cell	 phenotypes.	 Photomicrographs	 (400x)	 of	 (A)	
























































up‐regulation	 of	 antigen	 presentation	 molecules.	 ET‐1	 has	 been	 shown	 to	
stimulate	production	of	pro‐inflammatory	cytokines	in	various	cell	types	282;	327.	













































&	100pg/ml)	 and	pharmacological	 (1000	&	10,000pg/ml)	 doses	 did	 not	 elicit	



















































































































































Mϕ	 stimulated	 with	 100	 and	 500pg/ml	 ET‐1	 did	 not	 produce	 ET‐1	 (Fig	 4.4	
A&B).	 Interestingly,	 little	or	no	ET‐1	was	detectable	 in	 the	culture	media	after	
24h	incubation.	This	may	be	representative	of	proteolytic	ET‐1	degradation	or	

















































Mϕ	motility	and	signalling	are	 influenced	by	various	 soluble	 factors.	ET‐1	has	
been	implicated	as	a	chemoattractant	280.	Here	we	investigated	the	effect	of	ET‐




In	 the	 presence	 of	 ET‐1	 (10‐1000pg/ml)	 cells	 migrated	 across	 the	 transwell	
membrane	 (Fig	 4.5	 A‐G).	 This	 was	 a	 dose	 dependent	 effect	 with	 significantly	
more	 cells	 transmigrating	 at	 1000pg/ml	 compared	 to	 control	 (389.5±	 73.5	 vs	
68±	6	nuclei/lpf).	This	was	an	approximately	2‐fold	greater	effect	than	with	the	











































A‐G	 Mϕ	 migration	 assessed	 using	 transwell	 system	 to	 determine	 number	 of	
DAPI	stained	nuclei/lpf.	Mϕ	migrate	towards	a	chemo‐attractant	stimulus	as	in	
(A)	MCP‐1.	Non‐	viable	cells	(B)	cannot	transiently	pass	through	the	membrane,	
whereas	 low	 levels	 of	 viable	 cells	 without	 a	 stimulus	 can	migrate	 (C).	 In	 the	
presence	 of	 ET‐1	 however,	 cell	 migration	 is	 increased	 at	 (D)	 10	 and	 (E)	
100pg/ml.	This	is	a	statistically	significant	effect	at	(F)	1000pg/ml	compared	to	

































demonstrated	 some	 functional	 effects	 of	ET‐1	 administration	 and	ET	 receptor	
blockade.	 In	 addition	 to	 their	 migratory	 capacity,	 another	 key	 physiological	
function	of	Mϕ	is	their	phagocytic	ability.	Here	we	investigated	the	effect	of	ET‐
1	on	Mϕ	phagocytosis	of	bacterial	particles	 labelled	with	GFP.	Dexamethasone	





increased	 phagocytosis.	 The	 capacity	 to	 induce	 phagocytosis	 by	 DEX	was	 not	
significantly	different	to	that	of	100pg/ml	(physiological)	ET‐1	doses.	At	an	ET‐
1	 concentration	 of	 1000pg/ml	 (pharmacological	 dose)	 bacterial	 particle	
ingestion	was	approximately	2‐fold	higher	than	control	and	1	fold	higher	then	




























































C&D	 Photomicrographs	 (600x)	 of	Mϕ	 phagocytosis	 of	 GFP	 bacterial	 particles	
and	(C)	In	the	presence	of	physiological	concentrations	of	ET‐1	(100pg/ml),	Mϕ	


























E	 Graph	 of	 Mϕ	 phagocytosis	 of	 GFP	 bacterial	 particles.	 (E)	 Semi‐quantitative	
image	analysis	of	Mϕ	phagocytosis.	Data	are	mean	±	SD	(n=2),	analysed	by	1‐



















used	 the	 lysosomotropic	 agent	 chloroquine	 (CQ).	 The	 process	 of	 bulk	 phase	
endocytosis	 is	 largely	pH	dependant.	 	CQ	 is	an	agent	 that	prevents	endosomal	
acidification	 332.	 It	 accumulates	 inside	 the	 acidic	 components	 of	 the	 cell,	
including	 endosomes	 and	 lysosomes.	 This	 accumulation	 leads	 to	 inhibition	 of	
lysosomal	enzymes	that	require	an	acidic	pH,	and	prevents	fusion	of	endosomes	
and	 lysosomes.	 CQ	 is	 commonly	 used	 to	 study	 the	 role	 of	 endosomal	
acidification	 in	 cellular	 processes	 333;	 334	 such	 as	 the	 signalling	 of	 intracellular	
TLRs.	CQ	also	 inhibits	autophagy	as	 it	 raises	 the	 lysosomal	pH,	which	 leads	 to	
inhibition	 of	 both	 fusion	 of	 autophagosome	 with	 lysosome	 and	 lysosomal	
protein	degradation	335.		
Initially,	 to	 ensure	 CQ	did	 not	 affect	 ET‐1	 in	 culture	 conditions,	we	 incubated	
ET‐1	 and	 CQ	 alone.	 ET‐1	 concentrations	 remained	 stable	 after	 24h	 in	 culture	
































A‐D	 Mϕ	 handling	 of	 ET‐1	 by	 RIA.	 Mϕ	 supplemented	 with	 chloroquine	
degrade/remove	 physiological	 (A)	 30pg/ml	 (B)	 300pg/ml	 and	





































































spectrum	 protease	 inhibitor	 (PI).	 Initially,	 to	 ensure	 PI	 did	 not	 affect	 ET‐1	 in	
culture	 conditions,	 we	 incubated	 ET‐1	 and	 PI	 alone.	 ET‐1	 concentrations	
remained	stable	after	24h	in	culture	with	PI	(PI+	ET‐1	30,000pg/ml;	0h	vs	24h;	
31425	 vs	28053).	Mϕ	 exposed	 to	 PI	 alone	 for	 24	 did	 not	 elicit	 production	 or	
release	 of	 ET‐1	 (no	ET‐1	 detectable	 in	 the	media).	Mϕ	 exposed	 to	 PI	 prevent	
degradation	of	ET‐1	at	300,	3000	and	30000	pg/ml	concentrations	(Fig	4.8	A‐
D).		
4.9.3 Quiescent	Mϕ	do	not	 release	proteases	 responsible	 for	degrading	
ET‐1	
It	is	unclear	whether	the	protease(s)	released	by	Mϕ	responsible	for	degrading	
ET‐1	 are	 transiently	 released	by	quiescent	unstimulated	Mϕ,	 or	whether	 they	
are	released	in	response	to	an	ET‐1	stimulus.	For	this	reason	we	incubated	ET‐1	
at	 various	 concentrations	 with	 Mϕ	 conditioned	 media	 for	 24h.	 ET‐1	
concentrations	 remained	stable	over	24h	across	all	dose	 ranges	 (Fig	4.9	A‐D),	
indicating	that	Mϕ	at	rest	do	not	release	proteases	capable	of	degrading	ET‐1,	


































A‐D	Mϕ	handling	 of	 ET‐1	 by	RIA.	Mϕ	 supplemented	with	 protease	 inhibitors	


























































































































































Mϕ	 ET‐1	 uptake	 does	 not	 appear	 to	 occur	 by	 bulk	 phase	 endocytosis.	 Mϕ	
require	 stimulation	 with	 ET‐1	 in	 order	 to	 elicit	 protease	 release.	 The	 ET	
receptors	may	therefore	be	required	to	clear/uptake	ET‐1.	We	investigated	the	
mechanism	 by	 which	 ET‐1	 was	 taken	 up	 using	 selective	 ETR	 antagonists.	 At	
physiological	(15	pg/ml)	and	pharmacological	(15,000	pg/ml)	doses,	ET‐1	was	












































A&B	 ET‐1	 concentrations	 measured	 by	 RIA.	 After	 24h	 ET‐1	 (15pg/ml	 and	
15000	pg/ml)	added	to	Mϕ	alone,	and	those	pre‐treated	with	BQ123	or	BQ788	
is	removed	after	24h.	However,	at	24h	BQ788	attenuates	ET‐1	removal	at	(A)	15	
pg/ml	 (B)	 15,000	 pg/ml	 ET‐1	 compared	 to	BQ123	 or	 no	 antagonist.	 Data	 are	














































We	 concluded	 that	 ET‐1	 was	 not	 removed	 by	 endocytosis	 when	 initially	
assessed.	 However,	 upon	 addition	 of	 an	 agent	 (Nocodazole)	 responsible	 for	
disrupting	the	actin	cytoskeleton	by	inhibiting	microtubule	formation,	we	were	
able	to	show	that	Mϕ	were	not	able	to	remove	ET‐1	under	these	conditions	(Fig	











































































































ET‐1	 induced	Mϕ	 chemokinesis	was	 not	 affected	 by	 the	 presence	 of	 an	 ETAR	
antagonist	 (BQ123),	 with	 cells	 migrating	 across	 the	 transwell	 membrane	
towards	 increasing	 doses	 (10‐1000pg/ml)	 of	 ET‐1	 (Fig	 4.12	 A‐G).	 This	 effect	
reached	 significance	 at	 higher	 doses	 (Control	 vs	 100pg/ml	 vs	 1000pg/ml;		
nuclei/lpf)	 compared	 to	 control	 (70.5±	 3.5	 vs	 247±	 9*	 vs	 668.5	 ±	 10.6***).	














































response	 to	ET‐1	stimulation	at	 (D)	10	pg/ml.	This	 is	a	statistically	significant	
effect	at	(E)	100	pg/ml	and	(F)	1000	pg/ml	compared	to	control.	(G)	Data	are	
mean	±	SD,	analysed	by	1‐way	ANOVA	(n=2),	**p	<	0.01,	***p	<	0.005	compared	

























































 Contrary	 to	 our	 initial	 hypothesis,	 in	 response	 to	 ET‐1	 Mϕ	 are	 not	

























4.11.1 Human	Mϕ	possess	ET	 receptors,	but	are	not	 classically	activated	
by	ET	stimulation	
ET‐1	exerts	a	number	of	pro‐inflammatory	effects. It	is	a	widely	held	contention	






macrophages	 separated	 by	 heperosmolar	 Percoll	 gradient	 and	 purified	 by	
adhesion	 (See	 2.1.1.2	 for	 method).	 Obtaining	macrophages	 by	 this	 method	 is	




a	 purer	 macrophage	 population.	 This	 cell	 population	 purity	 issue	 should	 be	
taken	into	account	when	considering	this	data.	
There	 is	 some	 evidence	 to	 suggest	 that	 ET‐1	 can	 elicit	 classical	 pro‐
inflammatory	Mϕ	activation	by	the	NF‐κB	signalling	and	subsequent	release	of	
TNF‐α	337;	338,	although	this	result	has	not	been	consistently	observed	339;340.	ET‐
1	has	 been	 shown	 to	 stimulate	Mϕ	production	 of	 the	 chemokine	macrophage	
inflammatory	 protein‐1β	 (MIP‐1β).	 These	 changes	 may	 be	 part	 of	 an	 ET‐1‐
induced	alteration	 in	Mϕ	phenotype.	However,	data	 to	 this	end	are	scarce	but	
are	of	interest	in	light	of	the	potential	role	for	Mϕ	in	renal	repair	341.	In	these	in	






Human	Mϕ	and	DCs	have	been	 shown	 to	 synthesise	ET‐1	 in	 response	 to	LPS,	
PMA	 and	 LDL	 277;	 278;	 340.	 Based	 on	 these	 studies,	 we	 hypothesised	 that	 ET‐1	
would	induce	Mϕ	ET‐1	synthesis.	ET‐1	production	did	not	occur	and	24h	after	
addition	of	ET‐1	to	the	culture	media,	the	ET‐1	peptide	was	not	detected	in	the	
supernatant,	 suggesting	 that	 Mϕ	 remove	 this	 peptide.	 Therefore,	 the	
mechanism(s)	by	which	Mϕ	remove	ET‐1	were	investigated.		
Initially,	we	investigated	the	role	of	bulk	phase	endocytosis	in	the	clearance	of	
ET‐1	using	CQ.	 This	weakly	 basic	 compound	 is	 used	 experimentally	 to	 inhibit	
clathrin‐mediated	 endocytosis	 (CME).	 Experiments	 demonstrated	 that	 CQ	 did	
not	prevent	ET‐1	loss.		
We	also	investigated	the	role	of	proteolytic	degradation	in	Mϕ	handling	of	ET‐1.	
While	 broad‐spectrum	 PI	 prevented	 ET‐1	 loss,	 Mϕ	 CM	 did	 not	 effect	 ET‐1	
concentrations,	implying	that	ET‐1	is	removed	upon	contact	with	the	cells.		We	
hypothesised	 that	 this	 initial	 cell	 contact	 and	 subsequent	 proteolytic	
degradation	 was	 likely	 mediated	 by	 the	 ETBR,	 the	 receptor	 primarily	
responsible	for	clearing	ET‐1.	These	observations	were	confirmed	in	antagonist	
studies,	whereby	ET‐1	removal	was	partially	prevented	by	ETBR	blockade.		
While	 ET‐1	 does	 not	 induce	 pro‐inflammatory	 cytokine	 production,	 it	 does	
affect	other	functions	of	macrophages.	We	demonstrate	that	Mϕ	migrate	toward	
an	ET‐1	gradient.	 	The	mechanism	by	which	ET‐1	 induced	Mϕ	movement	was	
via	 the	 ETBR;	 antagonism	 of	 this	 receptor	 but	 not	 the	 ETAR	 prevented	 ET‐1	





receptor	 subtypes	 follow	 an	 arrestin	 and	 dynamin/clathrin‐dependent	




recycling	 pathway	 and	 co‐localised	 with	 transferrin	 in	 the	 pericentriolar	
recycling	 compartment,	 ETBR	 was	 targeted	 to	 lysosomes	 after	 ET‐induced	
internalization.	Both	receptor	subtypes	co‐localized	with	Rab5	in	classical	early	
endosomes,	 indicating	 that	 this	 compartment	 is	 a	 common	early	 intermediate	
for	 the	 two	 ET	 receptors	 during	 intracellular	 transport	 343.	 The	 opposing	
intracellular	 routes	 of	 ET‐1	 stimulated	 ETAR	 and	 ETBR	 may	 explain	 the	
persistent	signal	response	through	the	ETAR	and	the	transient	response	through	
the	 ETBR	 thus	 lysosomal	 targeting	 of	 the	 ETBR	 serves	 as	 a	 biochemical	
mechanism	for	clearance	of	plasma	endothelin	via	this	subtype	343.	
As	 CQ	 is	 a	 weak	 base	 that	 prevents	 late	 endocytic	 processes,	 i.e.	 it	 prevents	
endosomes	from	moving	into	the	multi‐vesicular	body	(MVB)/lysosome	stage,	it	
is	likely	that	the	observed	ET‐1	loss	from	the	culture	media	upon	addition	of	CQ	
corresponded	 to	 ET‐1	uptake	 into	 early	 endosomes	 via	 the	 ETA/BR,	 but	 likely	
prevented	 ET‐1/ETR	 complex	movement	 to	 other	 intracellular	 compartments	
(including	 lysosomes)	 at	 this	 stage.	 The	 ETR	 may	 then	 recycle	 back	 to	 the	
plasma	membrane	to	further	bind	and	internalise	more	ET‐1.	
Investigations	 into	 the	 protease(s)	 responsible	 for	 ET‐1	 degradation	 require	
further	 investigation.	 In	addition	to	degradation	of	ET‐1,	proteolytic	activity	 is	
required	 for	 several	 key	 processes	 in	 macrophages,	 including	 cell	 migration.	
The	best	 characterized	extracellular	protease	 families	 ‐	MMPs,	 cathepsins	 and	
urokinase‐type	 plasminogen	 activator	 are	 reviewed	 in	 reference	 to	 their	
involvement	in	macrophage	migration	344.	
We	 therefore	 speculate	 that	 ET‐1	 engagement	 of	 the	 ETBR	 leads	 to	 receptor	
internalisation	 and	 initiation	 of	 signalling	 pathways	 that	 induce	 macrophage	
migration	and	associated	expression	of	proteases.	Cathepsins	and	other	serine	
proteases	 usually	 presented	 on	 the	 leading	 edge	 of	 migrating	 macrophages	







along	 the	endocytic	pathway	 in	polarized	and	non‐polarized	cells	and	 in	yeast	
345;	 346;	 347.	Microtubules	are	 involved	 in	 late	steps	of	endocytosis,	 in	 the	 traffic	
between	 early	 and	 late	 compartments.	 When	 microtubules	 are	 disrupted,	
translocation	of	endosomes	and	lysosomes	is	inhibited	348;	349;350.		
We	 demonstrated	 that	 NZ,	 an	 inhibitor/disruptor	 of	 microtubule	 formation	
prevented	 ET‐1	 uptake	 suggesting	 that	 late	 endocytic	 processes	 and	
engagement/activation	 of	 the	 cytoskeleton	 and	 related	 intracellular	 signalling	
events	are	required	for	subsequent	removal/degradation	of	larger	quantities	of	
ET‐1.	
In	 addition	 to	 potentially	 being	 an	 active	 component	 of	 endocytosis	 of	 ET‐
1/ETBR	and	associated	cell	signaling	events,	the	actin	cytoskeleton	of	these	cells	
also	plays	a	central	role	in	 locomotion,	phagocytosis,	and	the	regulation	of	cell	
shape.	We	 demonstrated	 that	 ET‐1	 induced	macrophage	 chemokinesis.	When	
assessed,	this	appeared	to	be	an	ETBR	mediated	event.	
4.11.3 Further	investigations	
The	 phenotype	 of	 ET‐1	 stimulated	Mϕ	 remains	 to	 be	 determined	 and	 further	
investigations	 into	 the	phenotype	and	mechanisms	of	ET‐1	handing	should	be	
determined.	 ET‐1	may	 induce	 a	more	 ‘M2’	 type	macrophage.	 In	murine	 cells,	
markers	of	alternative	activation	such	as	Fizz‐1,	YM‐1	etc.	are	readily	available.		
Alternatively	activated	murine	Mϕ	produce	fibronectin	and	a	matrix‐associated	
protein,	 βIG‐H3	 75,	 arginase	 77,	 AMAC‐1	 78	 CD163,	 transcription	 factors	 FIZZ1	
and	 Ym1,	 79.	 Alternatively	 activated	 human	 Mϕ	 are	 more	 difficult	 to	
characterise.	When	considering	M2	phenotypes	in	human	cells,	it	is	more	likely	
that	 the	 ratio	 of	 a	 given	 set	 of	 receptors	 is	 altered.	 Human	M2	 Mϕ	may	 up‐
regulate	mannose	receptor	(CD206),	Scavenger	receptor‐A	(SRA)	(CD204)	and	
down‐regulate	 co‐receptors	 CD80/CD86.	 This	 is	 not	 always	 the	 case	 and	






We	 have	 described	 potential	 mechanisms	 of	 ET‐1	 handling	 via	 endocytic,	
proteolytic	 and	 ET	 receptor	 mediated	 processes.	 All	 studies	 performed	 were	
preliminary	 and	 require	 further	 analysis	 with	 increased	 numbers	 and	
alternative	reagents.	For	this	reason	the	assays	described	in	these	mechanistic	
investigations	are	described	 in	terms	of	 their	 trends	and	were	not	statistically	
assessed	 with	 an	 n	 of	 2	 only.	 The	 specific	 limitations	 of	 each	 assay	 will	 be	
addressed	in	this	section.		
	
When	 considering	 the	 role	 of	 the	 actin	 cytoskeletons	 in	 receptor	 endocytosis,	
repeated	 experiments	 with	 NZ,	 and	 alternative	 reagents	 such	 as	 colchicine,	
cytochalasin	 B352	 and	 Brefeldin	 A	 353	 to	 target	 microtubule	 disruption	 and	
clathrin‐coated	 pit	 internalisation	 should	 be	 considered.	 The	 pharmacological	
inhibitor	of	dynamin	(Dynasore)	may	be	employed	to	determine	whether	these	
are	 clathrin‐mediated	 processes.	 Downstream	 intracellular	 signalling	 events	
and	 proteins	 may	 also	 be	 investigated.	 	 siRNA	 knockdown	 of	 β‐arrestin	 2	 in	
human	 cells	 may	 be	 a	 useful	 tool	 in	 this	 process	 354.	 Reagents	 for	 these	
experiments	are	all	commercially	available	(Santa	Cruz	Biotch,	CA).	
	
Our	Mϕ	migration	assays	utilised	 transwell	 inserts	 containing	a	micro‐porous	
membrane.	We	concluded	that	these	assays	demonstrated	chemokinesis	due	to	
the	 duration	 of	 time	 taken	 for	 migration	 to	 occur.	 To	 definitively	 determine	
whether	 these	 are	 truly	 chemokinetic	 or	 or	 chemotactic	 processes,	 the	 use	 of	





using	 GFP	 bacterial	 particles.	 There	 were	 several	 issues	 relating	 to	 these	
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experiments.	 	 While	 this	 was	 a	 suitable	 means	 of	 assessing	 phagocytosis	 in	
principle,	there	were	issues	relating	to	determining	whether	the	particles	were	
truly	 internalised,	 or	 whether	 they	 were	 membrane	 bound.	 To	 attempt	 to	
address	 this	 issue,	 after	 particle	 ingestion	 the	 cells	 were	 treated	with	 trypan	




different	 particulate	 matter	 including	 apoptotic	 cells	 and/or	 latex	 beads.	






of	 ET‐1	 in	 Mϕ	 alone	 is	 to	 signal	 Mϕ	 for	 migration	 to	 an	 injured/inflamed	
environment,	an	ETBR	mediated	event.	Here	Mϕ	may	be	classically	activated	by	
other	pro‐inflammatory	mediators,	or	by	ET‐1	in	an	as	yet	unclear	fashion.	ET‐1	
activated	 Mϕ	 may	 exhibit	 more	 M2	 phenotypic	 changes	 to	 a	 pro‐resolution	
phenotype,	as	ET‐1	clearance	and	phagocytosis	are	increased.	Whether	ET‐1	is	






































In	 the	 previous	 chapter	we	 aimed	 to	 demonstrate	 that	 ET‐1	would	 classically	
activate	 human	 blood	monocyte	 derived	Mϕ.	 Our	 studies	 showed	 human	Mϕ	
expressed	the	ETAR	and	ETBR.	However,	despite	repeated	experiments,	Mϕ	did	
not	 respond	 to	 ET‐1	 as	 hypothesised.	 In	 response	 to	 physiological	 and	
pharmacological	dose	ranges	of	ET‐1,	these	cells	were	not	activated	to	produce	
pro‐inflammatory	 cytokines,	 did	not	 express	 surface	markers	 of	 classical	 (M1)	
activation,	 and	 did	 not	 produce	 ET‐1.	 Furthermore,	 ET‐1	 did	 not	 induce	 ET‐1	
production,	but	rather	depleted	ET‐1	from	the	media.		
5.1.1 Experimental	hypothesis	and	aims	
These	 initial	 observations	 led	 to	 the	 consideration	 that	 Mϕ	 could	 potentially	
serve	 to	 regulate	 ET‐1.	 We	 hypothesise	 that	 Mϕ	 regulate	 ET‐1,	 and	 the	
vasoactive	properties	of	ET‐1	are	exacerbated	in	the	absence	of	Mϕ.	With	only	a	
few	examples	 in	the	 literature	of	an	 indication	that	 inflammatory	cells	may	be	
involved	in	the	regulation	of	blood	pressure	via	regulation	of	vasopressors	355;	





the	 diphtheria	 toxin	 receptor	 under	 the	 control	 of	 the	 CD11b	 promoter302.	 In	
this	model,	administration	of	DT	results	in	blood	monocyte	and	resident	tissue	
Mϕ	 depletion.	 Following	 Mϕ	 depletion,	 we	 aimed	 to	 examine	 the	 pressor	
response	to	ET‐1	by	invasive	carotid	BP	measurement.		
The	specific	aims	of	these	experiments	were	to:	






I. Diptheria	 toxin	 (DT)	 (20ng/g	 i.v.)	 was	 administered	 to	mice	 to	 induce	
monocyte/	Mϕ	depletion	in	CD11b‐DTR	transgenic	mice	and	FVB	strain	
controls,	 and	an	equal	 volume	of	 saline	was	administered	 to	 treatment	
control	CD11b‐DTR	mice	24h	prior	to	BP	measurements.		
II. After	 24h	 mice	 were	 initially	 anaesthetized	 with	 Thiobutabarbital	
(100mg/kg	i.p.).		
III. Following	 this	 a	 tracheotomy	was	 performed	 and	 the	 jugular	 vein	 and	





VI. After	baseline	measurements	were	 recorded,	 the	effect	and	duration	of	
the	action	of	the	drugs	were	observed	and	recorded.	The	doses	of	ET‐1	





IX. After	 each	 drug	 administration,	 the	 BP	 of	 the	 animal	 was	 allowed	 to	






XII. Tissues	 (liver,	 kidney	 and	 spleen)	 were	 fixed	 in	 4%	 FA	 and	 F4/80	









administered	to	 induce	monocyte/	Mϕ	depletion	 in	 transgenic	mice	24h	prior	
to	experiments.	FVB/nj	mice	treated	with	DT	were	used	as	strain	controls	and	a	
CD11b‐DTR	treated	with	vehicle	(saline)	were	used	as	transgenic	controls.		
Monocytes	 were	 identified	 according	 to	 their	 size,	 granularity	 and	
immunophenotype	 by	 flow	 cytometry	 (see	 gating	 parameters	 in	 Chapter	 2	
Methods	section	2.2.2.1.2.1)	and	gated	into	subsets	1)	CD11b+,	CD115+,	Ly6G‐,	
Ly6Chi	 2)	 CD11b+,	 CD115+,	 Ly6G‐,	 Ly6Cint	 and	 3)	 CD11b+,	 CD115+,	 Ly6G‐,	
Ly6Clo.	 Administration	 of	 DT	 to	 CD11b‐DTR	 animals	 resulted	 in	 significant	
ablation	of	circulating	monocytes	at	24h	compared	to	control	DTR	mice	treated	
with	 saline,	 and	 sham	 DT	 treated	 FVB/nj	 mice	 (Fig	 5.1	 A‐D).	 Analysis	 of	 the	
three	 main	 monocyte	 subsets	 (Ly6Clo;	 Ly6Cint;	 Ly6Chi)	 demonstrated	 that	 all	
subsets	 are	 significantly	 depleted	 at	 24h,	 and	 there	 were	 no	 significant	
differences	in	monocyte	number	between	control	groups	(Fig	5.2	A‐C).	
5.3.2 Resident	renal	macrophages	are	depleted	by	DT	






















A‐F	 FACS	 analysis	 of	 whole	 mouse	 blood.	 Representative	 dot	 plots	 of	 (A)	
CD11b‐DTR	 mice	 treated	 with	 saline	 and	 (B)	 FVB/nj	 strain	 controls	 treated	
with	 DT	 demonstrating	 distinct	 Ly6Chi,	 Ly6Cint	 and	 Ly6Clo	 monocyte	
populations.	Monocytes	 are	 ablated	 by	 (C)	DT	 treatment	 of	 CD11b‐DTR	mice.	
(D)	Data	are	Mean	±	SD		analysed	by	1‐way	ANOVA	with	Bonferroni	corrections;	


































































monocyte	 subsets	 were	 depleted	 by	 DT	 treatment	 of	 CD11b‐DTR	 mice	
compared	 to	DTR	mice	 treated	with	 saline	and	FVB/nj	 strain	 controls	 treated	
with	DT.	Data	are	mean	±	SD	(n=4‐6)	analysed	by	1‐way	ANOVA	and	Bonferroni	
post‐tests.	 Stars	 represent	 significance	 compared	 to	 DTR	 saline	 controls;	





































































































































cortex	 and	 medulla	 of	 (A&E)	 DTR	 saline	 treated	 control	 (B&F)	 FVB/nj	 DT	
treated	 control	 and	 (C&G)	 DTR	 DT	 treated	 mice	 (D&H).	 Arrows	 represent	
individual	Mϕ.	Images	are	representative	of	10	fields/slide.	Data	are	mean	±	SD	
analysed	 by	 1‐way	 ANOVA	 and	 Bonferroni	 post	 tests;	 n=4‐6;	 Stars	 represent	
































































































































In	 vivo,	 basal	 blood	 pressure	 was	 unaffected	 by	 DT	 treatment	 in	 DTR	 mice	
compared	to	controls	(Fig	5.5	A).	The	pressor	response	to	ET‐1	in	these	animals	
was	 then	 assessed	 (see	 supplementary	 Fig	 2.2	 for	 BP	 trace	 analysis	
parameters).	 Administration	 of	 ET‐1	 did	 not	 produce	 a	 pressor	 response	 in	
control	DTR	saline	treated	and	sham	DT	treated	FVB/nj	strain	control	animals	
(Fig	5.5	B).	DT	treated	DTR	mice	were	more	sensitive	to	the	pressor	effect	of	ET‐
1	 and	 at	 the	 lower	 doses	 (0.01	 and	 0.1	 nmol/kg)	 as	 a	 pressor	 response	 was	
observed	in	these	animals.	At	the	highest	dose	(1nmol/kg)	all	mice	responded	
to	ET‐1.	 In	Mϕ	deplete	mice	however	a	 significantly	greater	pressor	 response	
compared	to	control	and	sham‐operated	was	observed.	To	determine	whether	
































curve	 (AUC).	 (C)	Duration	of	pressor	 response	 to	Ang	 II	 (1nmol/kg).	Data	are	
mean	±	SD	 (n=4‐7)	analysed	by	1‐way	ANOVA	(A&C)	 and	2‐way	ANOVA	with	
Bonferroni	post‐tests	(B).	Stars	represent	significance	compared	to	DTR	saline	


























































































































In	 the	 previous	 chapter	 we	 examined	 the	 effects	 of	 ET‐1	 on	 human	 Mϕ	
phenotype	and	function.	In	response	to	ET‐1	Mϕ	are	not	classically	activated	as	
hypothesised,	but	do	migrate	towards	ET‐1.	When	in	contact	with	ET‐1	Mϕ	are	
more	 phagocytic.	 ET‐1	 is	 then	 cleared	 from	 the	 media	 via	 the	 ETBR	 and	
proteolytic	degradation.	
	
This	 chapter	 investigated	 the	 impact	 of	 conditional	 Mϕ	 ablation	 on	 the	 pro‐
hypertensive	actions	of	ET‐1.	In	vivo,	Mϕ	ablation	resulted	in	an	exacerbation	of	
the	pressor	response	to	ET‐1.	BP	was	significantly	lower	in	mice	possessing	Mϕ.	
This	 effect	 was	 significant	 in	 terms	 of	 the	 duration	 and	 amplitude	 of	 the	
response,	and	in	the	peak	change	in	BP	in	response	to	an	ET‐1	bolus.	This	effect	
was	 not	 observed	 with	 Ang	 II.	 These	 early	 studies	 indicate	 a	 previously	
undocumented	role	of	macrophages	in	BP	regulation.		
	
In	 addition	 to	 the	 role	 and	 action	 of	 ET‐1	 in	macrophages,	 we	 also	 aimed	 to	



















immune	 cells	 in	 relation	 to	ET‐1.	Maurer	et	al.	 2004	 357	 found	 that	mast	 cells	
were	shown	to	limit	ET‐1	mediated	lethality	in	vivo	both	by	receptor‐mediated	
uptake	 and	 through	 the	 action	 of	 proteolytic	 enzymes.	 Mast	 cells	 increase	 in	
number	 in	many	 renal	 inflammatory	diseases	 and	may	have	a	 role	 in	 limiting	
renal	injury	357.	Regulating	the	effects	of	ET‐1	may	form	part	of	this	mechanism.	
This	protective	 role	of	mast	 cells	with	 regards	 to	ET‐1	may	be	 translatable	 to	
Mϕ.	To	address	 this	hypothesis,	we	used	a	model	of	CD11b‐DTR	302	mediated	
conditional	Mϕ	ablation.	 In	 this	model	we	monitored	 the	pressor	 response	 to	
ET‐1,	 hypothesising	 that,	 in	 the	 absence	 of	 Mϕ	 ET‐1	 mediated	 pressor	
responses	are	dysregulated	and	exacerbated.	
There	are	few	examples	in	the	literature	whereby	inflammatory	cells	may	have	
a	 new	 physiological	 role	 in	 acting	 as	 mediators	 or	 regulators	 of	
vasoconstrictors.	Machnik	et	al.	 (2009)358	describes	experiments	whereby	Mϕ	
regulate	salt‐dependent	volume	and	blood	pressure.	The	authors	attribute	this	
phenomena	 to	 a	 Tonicity‐responsive	 enhancer	 binding	 protein	
(TonEBP)/VEGFC	mechanism.	 In	 line	with	 this	work,	 they	have	now	extended	
their	 work	 demonstrating	 that	 the	 mononuclear	 phagocyte	 system	 depletion	
induces	 salt‐sensitive	 hypertension	 in	 rats	 359.	 Crowley	 et	 al.	 (2010)	
demonstrate	 chronic	 angiotensin	 II	 infusion	 in	 mice	 lacking	 ATII1	 on	 bone	
marrow	cells	results	in	augmented	hypertension	356.		These	findings	promote	a	
new	view	on	a	protective	role	 for	macrophages	 in	hypertension.	An	 important	
feature	in	this	scenario	is	also	sodium	homeostasis.	Therefore,	 it	 is	relevant	to	
know	whether	the	observed	blood	pressure	effects	after	macrophage	depletion	
in	 salt‐sensitive	 models	 of	 hypertension	 are	 reproducible	 in	 models	 where	
macrophage	action	has	been	associated	with	deleterious	effects.	
	
In	 a	 letter	 to	 Hypertension	 Schmaderer	 and	 colleagues360	 	 joined	 this	 debate,	





to	 administration	 of	 ET‐1	 was	 achieved	 by	 administering	 diphtheria	 toxin	 to	
mice	 carrying	 the	 CD11b‐DTR	 transgene,	 or	 controls	 on	 the	 same	 genetic	
background.	 In	 vivo,	 basal	 blood	 pressure	was	 unaffected	 by	DT	 treatment	 in	
DTR	mice	compared	to	controls.	The	pressor	response	to	ET‐1	in	these	animals	
was	then	assessed.	Administration	of	low	dose	ET‐1	did	not	produce	a	pressor	




control	 and	 sham‐operated	was	 observed.	 To	 determine	whether	 this	was	 an	





These	 studies	 were	 designed	 to	 assess	 the	 ability	 of	 Mϕ	 to	 regulate	 BP	
responses	to	ET‐1.	Initial	pilot	studies	were	promising	however	would	require	
further	 analysis.	 First,	 the	method	of	 drug	delivery	 and	BP	measurement	was	
via	 an	 invasive	 jugular	 route	 with	 carotid	 BP	 measurement.	 In	 this	 model,	
animals	respond	to	a	bolus	of	pressor.	These	conditions	are	an	extreme	and	a	
more	appropriate	method	of	delivery	would	be	via	osmotic	minipump.	The	use	
of	 osmotic	 minipumps	 has	 many	 advantages	 over	 other	 methods	 of	 delivery	
including	 i.p.	 and	 i.v.	 injection.	 Minipumps	 deliver	 drugs	 at	 a	 constant,	




Observations	 from	 Schmaderer’s	 group	 360	 	 demonstrate	 a	 lack	 of	 effect	 in	 a	
model	 of	 established	 hypertension.	 	 Our	 experiments	 show	 an	 effect	 to	 the	
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contrary	 and	 would	 require	 BP	measurement	 by	 radiotelemetry	 allowing	 for	
accurate	real‐time	BP	measurement.	It	may	be	the	case	that	Mϕ	have	a	role	to	
play	 in	 specifically	 limiting	 the	 early	pro‐hypertensive	effects	of	ET‐1	prior	 to	
established	hypertension.		
To	ensure	that	the	CD11b‐DTR	mice	and	control	animals	have	similar	baseline	
vascular	 responses	 to	 ET‐1,	 wire	myography	 estimation	 of	 ET‐1	 responses	 is	
required.	 Small	 resistance	 vessels	 are	 more	 sensitive	 to	 ET‐1	 than	 larger	




animals	were	 to	be	housed	 in	metabolic	 cages	 for	 timed	urine	 collections.	We	
were	unable	to	quantify	serum	ET‐1	in	these	animals,	as	ET‐1	quantification	by	
RIA	 requires	 a	 sample	 size	 of	 0.5ml	 to	 detect	 pg/ml	 quantities.	 Dilution	 of	
murine	serum	to	this	level	would	not	give	ET‐1	quantities	in	the	working	range.	
Method	development	for	use	of	a	novel	ET‐1	ELISA	kit	specifically	designed	for	
neonate	 samples	 is	 underway	 and	 would	 allow	 for	 murine	 serum	 ET‐1	
quantification	(Enzo	Life	Sciences).	
Lastly,	 future	studies	 to	 investigate	not	only	the	role	of	macrophages,	but	also	
the	 role	 of	 the	 respective	 ET	 receptors	 in	 hypertension	 may	 be	 addressed.	
Strategies	 include	 the	 generation	 of	mice	with	 targeted	 deletions	 of	 the	 ETAR	
and	 ETBR	 in	 neutrophils	 and	 Mϕ	 through	 crossing	 a	 LysM‐Cre	 line	 361 with	
strains	 carrying	 the	 floxed	 ETAR	 362	 and	 ETBR	 363	 alleles.	 Primary	 culture	 of	
murine	 macrophages	 with	 these	 targeted	 deletions,	 and/or	 siRNA	 gene	


































In	 this	 final	 chapter,	 the	 role	 of	 ET‐1	 in	 human	 podocytes	 is	 investigated.	
Podocytes	 have	 been	 shown	 to	 express	 both	 ETA	R195	 and	 ETB	R270	 on	 rodent	
podocytes.	 There	 is	 limited	data	 lacking	definitive	 expression	 of	 receptors	 for	
human	 podocytes	 271;	 272.	 However,	 it	 is	 likely	 that	 human	 podocytes	 also	
possess	both	ETAR	and	ETBR	273.	ET‐1	is	also	implicated	as	both	a	stimulus,	and	
a	 product	 of	 stimulation	 of	 podocytes.	 As	 previously	 discussed,	 murine	
podocytes	exposed	to	an	albumin	(or	IgG)	load	leads	to	disruption	of	the	actin	
cytoskeleton.	This	activates	transcription	of	preproET‐1	mRNA	leading	to	ET‐1	






nephrin	 and	 mutations	 of	 the	 nephrin	 gene	 lead	 to	 congenital	 nephrotic	
syndrome	 188.	 Nephrin	 is	 often	 used	 in	 experimental	 models	 as	 a	 marker	 of	
podocyte	injury.	In	vitro	studies	conducted	using	glomerular	endothelial	cells	as	
a	 source	 of	 ET‐1	 were	 cultured	 in	 pre‐eclamptic	 sera.	 Treatment	 of	 murine	
podocytes	with	conditioned	sera	induced	shedding	of	nephrin	272.	Furthermore,	
infusion	of	ET‐1	 into	 rats	 caused	nephrin	 excretion	 into	 the	urine	 263.	 In	both	
instances	these	effects	were	inhibited	by	ETA	receptor	antagonism.	
	










The	 experiments	 described	 in	 this	 chapter	 were	 designed	 to	 investigate	 the	
hypothesis	that	ET‐1	is	detrimental	to	podocyte	health.		
In	response	to	an	 initial	 insult	podocyte	effacement	or	de‐differentiation,	ET‐1	
production	 and	 pro‐inflammatory	 cytokine	 production	 occurs.	 This	 increased	
ET‐1	 production,	 likely	 mediated	 by	 stimulation	 of	 the	 ETAR,	 may	 act	 in	 an	













 Determine	 whether	 ET‐1	 administration	 would	 induce	 podocyte	 ET‐1,	
IL‐6	and	IL‐8	and	up‐regulation.	











I. Podocytes	were	cultured	 in	supplemented	RPMI	 in	75cm2	 flasks	(33°C,	5%	
CO2)	 to	propagate.	At	80‐90%	confluence	cells	were	 trypsinised	and	either	
reseeded	 into	 75cm2	 flasks	 at	 a	 ratio	 of	 1:5	 and	 maintained	 at	 33°C,	 or	







IV. Podocytes	 were	 stimulated	 with	 ET‐1	 (5‐100pg/ml)	 over	 a	 2‐48	 hour	
timecourse	to	determine	(maximal)	ET‐1	production	by	RIA.	








NB.	 The	 concentration	 of	 ET‐1	 and	 ETR	 antagonists	 were	 chosen	 based	 on	
















(33°C)	 where	 they	 propagated	 as	 a	 typical	 cobblestone	 monolayer	
(undifferentiated),	 and	 grew	 to	 70‐80%	confluence	 after	 3‐4	days	 (Fig	 6.1	A).	
Thermoswitching	 to	 37°C	 resulted	 in	 arrest	 of	 proliferation,	 followed	 by	












































A&B	 Differing	 podocyte	 cell	 phenotypes.	 Photomicrographs	 (400x)	 of	 (A)	
Undifferentiated	and	(B)	Differentiated	cells	under	LM.	Differentiated	cells	were	
identified	morphologically	displaying	enlarged,	irregular	cell	bodies	with	short	











Replication	 of	 the	 results	 seen	 by	 Saleem	 and	 colleagues	 (2002)287	









discovered	 as	 the	 gene	 aberration	 responsible	 for	 familial	 FSGS	 123.	 The	
immortalised	 human	 podocytes	 express	 nephrin	 and	 podocin	 protein	 and	
mRNA	(Fig	6.2	A‐H).	 IF	demonstrates	positive	staining	for	nephrin	(Fig	6.2	A),	
and	 podocin	 (Fig	 6.2	 B),	 with	 no	 primary	 antibody	 controls	 demonstrating	
negative	 staining	 with	 weak	 auto‐fluorescence	 (Fig	 6.2	 C&D	 respectively).	
Nephrin	and	podocin	were	also	detected	by	Western	blot	as	195kDa	and	42	kDa	
proteins	 respectively	 (Fig	 6.2	 E&F).	 Lastly,	 using	 primers	 for	 the	NPHS1	 and	




















for	 (C)	 anti	 mouse	 aleaxa‐fluor‐488	 (AF‐488)	 and	 (D)	 anti‐rabbit	 alexa‐fluor‐




































E‐H	 WB	 analysis	 of	 (E)	 Nephrin	 and	 (F)	 Podocin	 (lane	 1:	 ladder,	 lanes	 2‐5:	
1:100,	1:200,	1:300,	1:400	antibody	dilution	respectively.	RT‐PCR	(G)	of	NPHS1	
gene	encoding	nephrin	(520bp)	and	(H)	NPHS2	gene	encoding	podocin	(443bp).	






























co‐localize	 with	 the	 actin	 cytoskeleton	 115.	 Podocytes	 demonstrated	 strong	
cytoplasmic	expression	of	synaptopodin,	extending	from	the	cell	body	into	large	
primary	processes,	beyond	 the	 large	processes,	 expression	 is	 filamentous	 (Fig	
6.3	A)	with	a	comparable	staining	pattern	to	F‐actin	(Fig	6.3	B).	An	α‐goat	alexa‐
fluor‐488	secondary	antibody	alone	control	was	also	employed	to	demonstrate	
negative	 staining,	 with	 vague	 auto‐fluorescence	 detectable	 (Fig.	 6.3	 C).	 The	
antibody	used	to	detect	synaptopodin	by	IF	was	only	able	to	detect	the	epitope	
on	non‐denatured	protein,	 therefore	 synaptopodin	was	not	detectable	by	WB.	




































filamentous	 actin	 (red)	 with	 nuclear	 stain	 DAPI	 (blue).	 Arrows	 indicate	
sypnaptopodin	 expression	 along	 the	 large	 primary	 processes.	 (C)	 Secondary	
antibody	alone	demonstrating	negative	staining	(D)	RT‐PCR	products	of	SYNPO	



















Previously	 reported	 data	 regarding	 ET	 receptor	 expression	 by	 podocytes	 is	
somewhat	sparse	and	inconclusive.	Rebibou	and	colleagues273	demonstrate	the	
presence	 of	 ET	 receptors	 in	 human	 podocytes,	 however,	 these	 studies	 do	 not	
discriminate	which	receptor	type	is	expressed.	ETBR‐like	immunoreactivity	has	
been	 demonstrated	 in	 podocytes	 from	 rat	 kidney	 sections	 270.	 Prior	 to	
stimulation	of	podocytes	with	ET‐1,	 it	was	essential	 to	determine	whether	the	
cells	 expressed	 ETAR	 and	 ETBR.	 Receptor	 expression	 and	 localisation	 was	
therefore	 investigated	 in	vitro.	Positive	staining	of	both	receptor	subtypes	was	



























































































In	 response	 to	 various	 initial	 insults,	 podocytes	 have	 been	 shown	 to	 produce	
ET‐1	195.	ET‐1	production	occurs	in	an	autocrine	and	paracrine	manner	to	elicit	
cellular	 responses	 via	 stimulation	 of	 ETAR	 and	 ETBR	 216.	 Thus,	 in	 this	 assay	
podocytes	 were	 exposed	 to	 exogenous	 ET‐1	 (5‐100	 pg/ml)	 to	 determine	
whether	 an	 ET‐1	 insult	 would	 elicit	 ET‐1	 protein	 production.	 This	 was	
measured	 by	 RIA	 over	 a	 period	 of	 48h.	 The	 time	 course	 of	 ET‐1	 protein	
synthesis	by	podocytes	was	assessed	by	RIA	using	125I	radiolabelling.	A	detailed	
description	 of	 ET‐1	 stimulation	 and	 quantification	 can	 be	 found	 in	 Chapter	 2	
(see	section	2.1.2	&	2.1.4	respectively).	
6.6.1 Podocytes	 produce	 ET‐1	 over	 time,	 preceded	 by	 cellular	 ET‐1	
uptake	
Over	 a	 period	 of	 48h,	 administration	 of	 exogenous	ET‐1	 to	 cultured	podocyte	









be	 seen	 in	 all	 concentrations;	 however	 the	 net	 negative	 ET‐1	 values	 decrease	
across	all	concentrations.	This	suggests	that	ET‐1	is	being	produced	by	podocyte	
cells,	however	as	 the	values	do	not	exceed	the	 initial	concentration	added	this	
cannot	 be	 confirmed	 as	 true	 production.	 This	 apparent	 ET‐1	 production	
continues	to	occur	up	to	12	hours.	Cells	stimulated	with	10	and	20pg/ml	ET‐1	
after	12	hours	show	net	positive	ET‐1/protein	levels,	demonstrating	that	ET‐1	
levels	 exceed	 that	 of	 the	 concentration	 initially	 added,	 establishing	 definitive	
ET‐1	 production/release.	 After	 24	 hours	 in	 culture,	 with	 the	 exception	 of	





1	 production	 occurring	when	 stimulated	with	 10pg/ml.	 This	 increase	 in	 ET‐1	








the	 trend	 alters	 and	 by	 24h	 an	 inverted	 U	 dose	 response	 becomes	 apparent,	
however,	this	does	not	become	statistically	significant	until	48h	with	peak	ET‐1	
production	 at	 10pg/ml	 ET‐1	 stimulation.	 Post‐hoc	 Bonferroni	 comparisons	
reveal	 significantly	 higher	 ET‐1	 concentrations	 at	 5,	 10	 and	 20pg/ml	 ET‐1	
































the	absence,	or	presence	of	ET‐1	 stimulation	at	various	 concentrations	 (5,	10,	
,20,	 50,	 100	pg/ml).	 There	 is	 a	 time	 and	 concentration	dependent	 increase	 in	
ET‐1	 production,	with	 peak	 ET‐1	 production	 occurring	 at	 10	 pg/ml	 after	 48h	
stimulation	(p<0.001	to	control).	Data	are	mean	±	S.D.	ET‐1	values	are	adjusted	
for	protein	content.	Data	analysed	by	2‐way	ANOVA	with	Bonferroni	corrections	
(n=3).	 Symbols	 displayed	 above	 bars	 represent	 significance	 compared	 to	 0	
pg/ml	control			*	p<0.05,	**	p<0.01,	***	p<0.005,	****	p<0.001	
	


















































B	 Data	 are	 re‐presented	 to	 demonstrate	 the	 effect	 of	 time‐course	 on	 ET‐1	
production	 in	 podocytes.	 Data	 are	 mean	 ±	 S.D.	 ET‐1	 values	 are	 adjusted	 for	
protein	content.		
B 





























of	pro‐inflammatory	 cytokines	 365;	 366.	 In	 this	 assay,	 IL‐6	 and	 IL‐8	protein	was	
measured	 in	 response	 to	 stimulation	 of	 human	 podocytes	 with	 increasing	
concentrations	(0‐100	pg/ml)	of	exogenous	ET‐1	compared	to	media	alone	over	
48h.	The	effect	of	ET‐1	 treatment	of	mature	 cells	 for	48	h	was	 tested	because	
cytokine	 expression	 was	 expected	 to	 be	 rapid	 and	 maximal	 within	 this	 time	
period.	Furthermore,	the	short	half‐life	of	secreted	cytokines	made	it	important	
to	test	at	early	time	periods.	In	these	assays	the	24h	time‐point	was	determined	




pg/ml).	 Administration	 of	 exogenous	 ET‐1	 to	 cultured	 podocyte	 cells	
upregulates	 production	 of	 IL‐6	 in	 a	 dose	 dependant	 manner	 and	 becomes	
statistically	significant	at	100	pg/ml	(Fig	6.6	A).	Podocyte	IL‐8	production	(7378	
±	 886.4	 pg/ml)	 also	 occurs	 at	 baseline.	 ET‐1	dosing	 results	 in	 a	 similar	 trend	


































A&B	 Cytokine	 content	 in	 podocyte	 supernatant	 assessed	 by	 ELISA	 (A)	
Podocytes	 up‐regulate	 IL‐6	 production	 in	 response	 to	 ET‐1	 stimulation	 (B)	
Podocyte	 IL‐8	production	also	 increases	 in	response	 to	ET‐1	stimulation.	Data	
are	mean	±	SD	(n=13‐15)	analysed	by	1‐way	ANOVA	and	Dunnetts	comparisons	













































In	 response	 to	 soluble	 factors	 such	 as	 angiotensin	 II	 205	 and	 albumin	 195	 the	
cytoskeleton	of	podocytes	undergo	 rearrangement.	 	 Further	 studies	by	Morigi	
and	 colleagues	 in	 2006	 demonstrated	 a	 re‐organisation	 of	 F‐actin,	 with	
corresponding	intercellular	spaces	in	mouse	podocytes	treated	with	Shigatoxin,	
a	promoter	of	ET‐1	production	274.	In	this	assay,	filamentous	actin	organisation	
in	 podocytes	 exposed	 to	 ET‐1	 is	 assessed	 by	 direct	 IF	 phalloidin	 staining.	 To	
detect	disruptions	in	tight	junctions,	dual	staining	with	Zonula	Occludens‐1	(ZO‐
1)	is	performed.	In	addition	to	the	cytoskeleton,	ET‐1	may	also	cause	alterations	
in	 mature	 podocyte	 slit	 diaphragm	 proteins.	 Expression	 and	 localisation	 of	
nephrin	and	synaptopodin	from	podocytes	treated	with	ET‐1	(10‐1000	pg/ml)	
for	 7	 days	 was	 assessed	 by	 IF	 and	 PCR.	 Further	 WB	 analysis	 of	 nephrin	
expression	was	performed.	
6.8.1 ZO‐1	 staining	 was	 not	 sufficient	 to	 show	 abberations	 in	 tight	
junctions	
Prior	to	stimulation	of	cells	with	ET‐1,	podocytes	were	dual	stained	with	ZO‐1	
and	 phalloidin.	 Following	 permeablisation,	 the	 cells	 were	 exposed	 to	 mouse	
anti‐	ZO‐1	primary	antibody	(Invitrogen)	for	24h	at	4°C.	Rhodamine	conjugated	






were	 then	 stained	 solely	 with	 ZO‐1.	 In	 the	 absence	 of	 rhodamine	 phalloidin	
staining,	 the	 cells	 demonstrated	 a	 similar	 cytoplasmic	 and	 nuclear	 staining	
pattern,	 but	 no	 cell	 periphery	 staining	 (Fig	 6.7	 C).	 Appropriate	 IgG1	 control	
staining	 was	 also	 negative	 (Fig	 6.7	 E).	 For	 this	 reason	 we	 were	 unable	 to	






Unstimulated	 podocytes	 display	 linear	 F‐actin	 fibres	 arranged	 in	 parallel	 (Fig	
6.7	 B).	 ET‐1	 stimulation	 for	 2h,	 alters	 actin	 fibre	 arrangement	 to	 peripheral	
distribution	and	 lack	of	 trans‐cytoplasmic	 staining	 (Fig	6.7D).	Higher	doses	of	














































A‐E	 Phalloidin	 and	 ZO‐1	 tight	 junction	 protein	 IF	 staining	 of	 ET‐1	 treated	
podocytes.	 (A)	Dual	 filamentous	 actin	 (red)	 and	 ZO‐1	 (green)	 staining.	 Arrow	
indicates	 lack	 of	 ZO‐1	 staining	 at	 the	 cell	 periphery.	 (C)	 Single	 ZO‐1	 (green)	
staining	demonstrating	no	tight	junction	staining	and	(E)	IgG1	negative	control.	


















apparent	 after	 2h	 incubation.	 No	 changes	 in	 synaptopodin	 localisation	 were	
appreciated	under	IF	in	ET‐1	treated	cells	compared	to	untreated	controls	(Fig.	







following	 treatment	 with	 ET‐1	 at	 100	 pg/ml	 (q=3.312,	 p<0.05),	 1000	 pg/ml	
























A‐D	Photomicrographs	 (600x)	of	 synaptopodin	 localization	and	expression	by	
IF.	Staining	demonstrates	unstimulated	cells	express	nephrin	(A)	Expression	is	





































E&F	 Synaptopodin	 mRNA	 expression.	 	 RT‐PCR	 of	 (E)	 SYNPO	 gene	 encoding	
synaptopodin	(F)	mean	band	intensity	relative	to	β‐actin,	expressed	as	a	ratio	of	
the	 untreated	 control.	 Reduction	 in	 synaptopodin	 expression	 increases	 with	























































apparent	 after	 2h	 incubation.	 No	 changes	 in	 nephrin	 localisation	 were	
appreciated	under	IF	in	ET‐1	treated	cells	(24h)	compared	to	untreated	controls	
(Fig.	 6.8B	 G‐J	 respectively).	 WB	 was	 performed	 to	 quantify	 changes	 at	 the	
protein	level.	Nephrin	protein	expression	decreased	dose	dependently	following	
ET‐1	 treatment	 (Fig	 6.8B	 K).	 Semi‐quantitative	 band	 analysis	 indicates	 a	
significant	 main	 effect	 of	 ET‐1	 treatment	 on	 nephrin	 expression	 (p<0.0001)	
following	a	1‐way	ANOVA.	Dunetts	post‐test	revealed	a	significant	reduction	in	
nephrin	 following	 treatment	with	ET‐1	 at	 100	pg/ml	 (q=3.646,	 p<0.05),	 1000	




a	 significant	main	 effect	 of	 ET‐1	 treatment	 on	 nephrin	 expression	 (p=0.0086)	
following	a	1‐way	ANOVA.	Dunetts	post‐test	revealed	a	significant	reduction	in	
nephrin	 following	 treatment	with	 ET‐1	 at	 1000	 pg/ml	 (q=3.688,	 p<0.05)	 and	































stimulated	 cells	 express	 nephrin	 (G)	 Expression	 is	 unaltered	 in	 cells	 treated	



























K‐N	 Nephrin	 protein	 and	 mRNA	 expression.	 WB	 of	 (K)	 nephrin	 protein	
expression	 and	 RT‐PCR	 of	 (L)	 NPHS1	 gene	 encoding	 nephrin.	 Mean	 band	
intensity	of	protein	(M)	and	mRNA	(N)	relative	to	β‐actin,	expressed	as	a	ratio	of	
the	 untreated	 control.	 Both	 protein	 and	mRNA	 nephrin	 levels	 are	 reduced	 in	
response	to	ET‐1	stimulation.	Loss	of	nephrin	expression	is	more	profound	with	
increasing	 concentration.	 Data	 are	 mean	 ±	 SD,	 analysed	 by	 1‐way	 ANOVA	
followed	 by	 Dunnetts	 post	 hoc	 test	 (n=3).	 	 Symbols	 displayed	 above	 bars	








































































































and	 IL‐8	 production,	 F‐actin	 reorganisation,	 and	 a	 reduction	 in	 markers	 of	
podocyte	 differentiation.	 The	 following	 experiments	 aim	 to	 determine	 a	
mechanism	by	which	 ET‐1	mediates	 its	 effects	 on	 podocytes.	 In	 the	 following	
studies,	 previous	 experiments	 were	 replicated	 with	 the	 addition	 of	 BQ123	
(ETAR)	and	BQ788	(ETBR)	antagonists.		
6.9.1 Selective	ETAR	antagonism	reduces	ET‐1	induced	ET‐1	production		
Cells	 incubated	 for	 24h	 in	 the	 absence	 or	 presence	 of	 the	 selective	 ETAR	
antagonist	 BQ123	 show	 no	 significant	 difference	 in	 ET‐1	 production	 (53.06±	





Unstimulated	 cells	 in	 the	 presence	 of	 ETB	 antagonist	 produced	 approximately	
threefold	 higher	 ET‐1	 concentrations	 compared	 to	 control	 (158.4	 ±	 12.22	 vs	
53.06	±	6.781	pg/ml	 respectively),	 although	 this	 is	not	statistically	 significant.	
When	 stimulated	 with	 5pg/ml	 ET‐1,	 significantly	 higher	 (p	 <	 0.001)	
concentrations	of	ET‐1	were	detected	in	the	supernatant	with	ETBR	antagonism	
(554.4	±	46.09	pg/ml)	compared	 to	control	 (222.0	±	27.29	pg/ml).	This	 likely	
reflects	an	inability	to	clear	ET‐1,	as	opposed	to	an	up‐regulation	of	production.	




























A&B	 ET‐1	 content	 in	 podocyte	 supernatant	 assessed	 by	 RIA.	 Podocytes	 up‐
regulate	ET‐1	production	in	response	to	ET‐1	stimulation	at	24h.	This	effect	 is	
reduced	by	(A)	selective	ETA	antagonism,	whereas	(B)	selective	ETB	antagonism	
confers	 no	 change,	with	 the	 exception	 of	 5pg/ml	whereby	ET‐1	 production	 is	
greater.	 Data	 analysed	 by	 2‐way	 ANOVA	 and	 Bonferroni	 post‐tests	 (n=6).	






































































The	 following	 assays	 were	 performed	 in	 order	 to	 determine	 whether	 ET‐1	
induced	cytokine	production	is	mediated	by	the	ETAR	and/or	ETBR	via	selective	
antagonism	with	BQ123	and	BQ788	respectively.	
6.10.1 Selective	 ETAR	 antagonism	 reduces	 ET‐1	 induced	 IL‐6	 and	 IL‐8	
production		
Cells	 incubated	 for	 24h	 in	 the	 absence	 or	 presence	 of	 the	 selective	 ETA	
antagonist	BQ123	show	no	significant	difference	in	IL‐6	(4431	±	188.9	vs	3106	±	
663.8	pg/ml)	or	 IL‐8	(7823	±	1091	vs	4743	±	538.4	pg/ml)	production.	When	
stimulated	 with	 ET‐1	 however,	 ETA	 antagonism	 significantly	 reduces	 the	




Cells	 incubated	 under	 the	 same	 culture	 conditions	 challenged	 with	 the	 ETB	
antagonist	produced	comparable	IL‐6	concentrations	to	control	(5732±313.5	vs	
4431	±	188.9	pg/ml	 respectively).	A	 similar	 effect	was	 seen	with	 IL‐8	 (5693±	
3499	 vs	 7823	 ±	 1091	 pg/ml).	 Conversely,	 when	 stimulated	 with	 ET‐1	 ETBR	
























Figure	 6.10	 Selective	 ET	 receptor	 antagonism	 effects	 on	 ET‐1	 induced	
podocyte	cytokine	production		
A‐D	 Cytokine	 content	 in	 podocyte	 supernatant	 assessed	 by	 ELISA.	 Podocytes	
upregulate	IL‐6	and	IL‐8	production	in	response	to	ET‐1	stimulation.	This	effect	

































































































ET‐1	demonstrate	 actin	 fibre	disorganisation	and	 contraction,	with	peripheral	




6.11.2 ETB	 receptor	 antagonism	 prevents	 ET‐1	 induced	 F‐Actin	
reorganisation	
Contrarily,	treatment	of	podocytes	with	an	ETB	receptor	antagonist	in	addition	
to	 increasing	 concentrations	 of	 ET‐1	 results	 in	 cytoskeletal	 abberations.	
Exposure	 of	 podocytes	 to	 ETBR	 antagonist	 alone	 does	 not	 alter	 the	 cells	























A‐D	Photomicrographs	 (x600)	of	human	podocytes	 IF	stained	 for	F‐actin	with	
rhodamine‐conjugated	phalloidin.	(A)	Untreated	cells	with	no	receptor	blocker	
demonstrate	 linear	 trans‐cytoplasmic	 staining.	 Exogenous	 ET‐1	 induces	





















E‐H	 Photomicrographs	 (x600)	of	human	podocytes	 IF	 stained	 for	F‐actin	with	
rhodamine‐conjugated	 phalloidin.	 (E)	 BQ123	 alone	 does	 not	 alter	 F‐actin	
organisation.	 Selective	 ETA	 receptor	 antagonism	 prevents	 cytoskeletal	




















Fig	6.11	Cont.	 Selective	ET	 receptor	antagonism	effects	on	ET‐1	 induced	
cytoskeletal	changes	
I‐L	 Photomicrographs	 (x600)	 of	 human	 podocytes	 IF	 stained	 for	 F‐actin	with	















The	 following	 assays	 were	 performed	 in	 order	 to	 determine	 whether	 ET‐1	






ET‐1	 demonstrate	 a	 trend	 towards	 nephrin	 mRNA	 down‐regulation,	 with	
statistically	significant	effects	at	1000	pg/ml	 (p	<0.05).	 	Upon	exposure	 to	 the	




Treatment	 of	 podocytes	 with	 a	 selective	 ETBR	 antagonist,	 however,	 does	 not	
affect	ET‐1	induced	nephrin	down‐regulation,	and	a	significant	down‐regulation	
of	nephrin	upon	ET‐1	 treatment	at	1000pg/ml	 (p<0.05)	 can	 still	 be	observed.	

































A&B	 Gel	 images	 and	 semi	 quantitative	 band	 analysis	 of	 nephrin	 mRNA	
expression.	 RT‐PCR	 of	 (A)	 NPHS1	 gene	 encoding	 nephrin.	 (B)	 Mean	 band	
intensity	 of	 mRNA	 relative	 to	 β‐actin,	 expressed	 as	 a	 ratio	 of	 the	 untreated	
control.	Nephrin	mRNA	levels	are	reduced	in	response	to	ET‐1	stimulation.	Loss	
of	nephrin	expression	is	more	profound	with	 increasing	concentration.	BQ123	




































C&D	 Gel	 images	 and	 semi	 quantitative	 band	 analysis	 of	 nephrin	 mRNA	
expression.	 RT‐PCR	 of	 (C)	 NPHS1	 gene	 encoding	 nephrin.	 (D)	 Mean	 band	
intensity	 of	 mRNA	 relative	 to	 β‐actin,	 expressed	 as	 a	 ratio	 of	 the	 untreated	
control.	 Nephrin	 mRNA	 levels	 are	 reduced	 in	 response	 to	 ET‐1	 stimulation.	
Nephrin	 loss	 is	 more	 profound	 with	 increasing	 concentration.	 Addition	 of	
BQ788	 results	 in	 a	 similar	 ET‐1	 induced	 nephrin	 loss.	 Data	 are	 mean	 ±	 SD,	
















 Human	 immortalised	podocyte	 cells287	 propagate	 under	 growth	 permissive	
conditions	at	33°C	 in	a	 typical	 cobblestone	monolayer.	Thermoswitching	 to	
37°C	results	in	arrest	of	growth	and	maturation.	
 Cells	were	characterised	by	expression	of	podocyte	specific	markers	nephrin,	








 Cells	 undergo	 dedifferentiation	 or	 effacement	 in	 response	 to	 ET‐1,	 as	




















Multiple	 lines	 of	 evidence	 demonstrate	 the	 presence	 of	 an	 ET	 system	 in	
podocytes.	 Much	 of	 this	 evidence	 is	 derived	 from	 rodent	 models	 and	 human	
primary	tissue.	In	the	final	chapter	the	effects	of	exogenous	ET‐1	administration	
in	 vitro	 in	 human	 immortalised	 podocytes	 were	 investigated.	 Where	 ET‐1	
effects	 were	 observed,	 the	 mechanism	 was	 investigated	 using	 selective	 ETR	





While	 there	 is	no	direct	 evidence	 in	 the	 literature	of	 the	presence	of	ETBR	on	
human	podocytes,	 ETAR	 expression	has	 been	 confirmed	by	 agonist‐antagonist	
studies	 272,	 and	 rodent	 podocytes	 have	 been	 shown	 to	 express	 both	 receptor	
subtypes	 195;	 229;	 270.	 As	 such	 we	 hypothesised	 that	 these	 human	 podocytes	
would	express	 the	relevant	ET	receptors.	These	data	demonstrate	 that	human	
podocytes	 do	 poses	 a	 functional	 ET	 system;	 these	 cells	 express	 the	 ETAR	 and	




These	 data	 demonstrate	 a	 reorganization	 and	 redistribution	 of	 the	 actin	
cytoskeleton	 from	 a	 linear,	 trans‐cytoplasmic	 expression,	 to	 a	 disorganized	
peripheral	distribution	when	challenged	with	ET‐1.	As	previously	discussed,	the	
complex	 morphology	 of	 the	 podocyte	 is	 created	 and	 maintained	 by	 its	
cytoskeleton367;	 368;	 369.	Well‐regulated	actin	dynamics	are	crucial	determinants	
during	 foot	 process	maturation,	 junction	 formation,	maintenance	 of	 structure,	




In	 addition	 to	 cytoskeleton	 abberations,	 these	 experiments	 also	 demonstrate	
ET‐1	protein	production	 in	human	podocytes	when	 treated	with	physiological	
doses	 of	 ET‐1.	 Previous	 studies	 have	 demonstrated	 that,	 utilising	 murine	
podocytes,	 a	number	of	 stimuli	 can	elicit	podocyte	ET‐1	 synthesis.	Morigi	 and	
colleagues195	 have	 demonstrated	 actin	 cytoskeleton	 abberations	 and	 ET‐1	
synthesis	 in	murine	podocytes	 in	 response	 to	 IgG	or	 an	 albumin	 load.	 ET‐1	 is	
primarily	 regulated	 at	 the	 level	 of	 gene	 transcription.	 Morigi	 demonstrates	











Nephrin	 is	 commonly	 used	 in	 experimental	 models	 as	 a	 marker	 of	 podocyte	
injury.	There	are	limited	in	vitro	data	suggesting	that	ET‐1	may	lead	to	podocyte	
loss	 of	 nephrin,	 however	 a	 study	 by	 Collino	 et	 al.	 (2008)272	 demonstrates	






process	 morphogenesis	 and	 concomitant	 proteinuria	 and	 first	 implicated	
nephrin	 as	 a	 component	 of	 a	 signalling	 complex	 that	 directly	 integrates	
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cellular	 signalling. This	 is	 verified	 by	 evidence	 that	 nephrin	 serves	 as	 a	
signalling	 scaffold	 to	 recruit	 other	 podocyte	 proteins	 (including	 β‐Arrestins	




The	 literature	 describes	 podocytes	 as	 cells	 capable	 of	 responding	 to,	 and	
producing	 pro‐inflammatory	 effectors.	 Our	 studies	 in	 human	 podocytes	 also	
demonstrate	 an	 ET‐1	 dose	 dependant	 stimulation	 of	 pro‐inflammatory	
cytokines	IL‐6	and	IL‐8.	
Podocytes	 have	 the	 potential	 to	 contribute	 actively	 to	 recruitment	 of	
inflammatory	cells	and	glomerular	injury,	in	addition	to	self‐perpetuated	injury,	
by	up‐regulating	receptors	linked	to	pro‐inflammatory	cytokine	pathways,	most	
commonly	 associated	 with	 inflammatory	 cells	 such	 as	 macrophages	 and	
neutrophils.	 TLR‐2,	 4	 and	 6	 receptor	 expression	 is	 found	 on	 podocytes	 in	
nephritic	 glomeruli,	 and	 in	 vitro	 studies	 using	 immortalized	mouse	 podocytes	





in	 vitro	 demonstrate	 activation	 by	 TGF‐β	 378	 and	 by	 TNFα	 in	 a	 JNK/p38‐
dependent	 pathway	 197;	 198;	 199.	 In	 vivo,	 podocytes	 are	 a	 prominent	 source	 of	
TNF‐α	in	murine	anti‐GBM	nephritis	379	and	in	human	membranous	nephritis380.	




As	 noted,	 both	 integrin	 involvement	 and	 engagement	 of	 the	 nephrin	 receptor	
complex	are	capable	of	activating	NF‐κB	resulting	in	ET‐1	up‐regulation.	Studies	
also	 demonstrate	 an	 up‐regulation	 of	 pro‐inflammatory	 cytokines,	 many	 of	





and	 pro‐inflammatory	 cytokines,	 down‐regulation	 of	 nephrin	 and	 re‐











The	 role	 of	 the	 ETAR	 as	 the	 receptor	 primarily	 responsible	 for	mediating	 the	
pathologic	effects	of	ET‐1	in	renal	diseases	has	been	addressed.	Evidence	in	the	
literature	 demonstrates	 that	 ET‐1	 would	 likely	 induce	 F‐actin	 abberations	
acting	via	the	ETAR.	Further	work	by	Morigi’s	group	274	investigated	the	effect	of	
treating	 murine	 podocytes	 with	 shiga	 toxin,	 the	 agent	 responsible	 for	 post‐
diarrhoeal	 haemolytic‐uraemic	 syndrome	 (HUS).	 In	 this	 study,	 shiga	 toxin	
induced	podocyte	ET‐1	production	and	subsequent	autocrinal	disruption	of	the	
actin	 cytoskeleton.	 In	 this	 setting,	 ETAR	 blockade	 inhibited	 these	 effects.	
Furthermore,	Ortmann	et	al.	 275	 investigated	 the	 effects	 of	 ET‐1	 induced	 actin	
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fibre	 disruption	 in	 murine	 podocytes.	 Using	 selective	 ETR	 antagonists,	 this	
group	confirmed	 the	ET‐1	mediated	actin	 cytoskeleton	 reorganisation	 is	ETAR	
dependant.	Our	data	confirm	these	effects	and	demonstrate	that	pre‐treatment	
of	 human	 podocyte	 cells	with	 BQ123	 prevents	 disruption	 to	 the	 cytoskeleton	
and	ET‐1	production,	an	effect	that	remains	unchanged	with	BQ788.	
These	effects	were	mediated	by	the	ETA	receptor,	as	selective	antagonism	with	
BQ123	 inhibited	 these	ET‐1	 induced	effects.	Blockade	with	BQ788,	 a	 selective	
ETB	receptor	antagonist	did	not	alter	cytokine	production.	




primary	 mechanism	 involving	 engagement	 of	 this	 receptor	 drives	 EMT	 in	
ovarian	tumour	cells	through	β‐arrestin	signalling	135.	As	discussed	in	reference	
to	 macrophage	 migration	 and	 motility,	 receptor‐ligand	 binding	 activates	
canonical	G‐protein‐linked	receptor	phosphorylation	 leading	 to	recruitment	of	
the	 scaffolding	 protein	 β‐arrestin,	 receptor	 desensitisation	 and	
internalisation382;	 383	 with	 subsequent	 intracellular	 signalling	 cascades	 being	
activated.	These	pathways	that	are	convergent	with	those	discussed	in	relation	
to	 integrin	 and	nephrin	 stimulation	 include	MAPK	Ras/Raf/MEK/ERK1/2,	 the	
PI3K/AKT/IκB/NF‐κB,	 β‐catenin	 the	 RHO‐GEF/CDC42/PAK/JNK	 and	 others	
(Reviewed	in	384).		
In	 ovarian	 tumour	 cells,	 β‐arrestin	 is	 recruited	 to	 ETAR	 to	 form	 two	 trimeric	
complexes.	 The	 first	 is	 through	 the	 interaction	 with	 Src	 leading	 to	 epithelial	
growth	 factor	 receptor	 (EGFR)	 transactivation	 and	 E‐cadherin/β‐catenin	
tyrosine	 phosphorylation.	 EGFR	 overexpression	 and	 down‐regulation	 of	 E‐
cadherin,	a	key	component	of	intercellular	junctions,	are	both	known	to	disrupt	
cell–cell	 interactions	 and	 these	 processes	 are	 connected	 by	 the	 caveolae‐






Phosphorylated	 β‐catenin	 is	 then	 degraded	 in	 proteasomes	 by	 the	
ubiquitination	machinery.	
The	 engagement	 of	 β‐arrestin	 in	 these	 two	 signalling	 complexes	 concurs	 to	
activate	 β‐catenin	 signalling	 pathways.	 Silencing	 of	 both	 β‐arrestin‐1	 and	 β‐
arrestin‐2	 inhibits	 ETAR	 mediated	 signalling,	 causing	 suppression	 of	 Src,	
mitogen‐activated	 protein	 kinase	 (MAPK),	 AKT	 activation,	 as	 well	 as	 EGFR	
transactivation	 and	 a	 complete	 inhibition	 of	 ET‐1‐induced	 β‐catenin	
transcriptional	activity	and	cell	invasion.	
Based	on	these	studies,	it	is	reasonable	to	hypothesise	that	ET‐1,	acting	via	the	
ETAR	 would	 induce	 podocyte	 effacement	 by	 inducing	 an	 EMT‐like	 event	
involving	 β‐arrestin‐1.	 This	 would	 subsequently	 induce	 nephrin	 endocytosis	
and	 attenuated	 nephrin	 signalling,	 and	 activate	 downstream	 Src,	 MAPK,	 AKT	
and	 EGFR	 transactivation,	 β‐arrestin‐1/β‐catenin	 activation,	 increased	
transcriptional	 activity	 including	EDN1	 and	 cell	 invasion.	 EDN1	 up‐regulation	
and	 subsequent	 ET‐1	 formation	 and	 release	 would	 also	 elicit	 autocrinal	 and	
paracrinal	perpetuation	of	ETR	activation	(Fig	7.1). 
This	 hypothesis	 was	 tested	 by	 Buelli	 et	 al.	 (2014)387.	 In	 cultured	 mouse	
podocytes,	ET‐1	induced	dedifferentiation	and	EMT	(assessed	by	synaptopodin	







podocytes,	 however	 this	 is	 yet	 to	 be	 investigated.	 β‐catenin	 phosphorylation	
promoted	 gene	 transcription	 of	 Snail,	 and	 increased	 migration	 was	 Snail	





















phosphorylation.	 Activated	 ETAR	 recruits	 β‐arrestin‐1	 to	 form	 a	 trimeric	
complex	 with	 Src	 leading	 to	 two	 pathway	 mechanisms.	 The	 first	 is	 through	
interaction	 with	 Src	 leading	 EGFR	 transactivation	 and	 P‐cadherin/β‐catenin	
tyrosine	phosphorylation.	The	second	 is	 through	 the	physical	association	with	
AXIN	and	APC	to	β‐catenin	and	GSK‐3β.	GSK‐3β	is	released	and	inactivated	and	
β‐catenin	is	stabilised.	Phosphorylated	β‐catenin	is	degraded	in	proteasomes	by	
ubiquitination.	 Genes	 involved	 in	 EMT	 including	 Snail	 and	 MMP‐9	 are	
transcriptionally	 upregulated.	 ETAR/	 β‐arrestin‐1/Src	 complex	 also	 initiates	
other	 intracellular	 signalling	 cascades.	 ET	 receptor	 stimulation	 activates	 the	
MAPKs	Ras	and	Raf	with	subsequent	MEK/ERK1/2	signalling	to	and	NF‐κB/AP‐
1	 binding	 sites.	 The	 PI3K/AKT/IκB/NF‐κB	 pathway	 and	 the	 RHO‐





A	 body	 of	 evidence	 to	 demonstrate	 the	 mechanism	 of	 ETAR	 mediated	 ET‐1	
induced	 podocyte	 effacement	 exists.	 The	 potential	 intracellular	 signalling	
pathways	 leading	 to	 actin	 remodelling	 and	 gene	 transcription	 have	 been	
discussed.	 These	 data	 are	 almost	 exclusively	 derived	 from	 experiments	
conducted	 in	murine	 cells,	with	evidence	 in	a	human	setting	being	scarce	and	
ultimately	speculative.		
Our	 studies	 have	 demonstrated	 that	 ET‐1	 induces	 podocyte	 effacement,	 ET‐1	





induced	 ETAR	mediated	 podocyte	 activation.	 Investigations	 into	 this	 pathway	
mechanism	in	human	cells	would	be	a	necessary	next	step.		




When	 considering	 experiments	 performed	 to	 determine	whether	 ET‐1	 would	
induce	ET‐1	synthesis	in	podocytes,	several	caveats	should	be	noted.	ET‐1	was	
added	to	the	wells	and	ET‐1	concentration	in	the	media	was	measured.	After	an	
initial	 loss	 of	 ET‐1	 in	 the	 media	 at	 early	 time‐points,	 ET‐1	 synthesis	 then	
occurred.	 In	 order	 to	 accurately	 measure	 the	 ET‐1	 produced,	 the	 protein	
content	 of	 the	 wells	 were	 measured.	 The	 ET‐1	 concentration	 was	 then	
normalised	to	protein	content.	The	limitations	of	this	approach	are	threefold	1)	
the	cytotoxicity	of	ET‐1	on	podocytes	was	not	assessed.	 If	ET‐1	 is	cytotoxic	at	
the	 doses	 used,	 podocyte	 loss	would	 occur.	 Ultimately,	 less	 protein	would	 be	
retrieved	 from	 the	well,	 skewing	 the	 ET‐1	 data	 2)	 Similarly,	 the	 proliferative	








As	 the	 glomerular	 endothelial	 cells	 (GEnC)	 and	GBM	 are	 structurally	 relevant	
components	 of	 the	 glomerular	 filter,	 and	 have	 been	 shown	 to	 play	 a	 role	 in	



















































cell	 types	 is	 an	 autocrine	 and	 paracrine	 event.	 This	 ET‐1	 production	 is	 likely	
mediated	via	stimulation	of	the	ETAR,	with	the	ETBR	serving	to	clear	ET‐1.	ETAR	
mediated	 ET‐1	 production	 and	 subsequent	 ET‐1	 induced	 pro‐inflammatory	
cytokine	and	chemokine	gene	 transcription	 is	 likely	 reduced	with	 sitaxsentan,	
limiting	 the	 ability	 of	 glomerular	 cells	 to	 recruit	 resident	 interstitial	 Mϕ	 and	
blood	derived	monocytes.		
Taken	together,	in	consideration	of	the	literature	and	the	data	surrounding	ET‐1	
effects	 in	 renal	 and	 inflammatory	 cells,	 in	 vivo	 studies	 and	 human	 clinical	
evidence,	a	model	of	the	renal	ET‐1	system	has	emerged	(Fig	7.1).	In	podocytes,	
ET‐1	induces	alterations	in	the	actin	cytoskeleton,	foot	process	effacement	and	
loss	 of	 slit	 diaphragm	 proteins	 such	 as	 nephrin.	 This	 podocyte	 damage	 likely	
contributes	 to	 the	 development	 of	 proteinuria,	 a	 marker	 of	 renal	 disease	
progression	and	a	cause	of	further	podocyte	effacement.	Podocytes	also	produce	
ET‐1,	 which	 then	 acts	 in	 an	 autocrine	 and	 paracrine	 fashion	 to	 cause	 further	
podocyte	effacement	and	ET‐1	production.	It	also	serves	to	activate	other	renal	
cell	 types,	 including	 mesangial	 cells,	 to	 release	 pro‐inflammatory	 and	 pro‐
fibrotic	 cytokines,	 stimulate	 proliferation	 and	 increase	 production	 of	 matrix	
proteins	 leading	 to	 sclerosis.	 ET‐1	 is	 also	 chemo‐attractant	 to	 resident	
interstitial	Mϕs,	which	 infiltrate	the	glomerulus	where	they	 further	contribute	
to	renal	 inflammation.	A	regulatory	 feedback	mechanism	of	ET‐1	clearance	by	
Mϕ,	 and	 increased	phagocytosis	may	 then	occur.	Contrarily,	 if	 these	 recruited	
macrophages	 are	 then	 classically	 activated,	 their	 ETBR	 mediated	 clearance	
capacity	may	be	compromised.	ET	receptor	antagonists	have	been	studied	in	the	





as	 relatively	 few	pre‐clinical	 studies	 in	GN	have	been	performed.	Use	of	 these	
antagonists	 in	 other	 models	 of	 GN	 would	 be	 informative,	 allowing	 for	 the	
expedition	of	these	classes	of	drugs	into	clinical	trials.	Such	models	may	include	
any	 proteinuric	 disease	 i.e	 type	 2	 diabetic	 nephropathy	 (T2DN),	 models	 of	
obstruction	 such	 as	 unilateral	 ureteric	 obstruction	 (UUO),	 Thy1	 nephritis	 and	
IgA	 nephropathy.	 Taking	 in	 to	 consideration	 the	 research	 presented	 in	 this	
thesis,	 and	 previous	 pre‐clinical	 studies,	 endothelin	 receptor	 antagonists	
undoubtedly	 make	 very	 attractive	 candidates	 for	 clinical	 trial.	 Continued	

















through	 the	GBM	 to	 interact	with	podocytes	3.	 ET‐1	engages	 the	ETAR	on	 the	
plasma	membrane	of	podocytes	4.	ET‐1	activates	podocyte	ET‐1	and	cytokine	
production.	5.	 ET‐1	 acts	 in	 an	 autocrine	 and	 paracrine	 fashion	 and	6.	 moves	
back	 into	 the	 bloodstream	 where	 it	 may	 interact	 with	 blood	 monocytes	 or	
neutrophils	 7.	 ET‐1	 also	 induces	 down‐regulation	 of	 podocyte	 SD	 proteins	
including	nephrin	and	disruption	of	the	actin	cytoskeleton	8.	 In	addition	to	 its	
effects	 on	 podocytes,	 ET‐1	 also	 engages	 interstitial	 macrophages	 inducing	
migration	 likely	 via	 the	 ETB	 receptor	 towards	 an	 ET‐1	 gradient	where	 it	may	
clear	ET‐1	9.	ETB	receptor	engagement	may	also	induce	macrophage	release	of	
proteolytic	 enzymes	 so	 that	 the	 cells	may	 degrade	 ECM	 components	 allowing	
them	to	migrate.	These	enzymes	are	also	likely	capable	of	degrading	ET‐1.	
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